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Abstract
The progression to chronic lung disease in premature ventilated infants is now
recognised as having several causes which together may lead to a poor respiratory
outcome for the survivor. The premature lung, immature in structure and with a lack
of surfactant and anti-oxidant enzymes, is poorly equipped to deal with the stress of
ventilator barotrauma and oxygen toxicity. Recent studies have concluded that the
pathology of chronic lung disease also involves a significant pulmonary inflammatory
reaction and this is the subject of this thesis. Both clinical and laboratory studies were
carried out with the emphasis on the early initiators and mediators of the inflammatory
response.
The inflammatory response is orchestrated by the resident alveolar macrophages by
production of cytokines in response to stimuli. These stimuli have not yet been fully
identified although the genital mycoplasmas may have a role. The pro-inflammatory
cytokines interleukin-1 (TL-1) and tumour necrosis factor-a (TNF-a), are early
mediators and facilitate neutrophil migration by increasing the concentration of
interleukin-8 (IL-8) from alveolar macrophages, and fibroblasts and epithelial cells
lining the lung. IL-8 is one of the family of alpha-chemokines, and it acts as a
chemoattractant to neutrophils circulating peripherally. TNF-a increases the
permeability of the endothelial lining allowing the circulating neutrophils to migrate
into the lung. The IL-8 then activates the neutrophils which degranulate releasing
powerful enzymes and produce highly toxic oxygen radicals, both ofwhich exacerbate
the tissue damage initiated by the ventilation.
The clinical pilot study enrolled 26 infants and measured EL-8, TNF-a and
inflammatory cells in bronchoalveolar lavage samples. The results demonstrated that it
may be possible to predict a group of babies at extremely high risk for developing
chronic lung disease by early measurement ofDL-8 in tracheal secretions.
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To further investigate the role of the genital mycoplasmas, U. urealyticum and M.
hominis, a randomised study using an effective antibiotic, erythromycin, was carried
out. A low grade untreated infection could persistently stimulate an in vivo
inflammatory response, but we also wished to investigate the reported
anti-inflammatory properties of erythromycin. The inflammatory mediators and cells
present in bronchoalveolar lavage were measured. The infection rate in the study was
lower than expected (12% compared to 30% in a pilot study) and did not correlate
with outcome. There was also no correlation between outcome and treatment and the
inflammatory response, as measured by IL-8, did not correlate with outcome as it had
in our pilot study.
Surfactant has been an elective rescue treatment for infants with respiratory distress
syndrome, but there is debate as to whether natural or synthetic surfactants are more
appropriate. As part of a randomised trial of a natural and synthetic surfactant taking
place on our unit, bronchoalveolar lavage samples both pre and post surfactant were
analysed for cytokines and cells. Our results showed that Curosurf produced a
significantly lower inflammatory response compared to Exosurf 24 hours after
administration but there was no correlation between surfactant type and development
of chronic lung disease.
The cell population present in the lung effluent has been an area of controversy.
Conventionally it is thought that neutrophils are the main cells implicated in lung
damage, but longer term fibrosis would be under macrophage control. Most studies
employ a simple differential stain to evaluate cell types, but a recent study showed
that the use of this stain was inappropriate in sections of lung post-mortem tissue as it
underestimated the number of macrophages present. Standard cytospin smears of
bronchoalveolar lavage samples were compared using a differential stain and an
immunocytochemical stain which relies on monoclonal antibodies to identify specific
cell surface markers and is less subjective. Our results confirm that the differential
stain identifies neutrophils but it significantly under-estimates cells of the
monocyte/macrophage lineage.
Previous in vitro studies have demonstrated the ability of the genital mycoplasmas to
stimulate lung cells to produce cytokines. Laboratory investigations were carried out
to further elucidate and quantify the response of A549 human lung epithelial cells to
Ureaplasma nrealyticum, and an other genital isolates, a Gram-negative (Eschericia
coli). The cells were stimulated in the presence of TNF-a and high oxygen
concentrations, and with mediators used in the clinical management of these infants,
including surfactant, antibiotics and steroids.
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Summary
The progression to chronic lung disease in premature ventilated infants is now
recognised as a multi-factorial disease with recent studies investigating pulmonary
inflammatory reactions. Both clinical and laboratory studies were carried out for this
thesis with the emphasis on the early initiators and mediators of the inflammatory
response. These include interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a),
which facilitate neutrophil migration by increasing the concentration of interleukin-8
(EL-8) released from alveolar macrophages, fibroblasts and epithelial cells. IL-8
activates neutrophils which contribute to the tissue damage initiated by ventilation.
The clinical pilot study enrolled 26 infants and measured IL-8, TNF-a and
inflammatory cells in bronchoalveolar lavage samples. The results demonstrated that it
may be possible to predict a group of babies at extremely high risk for developing
chronic lung disease by early measurement of IL-8 in tracheal secretions.
To genital mycoplasmas, U. urealyticiim and M. hominis, may have a role in the
initiation of the inflammatory response. To further investigate their role, a randomised
study using erythromycin was carried out. Not only is erythromycin an effective
antibiotic, but has also been reported as an anti-inflammatory in adult lung disease.
The inflammatory mediators and cells present in bronchoalveolar lavage were
measured. The infection rate in the study was lower than expected (12% compared to
30% in a pilot study) and did not correlate with outcome. There was also no
correlation between outcome and treatment and the inflammatory response, as
measured by IL-8, did not correlate with outcome as it had in our pilot study.
Surfactant has been an elective rescue treatment for infants with respiratory distress
syndrome, but there is debate as to whether natural or synthetic surfactants are more
appropriate. As part of a randomised trial of a natural and synthetic surfactant taking
place on our unit, bronchoalveolar lavage samples both pre and post surfactant were
analysed for cytokines and cells. Our results showed that Curosurf produced a
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significantly lower inflammatory response compared to Exosurf 24 hours after
administration but there was no correlation between surfactant type and development
of chronic lung disease.
The cell population present in the lung effluent has been an area of controversy. Most
studies employ a simple differential stain to evaluate cell types, but it has recently been
shown that the use of this stain was inappropriate as it underestimated the number of
macrophages present. Standard cytospin smears of bronchoalveolar lavage samples
were compared using a differential stain and an immunocytochemical stain which is
less subjective. Our results confirm that the differential stain identifies neutrophils but
it significantly under-estimates cells of the monocyte/macrophage lineage.
Previous in vitro studies have demonstrated the ability of the genital mycoplasmas to
stimulate lung cells to produce cytokines. Laboratory investigations were carried out
to further elucidate and quantify the response of A549 human lung epithelial cells to
Ureaplasma urealyticum, and an other genital isolate, a Gram-negative (Eschericici
coli). The cells were stimulated in the presence of TNF-a and high oxygen
concentrations, and with mediators used in the clinical management of these infants,
including surf actant, antibiotics and steroids.
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APAAP Alkaline phosphatase anti-alkaline phosphatase
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BPD bronchopulmonary dysplasia
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CI confidence intervals
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NSB non-specific binding
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RDS respiratory distress syndrome
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Sem standard error of the mean
Stdev standard deviation
TBS Tris buffered saline
TNF-a tumour necrosis factor-a
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1.1 Normal Lung Development
At birth, the human infants' lungs must efficiently mediate gas exchange between
blood and air. To do this they have to have developed in utero to expand sufficiently
on inhalation without rupturing, neutralise toxic oxygen radicals and allow gas
exchange across a respiratory membrane that had recently held fluid. Lung
development can be separated into two distinct but related processes, growth and
maturation, where growth refers to the physical size, weight and structural
developments and maturation refers to the ability of the lung to function (DiFiore et
al., 1994).
1.1.1 Structural Development
Human lung development starts in the fourth week after fertilisation and ends in early
childhood with the mature organs. There are five pre-natal stages from conception to
birth (DiFiore et al., 1994) though the divisions are not sharp, rather they blend into
one another and there is variation between individuals. The embryonal stage begins as
a diverticulum from the foregut which later cleaves distally to form the lung buds. The
buds continue to elongate and at 6 weeks form the bronchopulmonary segments lined
with an epithelium. It is the interactions of the epithelium with the mesenchyme which
continues to promote the branching of the lung. This concludes at 8 weeks.
The pseudoglandular stage lasts from the 7th to 16th week. The bronchioles continue
to divide and by the 16th week the complete bronchial tree has formed. Any further
increase in bronchial size is due to elongation not branching.
The canalicular phase extends from the 17th to 26th weeks and results in the
formation of the gas exchanging capability of the lung. The blind ended, epithelial
lined airways continue to extend into the mesenchyme where the capillaries form a
network around the distal air passages. The alveolar epithelium begins to differentiate;
the cytoplasm thins, the air-blood barrier narrows and the gas exchanging cells, the
type I pneumocytes appear at 20-22 weeks. The surfactant producing cells -the type II
1
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pneumocytes - appear just after this differentiating from cells in the epithelium
(Chinoy et al., 1994).
During the saccular phase from the 26th to 36th weeks there is thinning of the airway
walls and a decrease in the interstitial tissue as the peripheral airways continue to
expand. The interstitium with its capillary network is thus sandwiched between
adjacent airways which have saccules attached to the end. These saccules grow and
divide and eventually become the alveolar ducts and sacs late in the saccular phase.
Surfactant secretion from the type II cells also begins during this stage.
The final in litero stage is the alveolar starting at 37 weeks. This lasts well into the
post-natal period. Early studies suggested that no alveoli were present initially, but
recently it is recognised that alveoli do form in litero although ~ 80% of alveoli
formation occurs postnatally. So even at birth the lungs have a substantial amount of
structural development to undergo until they are fully mature.
1.1.2 LungMaturation
Two major biochemical events occur within the lung which are essential for efficient
function, surfactant and anti-oxidant enzyme production. As both these events happen
at roughly the same time (approximately 30 to 32 weeks gestation) it has been
speculated that they are under the same corticosteroidal control (Frank et al., 1985).
Surfactant
By 28 weeks gestation, the alveolar epithelium has differentiated into Type I and Type
II pneumocytes and steroids from the adrenal stimulate the lung fibroblasts to produce
an oligopeptide known as fibroblast-pneumocyte factor (Scott and Das., 1993, Post et
al., 1984) which stimulates surfactant synthesis from Type II cells.
Surfactant is a complex lipopotein, the major component of which is
dipalmitoylphospatidylcholine (DPPC). There are four proteins A, B, C and D the
structures of which have been recently reviewed (Creuwels et al., 1997). Together
these reduce the surface tension at the alveolar air/liquid interface in the peripheral
lung and contribute to the alveolar stability associated with normal respiration
preventing the collapse of the alveoli. Surfactant lipids suppress the immunological
2
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activities of alveolar macrophages (AM) (Shimizu et al., 1988) and may also have an
immunomodulatory role.
The four proteins can be separated into two groups; two hydrophilic and two
hydrophobic. The two hydrophobic proteins SP-B and SP-C maintain the stabilisation
of the surface film by promoting rapid insertion of phospholipids into the monolayer
(Baatz et al., 1990), and the correct ordering of the lipids in the monolayers (Perez-Gil
et al., 1992) respectively.
The two hydrophilic proteins SP-A and SP-D have important functions in addition to
reducing surface tension. SP-A, the most abundant protein in surfactant, has a role in
regulating the uptake and secretion of surfactant (Ryan et al., 1989), opsonisation of
inhaled particles (Malhotra et al., 1993) and bacteria (Kalina et al., 1995) to facilitate
alveolar macrophage phagocytosis, and stimulating proinflammatory cytokine
production (Eizioni.,1994). SP-D, the most recently identified protein, has a similar
structure to SP-A and its functions also seems related to lung defence. It can opsonise
Gram-negative bacteria (Lim et al., 1994) and induce production of oxygen radicals
from alveolar macrophages (van Iwaarden et al., 1992) and has been suggested to
scavenge LPS which may be important in prevention of septic shock (Creuwels et
al.,\991).
Anti-Oxidant Enzymes
Exposure to increased oxygen concentrations at birth enhances the cellular production
of reactive oxygen species (ROS) such as superoxide (02"), hydrogen peroxide
(H2O2), and the hydroxyl radical (OH ) all of which can cause direct tissue damage.
To combat this the lungs have antioxidant enzymes; superoxide dismutase (SOD),
catalase and glutathione peroxidase which scavenge or detoxify these ROS. In animal
models these enzymes appear late in the third trimester of gestation and their
concentration increases rapidly over a very short time (Frank et al., 1987; review). In
humans this pattern does seem to be repeated with SOD (Dobashi et al., 1993). At 36
weeks gestation there is antileucoprotease present in the bronchial epithelium
(Willems et al., 1988) which is a potent inhibitor of elastase enzymes.
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1.1.3 Cellular Structure of the Bronchioles andAlveoli
The cellular structure of the bronchioles is shown in Fig 1.
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Epithelium Lamina Propria






Goblet Cell Blood Vessels
Figure 1-1: Diagram of the bronchial structure showing the ciliated epithelial cells
which facilitate the movement of the mucus which is secreted by the goblet cells.
Taken from (Widdicombe andDavies., 1991).
The walls of the alveolar ducts consist of a thin spiral of collagen and elastin and are
likened to a coil of a spring, they lengthen on inspiration and close on expiration. The
epithelium that lines the air side of the bronchiole is covered in mucus which is
secreted by specialised cells (Jeffrey et al.,1992; review). Goblet cells and the less
frequently found epithelial "serous" cell both secrete mucus. They are also responsible
in adults for repair of the injured respiratory mucosa as they can divide into ciliated
cells and other epithelial cells (Jeffrey et al., 1992). The mucus is distributed up the
epithelium by the many columnar ciliated cells which beat in a regulated manner to
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move the mucus and any debris it has caught from inspiration up to larynx where it is
expectorated or swallowed. The mucus also serves other purposes in that it warms
inhaled air, keeps the lining moist and is an effective anti-bacterial. The bronchioles
end in the alveoli which are the gas exchanging part of the lung (see Fig 1.2).

















Figure 1-2: Schematic drawing of a section of lung tissue showing an alveolus and
surrounding capillaries, as well as various cell types. Taken from (van Wynsberghe,
Noback, and Carola., 1995).
The alveoli are box-like structures with one open side, and their overall structure is
designed for maximum gas exchange. Surface tension must be reduced for adequate
distensibility and this is achieved by pulmonary surfactant which is secreted by Type II
cells. There is a single complete epithelium extending throughout all the alveoli which
is continuous with that of the airways. It is separated from the underlying connective
tissue by a basement membrane. The alveolar wall is rich in blood capillaries and on
5
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one side the capillary is closely applied to alveolar epithelium. Here the endothelial
and epithelial membranes lie very close and the air/blood barrier is at its thinnest
approximately 0.15pm. Type I and II cells are both present in the alveoli. Type I cells
have few cytoplasmic granules and have cytoplasm capable of spreading long
distances from the nucleus. Some may penetrate the wall of the alveoli through the
Kohn pores and so contribute to the lining ofmore than one alveolus. Their function
is to provide a complete but thin covering preventing fluid loss and facilitating gas
exchange but they are easily damaged. Type II cells cover much less of the surface
than Type I and usually occupy the "corners" of the alveolus. They have numerous
microvilli, secrete surfactant and can differentiate into type I cells should the need
arise.
1.1.4 Immune Cells
The alveolar macrophages are the most abundant immune cells in the lung constituting
80 - 90% of the total immune cell population. The remaining 10% is made up of
mostly lymphocytes with a very few polymorphonuclear cells. AM are present at the
air-tissue interface in the alveoli and alveolar ducts where they scavenge debris and
spent surfactant. They are in a unique position in that they are in constant contact with
airborne antigens and must therefore exert control on their responses to them. In this
respect they are similar to other macrophages at a mucosal surface such as the gut and
share many similarities in phenotype with them.
They are a heterogenous population within the normal lung (Spiteri and
Poulter.,1991; Rich et al., 1987) with cell surface markers identifying at least 3 distinct
types of cells (Spiteri and Poulter.,1991); an inducer phenotype RFD17RFD7", a
suppressive phenotype RFD1+/RFD7+, and a classic macrophage phenotype RFD1"
/RFD7+. The suppressor phenotype is important in normal lung functioning and
prevents the dendritic cells from antigen-presentation (Pollard and Lipscomb., 1990;
Holt et al., 1993) and the T-cells from proliferating (McCombs et al., 1982; Bilyk and
Holt., 1995), though not from becoming activated (Upham et al., 1997). Their role in
scavenging spent surfactant may also promote their immunosuppressive properties
(Speer et al., 1991; Thomassen et al., 1994; Zimmerman., 1995).
6
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Blood monocytes replace the resident AM population and do not have a suppressive
RFD7+ phenotype (Poulter et al., 1986) and have been shown in gut inflammation to
be capable of secreting many cytokines including IL-ip and TNF-a (Rugtveit.,1997).
The heterogeneous population of the normal lung may reflect the acquisition of the
suppressive phenotype as the monocytes mature in situ.
1.2 Inflammatory Responses Within the Lung
When an inflammatory response is required the AM must co-ordinate and control the
response which may require the recruitment of specialist cells for efficient clearing of
the organisms. They must also ensure that the response lasts no longer than necessary;
shutting down the response, clearing away debris and promoting healing
1.2.1 AlveolarMacrophages
During a local inflammatory response, activated monocytes infiltrate from the blood
and secrete cytokines. This influx of non-suppressive monocytes allows a T-cell
mediated response by increasing the number of antigen presenting cells in the lungs.
The cytokines granulocyte monocyte colony stimulating factor and TNF-a secreted
by these monocytes may alter the responsiveness of the resident AM (Bilyk and Holt,
1993; Bilyk and Holt, 1995), allowing them to overcome their suppressive phenotype,
and participate in the inflammatory process.
Also released are the pro-inflammatory cytokines IL-lfS and TNF-a which have
pleiotropic effects, promoting the up-regulation of adhesion molecules on the
pulmonary endothelium (Falconer et al., 1995b; Chinoy et al., 1994b) and causing the
release of chemokines. Both of these events trigger the infiltration of circulating
neutrophils into the lung, which is detailed in the following sections.
1.2.2 AdhesionMolecules
The endothelium expresses adhesion molecules in response to cytokine signals and
these regulate the influx of immune cells into the lung. They are a highly sophisticated
set of cell surface molecules (See Table 1-1 below) which are specific to cell types
7
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without which the lung would be unable to recruit cells capable of dealing with
pathogenic organisms.








L-selectin All Glycam-1, PSGL- Rolling
1, others
Integrins
aMP2 (Mac-1, Monocytes ICAM-1 (CD54) Firm adhesion
Mo-1, CDllb/CD18) ICAM-2 (CD102)3 Transmigration
fibrinogen
aLp2 All ICAM-1 Firm adhesion
(CD 11 a/CD 18) ICAM-2 Transmigration
a4pi All" VCAM-1 (CD 106) Rolling and firm
adhesion
a4p7 Mucosal MadCAM Rolling and firm
Lymphocyte subset adhesion
avP3 All PECAM (CD31) Transmigration
Ig Superfamily
IAP (CD47) All Thrombospondin Transmigration
PECAM All PECAM, avp3 Transmigration
Others
PSGL-1 PMN, monocytes, P-selectin (CD62P) Rolling
some lymphs L-selectin (CD621)
E-selectin (CD62E)
E-selectin
ESL PMN E-selectin Rolling
CD44 All Hyaluronate ?
a The role of MAC-1 interaction with ICAM-2 in transendothelial migration is unknown.
b While a4pi has an important role in transendothelial migration ofmonocytes and lymphocytes, its
role in PMN transendothelial migration is uncertain.
Abbreviations: NK, natural killer cells; PMN, polymorphonuclear neutrophil.
There is an ordered sequence of events which determine the flow of cells into the lung
and they begin with the selectins, which allow neutrophils circulating in the blood to
attach and "roll" along the endothelium. There are three known selectins; P, E and L-
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selectin which mediate rolling, but each also has a distinct role which probably
contributes to the finer points of cellular recruitment. L-selectin is expressed
constitutively by leucocytes and P-selectin is stored in compartments within
endothelial cells and rapidly translocated to the cell surface upon activation
(Wagner., 1993). Both these selectins can therefore respond almost immediately to
changes in endothelial cell surface receptors. E-selectin expression on the endothelium
happens only after transcription and translation and does not appear until hours after
P-selectin. In mediating neutrophil migration into the lung P- and L-selectin would
therefore appear to be required early (Mayadas et a/., 1993), whereas E-selectin is
involved in later events.
Once the selectins have appeared on the endothelial surface neutrophils attach but the
speed of the blood flow causes intense shear stresses. The selectin-ligand bonds form
rapidly but are also easily broken and this has the effect of the neutrophil "rolling"
along the endothelium, being taken in the direction of the blood flow. This attachment
to the endothelium is not stable until another group of surface adhesion molecules
becomes involved; the integrins.
The integrins are a family of transmembrane cell surface proteins that bind to the
cytoskeleton and communicate extracellular signals. Their bond with the leucocyte
ligands are much stronger than that of the selectins but they cannot form under the
shear stress conditions the blood flow creates. Therefore the binding of the leucocytes
via the selectins is a necessary prerequisite to integrin binding.
The endothelial cells up-regulate expression of ICAM-1 in response to the pro¬
inflammatory cytokines (Bloeman et al., 1993; Rothlein et al., 1988), which bind to the
leucocytes via their LFA-1 or Mac-1 integrins. Once the leucocytes are held firmly to
the endothelium the begin to migrate into the interstitium of the lung, against a
gradient of chemokine, which guides them to the site of inflammation. The AM
release other factors such as leukotriene B4 which increase microvascular permeability
(Ford-Hutchinson et al., 1984) and assist the transendothelial migration of leucocytes.
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Thus endothelial responses to cytokines will upregulate microvascular adhesion
mechanisms.
1.2.3 Chemokines
Chemokines are a family of basic heparin-binding proteins 7 - lOKd in size that share
significant sequence identity at the amino acid level. They are released in response to
the pro-inflammatory cytokines and cause the activation and chemotaxis of specific
cell types.
Based on conserved sequences of 4 cysteines at their NH2 terminal end, several sub¬
groups can be defined. The two major groups are the CXC or a-chemokines, which
have two cysteines separated by any other amino acid residue and the CC or (3-
chemokines which have two adjacent cysteines. These sub-groups are also specific for
cell types. The a-chemokines are specific for neutrophils and include IL-8. The P-
chemokines are specific for mononuclear cells and include MlP-la and P, MCP-1, 2
and 3 and RANTES. Their specificity allows the recruitment of different types of
effector cells at the site of an inflammation. The other sub-groups are the C family, of
which lymphotactin is the only member at present, and CX3C (Bazan et al., 1997)
which comprises only neurotactin.
The family of a-chemokines is diverse and can be separated into two major sub¬
groups: the ELR CXC chemokines and the non-ELR CXC chemokines
(Rollins., 1997). The ELR is a motif formed by three amino acids (glutamate-leucine-
arginine) between the N-terminus and the first cysteine. The ELR CXC chemokines
have predominantly neutrophils as their target cells and include IL-8, the GRO family,
epithelial cell-derived neutrophil-activating peptide (ENA-78) and the platelet basic
proteins which have varying degrees of potency in vitro.
EL-8 was the first of the a-chemokines to be described and has three forms with
identical biologic activity (Baggiolini et al., 1989). It is biologically active as a dimer
and a monomer (Rajarathnam et al., 1994) and acts via a seven-transmembrane-
domain (7TM) receptor, of which there are two expressed by neutrophils (CXCR1
and CXCR2). CXCR2 has a high affinity for all CXC chemokines but CXCR1 has a
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high affinity for IL-8 only (Baggiolini et al., 1994). IL-8 binding to either receptor
triggers Ca2+ changes and chemotaxis, but phospholipase D activation and respiratory
burst are only triggered by CXCR1 (Jones et al., 1996). Thus IL-8 can affect cells
differently depending on what receptors they are expressing.
The P-chemokines are likewise a large family of related chemokines whose primary
target cell is monocytes, although most of its member affect T lymphocytes and
eosinophils (Rollins., 1997). Monocyte chemoattractant protein (MCP-1) is the most
potent chemokine of those currently studied (Uguccioni et al., 1995) .
In lung inflammation IL-8 is arguably the most important chemokine, being produced
in greater quantities and faster than MCP-1 from monocytes (Liebler et al., 1994),
although animal studies have shown that MlP-la is important as an autocrine
stimulator ofAM and maintains high levels ofTNF-a (Ward.,1996).
PMN entering the lung microvascular bed are retained exclusively within the
capillaries (Lien et a/., 1987) where they can respond rapidly to signals from the AM.
Once the neutrophils have entered the alveolar space and are activated they
phagocytose particulate matter or produce lytic enzymes and reactive oxygen species
to kill invading pathogens.
1.2.4 Extracellular Matrix
The extracellular matrix (ECM) surrounds and supports the bronchial tree and is
composed of collagen, fibronectin, elastin, proteoglycans and laminins (Comper &
Laurent., 1978). It is essential in regulating the normal lung and its interaction with
matrix enzymes allows necessary developmental stages as well as normal growth
(Woessner.,1991, Matrisian.,1990). It interacts with pulmonary cells and growth
factors and cytokines, many ofwhich are produced during an inflammatory response.
The proteoglycans are composed of a protein core with many glycosaminoglycan
(GAG) chains attached (Kjellen & Lindahl.,1991). They have highly diverse functions
ranging from mechanical support as well as interacting with processes such as cell
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adhesion. Most of these functions are dependent on proteins binding to the GAG
chains. Hyaluronic acid (HA) is one of many of the GAG family, but is particularly
important in the wound healing. During development the lung concentration of
hyaluronan decreases with a concomitant increase in macrophage intracellular levels
of hyaluronan (Underhill et al 1993). In fetal rabbits (Mast et al., 1992) high
concentrations of HA decreased fibroblast infiltration and capillary formation but
showed an organised collagen deposition. In adults HA levels are low and it has been
speculated that HA may down-regulate the supply of growth factors such as TGF-(3
and PDGF thus preventing the wound healing process as seen in adults.
EL-1 and TNF-a promote the production of the metalloproteinases (MMPs) (Arend
and Dayer.,1998) which results in degradation of the ECM and the basement
membrane. During acute RDS associated with an inflammatory response, GAGs are
degraded (Murch.,et al 1996a) and this is likely to increase pulmonary leakage and
permeability as well as decrease compliance. The relationship between ECM and the
pulmonary cells is also disrupted and the effects can be devastating in the
restructuring of the lung. It is vital therefore that there is regulation of an ongoing
inflammatory response, and that the response lasts only as long as it is required to
remove the threat.
1.2.5 Down-Regulation of the Inflammatory Response
Once the danger has been eliminated a down-regulation of the inflammatory response
is essential to prevent continued recruitment of activated immune cells and damage
and degradation of the ECM. It is achieved in many ways. The alveolar macrophages
actively suppress the response by producing interleukin-10 (IL-10) (Thomassen et
al., 1996) in response to TNF-a (Wanidworanum et al., 1993) which inhibits further
TNF-a release, down-regulates ICAM-1 expression on epithelial cells (Mulligan et
al., 1993) and directly inhibits further IL-8 release from neutrophils (Cassatella et
al., 1993). The AM are also stimulated to produce transforming growth factor-P
(TGF-P) which prevents neutrophil migration by down-regulating the expression of
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E-selectin on the endothelial cell surface (Gamble et al., 1998) and directly inhibits the
production of IL-8 from endothelial cells (Smith et al., 1996).
The effector cells may become desensitised to cytokines by a reduction of surface
receptors (Colditz and Movat.,1984) and IL-8 is thought to become inactive by
binding to cells (Kunkel et al., 1991). The neutrophils are only short lived effector
cells and therefore die at the site of the inflammation. To prevent them leaking their
highly active cell contents into the lung and promoting further damage they undergo
apoptosis (Savill et al., 1989). This is a controlled suicide in which their cell surfaces
display proteins recognised by AM which then phagocytose and dispose of the debris
of these cells without provoking further inflammation.
1.2.6 Repair ofDamage
After an inflammatory insult damaged cells must be replaced and damaged tissue must
be repaired. The fibroblasts proliferate stimulated directly by the macrophage derived
cytokines platelet derived growth factor (PDGF) and transforming growth factor-P
(TGF-P) (Thornton et al., 1990; Kovacs.,1991; Kovacs and DiPietro.,1994). These
growth factors also increase synthesis of collagen and fibronectin (Matrisian.,1990;
Ignotz et al., 1987) to replace the degraded matrix components, and increase cell
affinity for collagen and fibronectin (Matrisian.,1990). They achieve this by
upregulation of integrins (Ignotz and Massague.,1987; Ignotz et al., 1989) which are
involved in cell-matrix and cell-cell interactions. These interactions are important in
the remodelling process following injury.
To prevent further matrix degradation fibroblasts and AM are induced to produce
tissue inhibitors ofmetalloproteinases (TIMPs) (Edwards et al., 1987).
The whole inflammatory response is normally held in check by a series of stringent
controls designed to remove harmful stimuli without causing damage to the host.
However it is clear that many pulmonary diseases are caused by an imbalance in one
or more of the factors that regulate the inflammatory response, and this is discussed




Premature birth results in an immature lung structure with a thick respiratory
membrane which is however more permeable to small molecules. There are less
terminal airspaces and a greatly reduced surface area for gaseous exchange (Langston
et al., 1984). The chest wall is highly compliant and does not allow the generation of
sufficient pressure for efficient lung inflation and lung fluid levels are higher than at
term birth. In infants born < 30 weeks gestation, surfactant (Avery & Mead., 1959)
and antioxidant enzyme (Grigg et al., 1993) production are deficient, and these infants
are born with respiratory distress which may require ventilation and a high oxygen
supplement.
1.3.1 Ventilation
Mechanical ventilation may be vital for infant survival, but the high inspired oxygen
required and the barotrauma ventilation produces are both likely to cause damage to
an immature lung. The increased oxygen concentrations increases the cellular
production of reactive oxygen species (ROS) which can cause direct tissue damage if
not effectively removed. Antioxidant enzymes which do this job do not develop until
after about 30 weeks gestation and so the preterm infant is deficient in the defence
mechanisms designed to prevent oxidative damage.
The barotrauma of forced ventilation facilitates oxygen delivery, but with each breath,
collapsed alveoli are ripped open and there may be disruption of the bronchiolar and
alveolar epithelium. The immature cell lining is more permeable to small molecules
and this is greatly increased by mechanical ventilation.
1.3.2 Surfactant Deficiency andRespiratory Distress Syndrome
The main role of surfactant is to reduce surface tension at the air/alveolar interface
and to prevent the collapse of the alveoli. Once ventilated, infants may require
ventilation for only a few days after which time their oxygen requirement declines and
they recover with no long term effects. There is a group of infants however whose
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RDS is complicated by other factors such as pneumothorax or pulmonary
haemorrhage. These infants remain ventilated for prolonged periods of time and
develop chronic lung disease of prematurity or bronchopulmonary dysplasia.
1.4 Chronic Lung Disease of Prematurity
Chronic lung disease or bronchopulmonary dysplasia has been defined in two ways;
i) a baby who has been ventilated and has an oxygen requirement at 28 days with
abnormalities on x-ray
ii) a baby who has been ventilated and has an oxygen requirement at 36 weeks
corrected gestational age with abnormalities on x-ray
Only the second definition predicts abnormal findings at follow-up in infants (<30
weeks gestation (Shennan et al., 1988).
In this thesis chronic lung disease of prematurity or bronchopulmonary dysplasia will
be referred to as chronic lung disease (CLD). For the definition of chronic lung
disease used for clinical studies presented here, please refer to the individual chapters.
Classically chronic lung disease has been seen as the disordered repair of damaged
tissues, the damage having been caused by treatment for RDS. The principle factors





It has recently been recognised, however, that together these factors stimulate an
inflammatory response within the lungs which starts within hours of birth (references
below) and which has even been speculated to start in ntero (Ghezzi et al., 1997).
Infection with the genital mycoplasmas has also been suggested as a possible chronic
stimulant of the inflammatory response.
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In infants that develop chronic lung disease the inflammatory response is persistent,
resulting in long term hospitalisation and frequent respiratory problems in infancy.
This inflammatory response and the role of the genital mycoplasmas is explored more
fully in the following sections.
1.5 Preterm Neonatal Immune Responses
The immune system has two distinct defences; innate and adaptive. The innate
response is the first line of defence against foreign antigens, whereas the adaptive
system is antibody mediated and involves specific recognition and memory by cells.
Newborn infants, term and preterm are more susceptible to infection and this may be
related amongst other things to a deficiency in the neutrophil storage pool in the bone
marrow (Liau et al., 1996) and that these neutrophils are functionally immature (Silver
etal., 1996).
1.5.1 Functions ofNeonatal Phagocytes
In healthy term infants cord blood monocytes are much slower at phagocytosis than
adult cells (Schuit et al., 1980) and alveolar macrophages undergo significant
biochemical, morphologic and functional postnatal development (Bellanti et a/., 1979),
with their ability to kill phagocytosed microbes only developing during the first
postnatal month (Bellanti et al., 1979). Cord blood monocytes also produce
significantly less of the pro-inflammatory cytokines IL-8 (Rowen et al., 1995) and
TNF-a (Gerdes et al., 1992), whilst the data on IL-lp is not as clear they have been
reported as producing less IL-ip (Gerdes et al., 1992) or similar levels to adults
(Pillay et al., 1994). They also have significantly reduced cell surface TNF-a receptors
(Chheda et al., 1996) and so are unable to respond as well as mature cells. They
produce less leukotriene B4 (Rowen et al., 1995) and IL-10 (Cheda et al., 1996) and
do not respond as well as adults to EFN-y (Marodi et al., 1994).
Preterm infants monocytes isolated from cord blood produce significantly lower
TNFa (Weatherstone et al., 1989; Gerdes et al., 1992), EL-6 (Yachie et al., 1992) and
IL-8 (Schibler et al., 1993) to various stimuli than term or adult monocytes. EL-ip has
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been shown to be reduced (Gerdes et al., 1992) or equal (Weatherstone et al., 1989) to
term/adult levels, but there is no correlation between gestational age, birthweight and
TNF-a/IL-1 levels (Gerdes et al., 1992).
TNF-a is in part responsible for the fever seen in inflammation so this lower level of
TNF-a may be why preterm infants don't get fever. However, it is not just poor TNF-
a production which fails to stimulate EL-8 production, as exogenous TNF-a
stimulated preterm cord monocytes show decreased IL-8 (Schibler et al., 1993) and
IL-10 (Chheda etal., 1996) production.
Normal PMN are important effector cells but neonatal PMN have an inability to
mobilise free Ca2+ ions intracellularly (Santoro et al., 1995) and this is an important
trigger of chemotactic and phagocytic functions in PMN. Accordingly, studies on
chemotaxis and phagocytosis have shown these cells are deficient (Falconer et
al., 1995b; Hill.,1987; Eisenfeld etal., 1994; Santos et al., 1993).
The motility of preterm PMN cord blood cells is more severely impaired than term
infants (Eisenfeld et al., 1994). L-selectin is normally associated with adhesive
functions of neutrophils and is expressed constitutively. Leucocytes from preterm
infants have decreased resting levels of L-selectin compared to adults, but there is no
inability to up-regulate expression on stimulation (Rebuck et al., 1995). Mac-1, which
mediates firm binding to the endothelium, is seriously deficient on the surface of
preterm neonates neutrophils and monocytes (McEvoy et al., 1996) and is poorly up-
regulated upon stimulation compared to adults (Torok et al., 1993).
The FcRIII is a member of the immunoglobulin superfamily and is important in
binding opsonised bacteria and triggering the oxidative burst. In a normal fetus FcRIII
is at low levels until 33 weeks gestation when it rapidly rises to reach adult levels at
birth. Neonates have significantly less FcRIII on their neutrophil cell surface
compared to adults (Falconer et al., 1995a) but whether this is due to shedding of
FcRIII more easily or being unable to transport FcRIII from vesicles within the cell
where it is stored (Payne et al., 1993a) is unclear. A recent study (Carr et al., 1992a)
measured soluble FcRIII in fetal and preterm plasma and found that preterms have
low levels at birth but within the first 3 weeks of life have achieved adult levels. This
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suggests a programmed increase in protein synthesis not a sudden increase in receptor
release and this is probably in response to external stimuli. PMN random migration in
preterm infants has reached the level of term infants by 3 weeks postnatal age, but
chemotaxis is still reduced in preterm infants (Usmani et a/., 1991; Carr et al., 1992). It
seems likely that birth causes maturation of PMN functions, with chronological age
being more important to PMN functionality than gestational age.
Preterm PMN respiratory burst activity, important in generating reactive oxygen
species, is severely impaired compared to term infants (Jaswon et al., 1994) but study
populations are very heterogeneous with some neonatal PMN able to produce high
concentrations ofH202(Ueda et al., 1992).
1.6 Studies on Lung Inflammatory Mediators in Premature Neonates
Recent studies have focused on the measurement of inflammatory mediators in the
bronchoalveolar lavage fluid of neonates <30 weeks gestation in an attempt to
correlate levels with outcome. Bronchoalveolar lavage is a routine procedure in
intubated infants involving the squirting of sterile saline down an endotracheal tube
with the subsequent removal of the saline and lung fluid by suction. It is performed
routinely, and requires no ethical permission unless the procedure differs from the
routine, and the sample collected can be analysed for cells and mediators (see
"Chapter2 p30"). The measurement of cells is generally done by differential stain,
whilst the fluid can be measured for levels of inflammatory mediators.
1.6.1 Cytokine Responses
Previous studies have not used exactly the same protocol for bronchoalveolar lavage,
nor have they followed exactly the same analysis of samples. This makes comparisons
between studies difficult. However, within 24 hours of birth there is a clear rise in
markers of inflammation such as IL-ip (Jones et al., 1996; Liau et al., 1996), IL-6
(Bagchi et al., 1994), IL-8 (Jones et al., 1996), MEP-la (Murch et al., 1996b) and
fibronectin (Watts et al., 1992b) in infants with RDS compared to those without. IL-
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10 is undetectable within the first 96 hours of life in preterm infants, but present in
term infants (Jones et al., 1996).
At 2-3 weeks infants that later develop chronic lung disease have elevated soluble
ICAM-1 (Kotecha et al., 1995; Silver et al., 1996), TNF-a (Murch et al., 1992; Bagchi
et al., 1994), IL-8 (Groneck et al., 1994a; Kotecha et al., 1995a), C5a (Groneck et
al., 1994a), fibronectin (Watts et al., 1992b), IL-6 (Ng.,1993), IL-1(5 (Murch et
al., 1996b) and MBP-la (Murch et al., 1996b). There are no control groups in these
studies as infants that recover are not ventilated and this makes drawing conclusions
difficult. However, the persistence of these mediators suggests an ongoing
inflammatory response which is doubtless contributing to tissue damage and fibrosis.
1.6.2 Cellular Response
The cellular influx is equally rapid with neutrophils predominating, though there is
debate as to whether macrophages, which are essential for the progression to fibrosis,
are also present early on.
Merrit et al (1981) described the cellular influx in bronchoalveolar lavage in infants
that had RDS and subsequent chronic lung disease and divided them into three
classes. Infants that had no lung disease or RDS at birth generally had no immune
type cells but between 3 to 10 days there was a rapid PMN influx. After ~ day 8
macrophages were the predominant reactive cell types. In infants with RDS that
developed into chronic lung disease PMN numbers remained high, although
macrophages were present, and there was microscopic evidence that these cells were
reactive; they had abundant mitochondria in their cytoplasm. Subsequent studies using
differential stains for cell identification have confirmed that a rapid neutrophil influx
occurs within 48 hours, which in resolving RDS are replaced by macrophages but
which persist in infants developing chronic lung disease (Ogden et al., 1984; Arnon et
al., 1993).
Murch et al (1996b) do not share this view. They point out that neutrophils are easier
to identify on differential stain compared to the heterogeneous monocyte/macrophage
population. They investigated monocytes/macrophages using cell surface markers and
concluded that in the group developing chronic lung disease, that
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monocytes/macrophage numbers are significantly elevated as early as 48 hours
postnatal age and remain so throughout the course of their stay. This was in contrast
to the neutrophils which were only evident at day 3 onwards, but were also
significantly raised in the chronic lung disease group. Macrophages and their products
are important in the development of fibrosis (Finkelstein et al., 1992; Sanders et
al., 1994; review) and given the disordered repair of tissues seen in chronic lung
disease it is not surprising that they will be evident early on.
Once an inflammatory response is no longer required, neutrophil apoptosis is an
important method of clearing activated cells to prevent them for doing damage to
surrounding tissue. Grigg et al (1991) reported neutrophil apoptosis in 8 newborn
infants after 3-5 days ventilation. This small study, however, does not correlate this to
the clinical outcome of these infants and further studies will be required to establish
whether this process is defective in infants developing chronic lung disease.
1.6.3 Neutrophil Elastase
The presence of such a large number of active neutrophils in the lung results in
significant production of powerful enzymes such as elastase which attack the
extracellular matrix. Elastase has also been shown to degrade surfactant protein A
(SP-A) (Liau et al., 1996) which reduces surfactants ability to adsorb and increases
surface tension. In infants with RDS that develop chronic lung disease elastase activity
is significantly raised compared to infants with resolving RDS (Merrit et al., 1983).
Moreover, high elastase levels in preterm lungs are not associated with a-proteinase
inhibitor activity (Speer et al., 1993) the main deactivator of elastase. This
elastase/proteinase inhibitor imbalance is likely to result in chronic lung inflammation
and tissue damage (Ohlsson et al., 1992; Ogden et al., 1984).
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1.7 Potential Infectious Initiators of the Inflammatory Response
1.7.1 GenitalMycoplasmas
The mycoplasmas are the smallest free-living bacteria. They have no rigid cell wall but
their cytoplasmic contents are enclosed by a well developed plasma membrane. This
makes them resistant to antibiotics such as penicillin that interfere with the integrity of
the cell wall. The mycoplasmas are surface parasites of mucosal membranes; the
respiratory and genital tracts. They attach via surface adhesins (Henrich et al., 1993)
and their infectivity is greatly reduced when monoclonal antibodies to these adhesins
are applied (Smith et al., 1994). Once attached they provoke an inflammatory response
and are thought to damage host membranes by the production of hydrogen peroxide,
though this is still speculative. They are Gram negative but stain poorly, and are not
detected using the routine bacteriological media employed in our unit.
The genital mycoplasmas comprise M. hominis and V urealyticnm. M. hominis is
roughly 100 - 300 pm whereas U. urealyticum is only 15 - 30pm. Both these
organisms are commonly found in the vagina of sexually active asymptomatic women
and are probably transmitted during sexual intercourse. U. urealyticnm has been
isolated from the genital tract of ~ 70% of pregnant women, and the rate of vertical
transmission to preterm infants has been reported as up to 55% (Sanchez., 1993).
Transmission is not affected by the mode of delivery, but is significantly increased if
chorioamnionitis is present.
1.7.2 GenitalMycoplasmas and the Development ofChronic Lung Disease
In recent years there has been increasing evidence for a role of the genital
mycoplasmas in prematurity and disease of newborns (Cassell et al., 1993). Whilst
these organisms have been associated with histological chorioamnionitis, they have
not been associated with premature labour or birth (Eschenbach.,1993). In four
studies reviewed by Wang et al 1993, infection with the genital mycoplasmas was not
shown to be causal of chronic lung disease, but they were isolated more often from
the respiratory tract of infants who developed chronic lung disease compared to those
who did not. Differences in study design and taking into account other aetiological
factors did not affect the relative risk in the infected group of developing chronic lung
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disease. Infection rates in these studies varied between 17 - 30% for U. urealyticum
isolated from bronchoalveolar lavage samples (Payne et al., 1991; Wang et al., 1988;
Cassell et al., 1988). All of these studies showed an association between U.
arealyticam colonisation and the development of chronic lung disease, with infants <
1250g birthweight at an increased risk. In contrast, Heggie et al 1994 reported an
infection rate of the genital mycoplasmas in bronchoalveolar lavage of 17%, but in
infants between 26 and 29 weeks gestation there was no correlation with chronic lung
disease (defined at either 28 days or 36 weeks corrected gestational age).
A pilot study carried out within our unit (lies et al., 1996b) found 30% of a group of
preterm infants < 30 weeks had tracheal aspirates positive for M. hominis and/or U.
urealyticum, and of these infants 87% developed chronic lung disease compared to
41% of non-infected infants (p = 0.019).
Whilst the evidence for an association between the genital mycoplasmas and chronic
lung disease is strong, the mechanism of the association is still speculative. We
hypothesised that if these organisms are causal, the problem of chronic lung disease
might be significantly reduced by antibiotics effective against these organisms.
1.7.3 GenitalMycoplasmas and the Inflammatory Response
The absence of a cell wall on the genital mycoplasmas means that they have no
lipopolysaccharide and the major antigenic determinants appear to be cell membrane
glycolipids and proteins. An antigen capable of great variation has been isolated on U.
urealyticum which is predominantly recognised by humans during infection (Zheng et
al., 1994).
Only a few clinical and in vitro studies have shown their ability to provoke an
inflammatory reaction. Infants colonised with U. urealyticum show increased IL-1|3,
IL-8 and neutrophil counts in bronchoalveolar lavage samples (Groneck et al., 1996).
In a study of 99 infants, those colonised with the genital mycoplasmas had higher
levels of inflammatory mediators (including IL-8 and IL-6) on days 1 and 5 of life
than non-colonised infants (Groneck et al., 1994b). Colonisation with U. urealyticum
has also been shown to increase PMN counts in tracheal aspirates (Payne et
al., 1993b) and white blood cell counts (Ohlsson et al., 1993).
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In vitro studies have shown U. urecilyticum can provoke EL-6 and IL-8 release from
fibroblasts (Stancombe et al., 1993). Mycoplasma species have been shown to induce
TNF-a from a monocytic line (Sugama et al., 1990), EL-6 from human monocytes
(Quentmeier et al., 1990) and a range of cytokines from immunocompetent cells
(Stuart.,1993).
1.8 Chronic Inflammation
Whilst neonatal phagocytes appear to have impaired chemotaxis in vitro, clinical
studies show that a large influx of phagocytes does occur in ventilated preterm infants
lungs. On stimulation however neonates may be responding with functionally
immature phagocytes which may be unable to effectively remove a bacterial infection
in the lungs due to impaired phagocytosis and microbial killing (Bellanti et al., 1979).
Tissue damage caused by barotrauma, hyperoxia and surfactant deficiency will
contribute to the problem by stimulating more leucocytes to migrate into the lungs
and these cells will continue to produce TNF-a, EL-1P, IL-8 and MlP-la. The
neutrophils and AM will produce toxic oxygen radicals which cannot be neutralised,
and the balance ofMMPs and TIMPs may be altered (Ricou et al., 1996) affecting the
stability of the extracellular matrix. Unable to down-regulate the response through
cytokines such as EL-10 (Cheda et al., 1996), surfactant or antioxidant enzymes,
preterm infants will then suffer from a chronic inflammatory response. This will
promote the proliferation of fibroblasts, the accumulation of connective tissue and an
irreversible alteration of the tissue architecture, leading to fibrosis and chronic lung
disease.
1.9 Clinical Interventions
Recent clinical interventions have reduced the severity of acute RDS due to surfactant
deficiency, but so far have had little impact on the outcome of chronic lung disease.
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1.9.1 Exogenous Surfactant Therapy
Exogenous surfactant therapy has for the last 3-4 years been used as a routine rescue
treatment for RDS. This has resulted in a decrease in the pulmonary complications of
RDS, a reduced oxygen requirement and reduced ventilator pressure support for the
initial stages of the disease. It has not contributed to reducing the numbers of infants
developing chronic lung disease (Sinclair and Bracken., 1992). This may be a
reflection of the increasing numbers of infants that would previously have died early
from respiratory failure due to severe RDS, but with surfactant therapy now go on to
develop chronic lung disease.
Exogenous surfactant is available in many forms e.g. Survanta (bovine), Curosurf
(porcine), ALEC (synthetic) and Exosurf (synthetic). Curosurf and Exosurf were the
two surfactants used by our unit during the study period of this thesis. Curosurf is
derived from the minced lungs of pigs and contains both the lipid and protein parts of
surfactant. Exosurf is synthetic and contains lipids but no proteins. Instead it contains
two synthesised components hexadecanol and tyloxapol which mimic the proteins SP-
B and SP-C, and which are essential if the surfactant is to form a surface film at the
air/water interface.
There has been debate about the merits of natural versus synthetic surfactants; natural
surfactants may be more immunogenic due to their proteins, but synthetic surfactants
may not work as efficiently due to the lack of proteins. Halliday (1995) recently
reviewed eight clinical trials of natural versus synthetic surfactant and concluded that
there was reduced neonatal mortality and a reduced incidence of pulmonary air leaks,
retinopathy of prematurity and chronic lung disease in the group receiving natural
surfactant.
Surfactants have properties other than reduction of surface tension. They are
important modulators of immune functions of the resident alveolar macrophages and
because the aetiology of chronic lung disease involves a significant pulmonary
inflammatory response it may be that surfactants can influence the inflammatory
response. The role of normal surfactant proteins in immunomodulation has been
discussed previously (see under " Surfactant p2"), and in vitro and animal studies of
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Curosurf and Exosurf have shown them to have differing effects on immune
responses.
Exosurf inhibits alveolar macrophage production of IL-ip, TNF-a and IL-6
(Thomassen et al., 1994) but not EL-8 (Thomassen et al., 1992) and may function as an
antioxidant by scavenging oxygen radicals (Ghio et al., 1994). Curosurf in contrast
inhibits monocyte TNF-a and superoxide anion production (Ciccimarra.,1994) and
phagocytosis of S. aureus (Speer et al., 1991). Exogenous surfactant has been shown
to promote endogenous surfactant production (Gerdes et al., 1992).
In rabbits decreased bactericidal killing by newborn alveolar macrophages is seen with
both natural and synthetic surfactant (Sherman et al., 1988), but Exosurf limits the
proliferation of group B streptococci in preterm rabbits more than Curosurf (Sherman
et al., 1994). Curosurf treatment results in higher numbers of alveolar macrophages in
bronchoalveolar lavage at days 5 and 7 but this does not correlate with outcome
(Arnon et al., 1993).
1.9.2 Steroids
Maturation of the fetal lung is under corticosteroid control (Gross., 1990) and
dexamethasone is given routinely in our unit in the ante-natal period for mothers
threatening a premature delivery. It is hoped that this will promote lung maturation in
utero, stimulate surfactant production, improve lung compliance and decrease the risk
of respiratory distress syndrome (RDS).
In a meta-analysis of 12 clinical trials by Crowley et al 1990, administration of ante¬
natal steroids was shown to reduce RDS and the severity of RDS, and to reduce the
incidence of intra-ventricular haemorrhage.
Clinical studies investigating dexamethasone treatment postnatally in preterm infants
at risk for chronic lung disease have shown it improves surfactant function (Kari et
al., 1994), reduces collagen synthesis (Co et al., 1993) and decreases levels of albumin
and fibronectin (Watts et al., 1992a), in bronchoalveolar lavage fluid of treated infants.
This suggests that the integrity of the alveolar capillary barrier is improved, surface
tension is reduced and long term fibrosis avoided. Markers of lung inflammation,
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neutrophils, neutrophil elastase, leukotriene B4 and IL-ip (Groneck et al., 1993 c,
Murch et al., 1996b), TNF-a, MlP-la and elastase (Murch et al., 1996b) and C5a
(Groneck et al., 1993b) were also reduced in bronchoalveolar lavage.
Rastogi et al (1996) conducted a randomised double-blind placebo-controlled trial
giving dexamethasone within 12 hours of birth and for 12 days to at risk infants (> 24
weeks gestation, < 1500g birthweight). The treatment group was weaned from the
ventilator earlier and the incidence of chronic lung disease and death were
significantly reduced compared to controls. Kari et al (1993) conducted a randomised
double-blind placebo-controlled trial giving dexamethasone after 10 postnatal days in
the same at risk group for seven days. The short term pulmonary outcome was
improved in the treatment group, but not the longer term outcome ofmortality, length
of stay in hospital or oxygen requirement. A short course of dexamethasone (two
treatments within the first 36 hours of life) will also reduce the short term ventilatory
support but does not reduce the incidence of chronic lung disease (Sanders et
al., 1994). Early and prolonged treatment would seem to be more beneficial in
reducing the long term complications.
Dexamethasone has side-effects (Ng.,1993), though in the three studies above, the
only side-effects shown was a higher incidence of hypertension in the studies by Kari
and Sanders.
The mode of action of dexamethasone is not known, but as it is an anti-inflammatory
agent it may improve outcome by suppression of the inflammatory response in the
lungs of ventilated infants.
1.9.3 Antioxidants
There are relatively few studies which have investigated the administration of
exogenous anti-oxidants and related them to outcome. Vitamin E was shown to be
ineffective in reducing chronic lung disease (Saldanha et al., 1982), but recombinant
superoxide dismutase has been reported to reduce the levels of inflammatory markers
(albumin and elastase) in bronchoalveolar lavage fluid (Rosenfeld et al., 1996).
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1.9.4 High Frequency Oscillatory Ventilation
Recent studies have focused on the use of high frequency oscillatory ventilation
(HFOV) which accomplishes gas exchange at lower intrapulmonary distending
pressure, so reducing the barotrauma of intermittent forced ventilation. Whilst this
ventilator is still being investigated it has in early studies been shown to reduce the
outcome of chronic lung disease, when used early and continuously in infants with
RDS (Gerstmann et al., 1996; Clark et al., 1992). Our unit acquired HFOV recently
and it was used only towards the end of this thesis study period. However preliminary
data on a small cohort suggests that whilst death is delayed there is no reduction in
overall mortality (Laing, 1997; personal communication).
1.9.5 Erythromycin
Erythromycin is one of the family of macrolide antibiotics which affects bacterial
protein translocation at the ribosomal level. It is bacteriostatic at low concentrations
and bactericidal at higher concentrations. It is readily internalised by phagocytes
against a concentration gradient (Hand et al., 1983) and is not degraded by
intracellular metabolism (Washington et al., 1985). Whilst the exact mechanism by
which phagocytes internalise erythromycin is as yet unknown it is energy (Viggiano et
al., 1994) and calcium ion dependent (Rowen et al., 1995) and phagocytosis of
particles increases its intracellular concentration (Santoro et al., 1995). It is effective
against the genital mycoplasmas (whereas gentamicin and penicillin are not) and is the
treatment of choice in neonates (Waites et al., 1993). It is not used routinely in our
unit.
The immunomodulating effects of erythromycin are currently under debate. Several
clinical studies have shown low-dose long term erythromycin treatment to be effective
in adult chronic airway diseases (Sawakai et al., 1986; Kudoh et al., 1987) where
Pseudomonas infections persist. Its effectiveness possibly lies in its ability to reduce
neutrophil recruitment into the lungs. This is supported by in vitro studies on the
effect of erythromycin on neutrophil chemotaxis (Nelson et al., 1987; Esterley et
al., 1990). Neutrophils show less elastolytic activity (Ichikawa et al., 1992) and
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reduced phagocytosis (Hand et al., 1990). The mode of action of suppression of
phagocytosis and chemotaxis may be related to disrupted mobilisation of calcium ions
in the cells. It is known that calcium ions are important in microtubule assembly which
is essential for PMN migration. Recently it has been suggested that erythromycin can
perturb cAMP intracellular^ (Aoshiba et al., 1997) promotes neutrophil apoptosis
(Rossi et al., 1995). Apoptosis is the programmed cell death of neutrophils which are
then phagocytosed by macrophages. The neutrophils invading the lung may therefore
be programmed to die before any damage can be done.
Oishi et al., 1994 evaluated IL-8 levels in bronchoalveolar lavage samples from adults
with chronic airway disease and saw a reduction in IL-8 in the treatment group. They
confirmed their findings using in vitro studies which showed erythromycin suppressed
neutrophil, but not alveolar macrophage, derived IL-8. In vitro studies on the effect of
erythromycin on cytokine production have shown that in response to LPS monocytes
will increase IL-6 production (Bailly et al., 1991), but epithelial cells have their IL-6,
EL-8 and IL-ip synthesis reduced (Khair et al., 1995). However, the method by which
it affects the production of cytokines is as yet unclear.
Clinical studies using erythromycin in neonates for the eradication of the genital
mycoplasmas in respiratory infections are few. Heggie et al (1994) treated infants
with erythromycin after positive identification of the genital mycoplasmas from either
CSF or bronchoalveolar lavage. They found no difference in the clinical outcome for
colonised vs. non-colonised infants after treatment. However, the method they used
for isolation of the genital mycoplasmas may have resulted in a large number of false
negatives (Waites et al., 1995) and the mean start of treatment was 16.4 days after
admission to their unit. It is possible the damage might already have been done by the
infecting agent and subsequent inflammatory response.
1.10 Aims of this Thesis
i) To investigate the early inflammatory response both cellular and cytokine in




ii) To further investigate the genital mycoplasmas as a mechanism of stimulation of
the inflammatory response, and to assess the effectiveness of erythromycin in
reducing adverse outcome.
iii) To develop a cell based model of lung inflammation to better understand the
interactions of lung epithelial cells, bacteria and mediators used in the clinical
management of preterm infants.
iv) To compare a differential stain to an immunohistochemical stain for the
identification ofmonocyte/macrophage cells in bronchoalveolar lavage samples.
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2. Bronchoalveolar Lavage
2.1 Introduction
Bronchoalveolar lavage is a routine p'rocedure in intubated infants as they can not
cough to remove mucus. It involves the squirting of sterile saline down the
endotracheal tube and then the insertion of a catheter to remove the saline and mucus
by suction. It is performed routinely, requires no ethical permission and the sample
collected can be analysed for cells and mediators. There are several protocols used for
bronchoalveolar lavage which vary in volume of saline instilled and in number of
lavages performed at sampling time. There is also debate about whether dilution of
the epithelial lining fluid (ELF) by saline can be corrected for by using a reference
protein. This makes comparison between studies difficult. The technique employed in
our unit is constrained within clinical guidelines and these are discussed below, as is
the reason for not using a reference protein to correct for dilution of the ELF.
2.1.1 Sample Size
In infants the lavage technique is blind i.e. the suction catheter is pushed down the
endotracheal tube and suction is applied when resistance to the distal tip of the tube is
felt by the operator. This means that the area being sampled can not specifically be
known. A significant volume of aspirated sample is required to allow the measurement
of several mediators (and also to ensure that there is enough sample to detect those
mediators). For obvious reasons only small volumes of saline can be instilled into the
bronchial tree and there is considerable loss of saline on aspiration. Some studies have
used a fixed volume of saline regardless of infant size (Groneck et al., 1994a), whilst
others use a volume related to infant size (Grigg et al., 1992). One way to increase
sample volume is to sequentially sample the lungs by repeated bronchoalveolar lavage
and to pool the aspirates. The first aliquots are known to sample trachea, with
subsequent aliquots sampling more distal parts (Grigg et al., 1992). Although
bronchoalveolar lavage is not harmful to infants, our clinical staff believe it is
distressing and so sequential sampling was considered inappropriate. We chose 0.5 ml
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saline for all infants, as this was a compromise between drowning and effective
aspiration. As only a single sample was taken at each time point, the sample volume at
each point was inevitably low. The recovered sample volume for each
bronchoalveolar lavage sample was recorded.
2.1.2 Sample Timing
Times of sampling in the literature vary enormously between studies. In this study we
felt that an initial sample taken as soon as possible after birth and prior to surfactant
administration was important as a baseline. Infants are routinely sucked out on labour
ward before intubation and their transfer to the Neonatal Intensive Care Unit (NICU).
After arrival at the NICU a proper bronchoalveolar lavage was performed and the
sample collected for processing. Samples were then collected as close to 24 hours
intervals as possible when clinically indicated. Infants were sampled initially daily for
as long as the infant was intubated, but after our pilot study and given that we wished
to investigate the early inflammatory response we subsequently collected samples for
the first five days of life only.
2.2 Markers ofDilution of Epithelial Lining Fluid
The recovered bronchoalveolar lavage fluid consists of epithelial lining fluid diluted in
saline, and this contains cells, proteins and inflammatory mediators. It is difficult to
know how much epithelial lining fluid has been recovered, but there have been
suggestions that the dilution effect can be estimated by measurement of proteins in the
epithelial lining fluid and by comparison of these with their concentration in plasma.
This assumes that concentrations are the same in plasma and epithelial lining fluid and
that they do not change during the disease process. Albumin (Reynolds., 1987), urea
(Rennard et al., 1986) and the secretory component of IgA (Watts et al., 1992b)
amongst others have been investigated.
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2.2.1 Albumin
Albumin is present in the epithelial lining fluid at about 1/3 concentration of that in
plasma due to oncotic pressure of most interstitial fluids (Walters et al., 1991), it
increases in some disease states (Jones et al., 1990) and can be affected by treatment
(Duddridge et al., 1990). It also increases in serum with postnatal age (Watts et
al., 1995).
2.2.2 Urea
Kelly et al 1988 showed that the fluid dynamics during lavage are complex, and that
during injection of fluid water passes from the bronchopulmonary segment into the
blood or interstitium and at aspiration water is drawn from the plasma. Urea almost
certainly moves into the lavage fluid from the plasma during the procedure by
diffusion down a concentration gradient (Marcy et al., 1987).
2.2.3 Secretory Component ofIgA
Watts and Bruce 1995 claim that secretory component in epithelial lining fluid is
independent of capillary leak, gestational age and post-natal age during the first month
of life. However, they only studied samples from day 2 onwards and Groneck et al
1994a, showed that secretory component was significantly lower on day 1 of life
compared with day 3. It would therefore be of no use for our initial samples.
Stoltenberg et al 1993 investigated post-mortem lung tissues and stained them for the
cells expressing secretory component, the bronchiolar epithelium. Premature infants of
<35 weeks gestation that only lived for 1 week postnatally had significantly less cells
staining positive for secretory component than in mature infants with the same
post-natal age.
It is known that secretory component expression is upregulated by several cytokines
including TNF-a (Kvale et al., 1988) and TNF-a is detectable in many of the
bronchoalveolar lavage samples of these infants (Murch et al., 1992).
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2.2.4 Conclusions
It is clear from the literature that none of these proteins is suitable and that so many
studies use different proteins or none at all shows there is as yet no consensus on what
substance should be used as a reference for the dilution effect seen during lavage.
It was decided for the erythromycin trial (see "Chapter 5 p77") that urea
measurements should be made on our samples because our sample size was too small
for secretory component ELISA and the Department of Paediatric Biochemistry at
RHSC was capable of measuring urea in 50 pi of sample. The results were to be
compared both with and without the correction for urea.
2.3 Bronchoalveolar Lavage Method
Bronchoalveolar lavage was performed by instillation of 0.5 ml 0.9% sterile saline
down the endotracheal tube. The ventilator was reconnected for 3-4 breaths and a
suction catheter (6 FG) was pushed down the tube until resistance to the distal tip of
the tube was felt. Suction was applied and the catheter removed. The sample was
collected into a mucus trap (Vygon, UK) and stored at 4°C until processed.
2.4 Bronchoalveolar Lavage Sample Preparation
2.4.1 Introduction
There is no standardised method of sample preparation. We have attempted to
develop a technique which allows us to conduct all the studies we wished to do
without significantly altering the sample.
2.4.2 Time to Processing
There are conflicting data on how long samples should be stored at 4°C before
processing (Schumann etal., 1992), with some reports that samples are satisfactory up
to 4 hours (Linder et al., 1988) and others suggesting that cells are lost within 30
minutes. We kept the time to sample processing to a minimum and there was always
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someone on-call to process the sample within 4 hours of it being collected. The
average time to sample processing for samples for each study is given.
2.4.3 Fixatives
The use of fixatives to stabilise the sample for transport was inappropriate as we
wished not only to measure inflammatory mediators but also perform
immunocytochemistry on the cells. The sample also only had a five minute journey to
the lab and was then processed immediately so it was not considered to be necessary.
2.4.4 Mucus
Mucus may affect the sample by introducing a population of inflammatory cells as
well as creating a poor staining environment (Schumann et al., 1992). An experiment
to remove mucus from four samples was performed and the effect on the cell
populations investigated.
Methods
Four samples were collected and processed as described above. The sample was
strained through a sterile strainer (Becton Dickinson, Cat No. 2350, Pore size 70p.m)
with 1 ml of RPMI-1640 medium (PFC, Edinburgh) and the fluid collected into a 1.5
ml sterile tube. The mucus was removed by inverting the strainer and flushing 1 ml of
RPMI-1640 in the opposite direction collecting the mucus containing fluid into a
sterile 1.5 ml tube. Both samples were spun separately at 140g for 15 minutes at 4°C
(Jouan, CR55) and the supernatant discarded. The cell pellets were both resuspended
in 200pl medium and cell counts made in a haemocytometer (Neubauer). Viability
was assessed by trypan blue exclusion. The cell concentration was adjusted to 4 x 105
cells/ml and lOOp.1 was added to a cytospin slide and spun at 1000 rpm for 3 minutes
(Shandon, Cytospin 3). The slide was air dried, stained differentially (Dade,
Diff-Quik) and 300 cells were counted.
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Results
Table 2-1: Mucus Extraction Experiment Results.
Cellpercentages with mucus removed and not removedfrom bronchoalveolar lavage
samples.
Cells Mucus Removed Mucus Remaining Paired t-test
% Viability 83 68
75 100
88 83
87 56 p = 0.62
% Neutrophils 70 71
80 79
84 93
62 76 p = 0.20
% Macrophages 23 26
18 18
16 3
35 23 p = 0.27
% Epithelial cells 7 3
3 4
0 4
3 3 p = 0.89
Discussion
There was no significant differences between the counts using a paired t-test nor when
the values are log transformed (data not shown). Removal ofmucus makes the sample
easier to process and the differential stain clearer therefore our samples were strained
before analysis.
2.4.5 Removal ofSupernatant
The sample volume was estimated visually and the mucus was removed by straining
the sample through a sterile cell strainer (Becton Dickinson, Cat.No. 2350, Pore size
70pm). The sample was flushed through with a small amount of RPM3-1640 if
necessary, to make the volume of sample up to a maximum of 0.5 ml. Any extra
35
Chapter 2: Bronchoalveolar Lavage
volume added to the sample was noted. The sample was placed into a sterile, labelled
1.5 mis tube and spun at 140g for 10 minutes at 4°C. 50gl of the supernatant was
aliquoted into sterile, labelled 0.5 ml tubes and frozen at -70°C immediately.
2.4.6 Blood Stained Sample
If the sample was blood stained then after removal of the supernatant for freezing
500pl of distilled sterile water was added and this was left for approximately 1 minute
to lyse the red blood cells. 500pl of medium was added and this was spun at 140g for
10 minutes at 4°C. The supernatant was discarded and the cells processed as below.
2.4.7 Cell Preparation
After lOOpl of medium had been added the cells were resuspended by gently flicking
the bottom of the tube.
The haemocytometer was prepared by wiping with alcohol and placing the coverslip
over the counting chamber so that interference rings could be seen. A viability count
was done by exclusion of trypan blue. The cell concentration was adjusted to 4 x 10^
cells/ml in medium and lOOpl was added per slide in a cytospin and spun at 1000 rpm
for 3 minutes. Slides were allowed to air dry and one slide was immediately stained
for differential cell count. The other slides were left overnight at room temperature
before being frozen at -20°C with desiccant for later immunocytochemical stain (see
"Chapter 6 pi 17").
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3. Development of Interleukin-8 Radioimmunoassay
3.1 Introduction
The principles of radioimmunoassay are relatively simple. A fixed concentration of
antibody is incubated with varying concentrations of antigen. A fixed concentration of
radioactively labelled antigen (tracer) is then added which binds any remaining
antibody sites and will compete within the non-radioactively labelled antigen until an
equilibrium is reached. Any unbound antigen is removed. The bound fraction is
counted in a gamma counter and the amount of labelled antigen counted is inversely
related to the concentration of known antigen. This gives a standard curve from which
unknown antigen values can be calculated.
To develop a suitable assay for measuring unknown antigen concentrations requires
several things;
1. a specific antibody and the calculation of its concentration
2. a labelled antigen which can be measured precisely
3. a suitable standard from which unknown concentrations can be calculated by
comparison
4. a means of efficiently separating free from bound antigen.
A suitable antibody must be both specific for and bind strongly to the antigen. The
primary IL-8 antibody used in this study was raised in a rabbit and was a gift. It had
previously been used in a radioimmunoassay (Kelly et al., 1994) and its characteristics
are discussed below. Commercially available standard of high purity is readily
available and this was labelled with iodine-125 (I23I) in-house for our tracer.
The separation of bound from free antigen is necessary to allow calculations about the
unknowns in our samples. There are several methods employed but the most common
and simplest is the use of a second antibody directed against the first antibody. This
primary-secondary-antigen complex can then be separated by centrifugation from any
unbound antigen. A donkey anti-rabbit antibody was available to us free of charge and
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will bind specifically to the primary rabbit anti-IL-8 antibody. Precipitation of the
antigen-antibody complex only occurs at high antigen-antibody complex
concentrations and so a carrier protein is used from the species in which the primary
antibody was raised. Normal rabbit serum in a solution of assay buffer and
polyethylene glycol was used as this is quick, specific and simple allowing
reproducibility and increased sensitivity. The separation would ideally be 100% but in
practice this never occurs. A portion of the free tracer behaves as if it were bound and
this is measured as the non-specific binding (NSB). There may be "free" tracer caught
up in the antigen-antibody complex, tracer impurities or it may adsorb to the assay
tubes. The NSB is measured by adding only assay buffer and tracer to a tube and
treating it as any other sample. It is then deducted from the counts before any
calculations are made.
The values of the unknowns are calculated by comparison to a set of standard known
values. The tracer concentration is fixed and varying amounts of the unlabelled
standard are added. The value at which no unlabelled standard is added represents the
maximum binding (Bo) and all subsequent values are expressed as a percentage of
this. The percentage of tracer bound is progressively reduced with increasing
concentrations of standard added. A straight line representing the range of the assay




The IL-8 antibody was a gift from Dr Rodney Kelly (Medical Research Council
Reproductive Biology Unit, Edinburgh). It was supplied as a freeze-dried powder
which was reconstituted in assay buffer, aliquoted and frozen at -20°C.
It was shown to have no cross-reactivity with EL-1, IL-2, LL-6 and IL-10 (Kelly et
al., 1994).
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3.2.2 Standard
The IL-8 standards and quality controls came from NIBSC (batch 89/520) and R&D
Systems, Massachusetts. The NIBSC standard was diluted to 40ng/ml and frozen at
-20°C in 500pl aliquots. The R&D standard was diluted to 50p.g/ml and stored at
-20°C in lOjul aliquots.
3.2.3 Iodination ofIL-8
Iodinated IL-8 tracer was supplied by Dr Kelly.
Iodination and purification were carried out as follows;
Gloves were washed to remove any starch and safety procedures for handling
radioactive materials were followed.
1. 0.75mCi (7.5pl) 125j was pUt jnt0 an iodination tube containing lOpg IL-8.
2. lOpl chloramine T [5mg/ml chloramine T in 0.5M iodination buffer pH 7.4
(oxidising agent)] was added and vortexed.
3. This was incubated for 20 seconds then 20pl sodium metabisulphite [7mg/ml
sodium metabisulphite in 0.5M iodination buffer pH 7.4 (reducing agent)] was added
and vortexed.
4. 0.5ml 2 x iodination buffer (with detergent and bovine serum albumin) was added
to the iodination tube and mixed.
5. A PD-10 Sephadex G25 column was washed with 2 x iodination buffer (with
detergent and BSA).
6. Using a glass pipette the iodination mixture from (4) was added to the column.
7. 3ml non stick buffer was allowed to drip through the column twice and this was
collected and used as labelled IL-8.
The labelled EL-8 was stored at 4°C until use.
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3.3 Optimisation of Antibody Concentration and Assay Volumes
Typically a bronchoalveolar lavage would yield only 100 to 200jj.l of sample and in
order to carry out the several measurements we wished to perform it was necessary to
dilute the sample up to 500pl. These small sample volumes meant that we needed to
develop a sensitive assay and several experiments were done to optimise this.
The antibody concentration chosen is usually the amount of antibody which binds
50% of the antigen. At this concentration the addition of further antigen leads to an
increase in the free compared to the bound fraction. As the BO decreases the
sensitivity of the assay increases but precision can be lost and there is a lower limit of
20% beyond which precision is too variable (Burdon and van Knippenberg.1987). We
wished to improve the sensitivity of the assay and so were aiming for about 25-30%
binding with no loss in precision.
3.3.1 Methods
Antibody dilutions
The assay previously described (Kelly et al., 1994) used 1:20,000 initial dilution of
IL-8 antibody. When referring to antibody dilutions in this thesis all references are to
initial dilutions unless otherwise stated. A series of antibody dilutions were made in
assay buffer at 1:10,000, 1:20,000, 1:30,000, 1:40,000 and 1:50,000 dilutions.
Tracer
5000 counts per minute (cpm) in each of the different volumes.
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Table 3-1: Volumes ofassay constituents.








These volumes were made up in duplicate and incubated for 48 hours at 4°C. 200pl of
the precipitating antibody solution was then added to each tube after a further
incubation for 1 hour at 4°C, separation of bound and free were effected by
centrifugation at 3900g (Jouan, CR422). The supernatant (containing the free
fraction) was aspirated and the pellet (containing the bound fraction) counted in a
gamma counter (Packard Bell).
3.3.2 Table ofResults
Table 3-2: Values are expressed as % of the total counts.
Antibody 50pl 50|il 50pl lOOpl 25pl 25pl 25pl
Tracer 50pl 50pl 50pl lOOpl 25pl 25pl 25pl
Buffer (sample) 50pl lOOpl lOOpl lOOpl 50pi lOOpl 200pl
NSB 5.2 2.1 1.8 2.2 1.6 2.0 2.9
1:10,000 38 35 35 39 37 38 37
1:20,000 34 32 30* 36 35 35 34
1:30,000 33 33 31 34 30* 29* 24*
1:40,000 33 31 31 34 29* 28* 24*
1:50,000 31 28* 28* 31 25* 25* 21
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3.3.3 Discussion
Several values (*) are within the 25-30% range, with the majority at tracer and
antibody volumes of 25pl, but variable sample volume. At these volumes an antibody
concentration less than 1:30,000 would appear best. The intra-assay variability with
these parameters was less than 10% for all samples (results not shown) so precision is
not lost.
3.4 Sample Volumes
The sample volumes in the assay needed to be as small as possible to allow other
measurements from the small lavage samples. The improvement in sensitivity of the
assay at lower Bo must be offset with the loss of accuracy that can occur at lower
volumes and concentrations of the other constituents.
3.4.1 Methods
Antibody
Antibody was diluted to 1:30,000 and 1:60,000 in assay buffer.
Tracer
The tracer was diluted to 5000cpm in assay buffer.
Standard
IL-8 (NIBSC) standard was diluted in assay buffer to give a range of standards from 5
ng/ml to 10 pg/ml concentrations.
Tubes of standard and antibody, as in
Table 3-3: Volumes of Assay Constituent below, were prepared in triplicate and
incubated for 24 hours at 4°C. Tracer was then added to each and further incubated
for another 24 hours at 4°C, before separation.
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Table 3-3: Volumes ofAssay Constituents
EL-8 Antibody Tracer Standard
50pl 50nl lOOpl
50(41 50pl 200|4l
25 |il 25pl 50pl
25|il 25pl 100|il
25|ft 25p.l 200(41
200jj.1 of the precipitating antibody solution was added to each tube and after a further
hour at 4°C separation of bound and free was achieved by centrifiigation at 3900G
(Jouan, CR422). The supernatant was aspirated and the pellet counted in a gamma
counter (Packard Bell).
3.4.2 Results andDiscussion
Table 3-4: Antibody concentration at 1:30,000. Results expressed as % bound +B0.
Antibody 50|4l 50pl 25pl 25pl 25(41
Standard lOOpl 200p.I 50(41 100(41 200(41
Tracer 50pl 50pl 25(41 25pl 25(41
NSB (%) 1.6 1.6 2.0 2.1 2.1
B0 29 27 29 24 21
10 pg/ml 100 99 95 99 94
50 pg/ml 98 88 93 88 75
100 pg/ml 88 70 82 70 54
500 pg/ml 47 29 45 29 19
1000 pg/ml 24 15 23 14 13
5000 pg/ml 11 12 11 8 5
Table 3-4 shows the results for the antibody concentration 1:30,000. There is good
reproducibility in the triplicates (results not shown), with low NSB in all sample
volumes. The value for Bo is between 25-30% for all but the 200pil sample volume
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which is approaching the 20% threshold. At antibody and tracer volumes of 50pl a
sample volume of 200pl gives good discrimination at the sensitive end of the range
(10 - 50pg/ml), but 200(il is a very large sample size for our intentions and the assay
would need to be very sensitive if we were to dilute the samples to this value. At
antibody and tracer volumes of 25pi there is better discrimination at the sensitive end
of the range for the sample volume lOOpl compared to 50pl (see Graph 3.1) and in
fact the sensitivity is comparable to the previous 200pl sample volume.
Table 3-5 shows the results for 1:60,000 antibody dilution. The Bo is below the
threshold for all these samples.
Table 3-5: Antibody concentration at 1:60,000. Results expressed as % bound -hBo.
Antibody 50pl 50pl 25pl 25pl 25pl
Standard lOOpl 200pl 50pl lOOpl 200pl
Tracer 50pl 50pl 25pl 25pl 25pl
NSB 1.7 2.0 1.9 3.1 1.8
B0 20 17 19 17 13
10 pg/ml 94 89 92 84 83
50 pg/ml 82 67 79 68 52
100 pg/ml 65 43 64 39 14
500 pg/ml 28 15 26 10 0
1000 pg/ml 15 7 18 7 0
5000 pg/ml 7 2 9 2 0
3.4.3 Conclusions
Based on the results from these two experiments sample volumes will be lOOpl and
the other assay constituents will be 25pl.
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3.5 Evaluating the In-House Tracer
The in-house labelling and purification of tracer is a cheap and reliable way of
producing labelled antigen, but may not produce as high quality tracer as those
commercially available. Commercially available tracers may have a more efficient
iodination procedure i.e. less unlabelled IL-8 in the tracer and less impurities. Both of
these will significantly reduce the non-specific binding and improve assay sensitivity.
IL-8 has a tendency to dimerise in storage and so it was important to assess the
shelf-life of the tracer.
A commercially available tracer (Amersham) was bought to compare to the in-house
tracer. This was expensive and would have needed to significantly improve the
sensitivity to be viable for our project.




Standard (NIBSC): 5ng/ml to 5pg/ml diluted in assay buffer.
Antibody
IL-8 Antibody diluted in assay buffer to 1:20,000 and 1:30,000.
Tracer
Tracer from Amersham and in-house both diluted in assay buffer to 15000 cpm.
Volumes
25jil tracer + 25pl antibody + 100pl standard
Antibody and standard were added to triplicate tubes and incubated overnight at 4°C.
The tracer was then added and the tubes left to incubate at 4°C for a further 24 hours.
200pl of the precipitating antibody solution was added to each tube and after a further
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hour at 4°C separation of bound and free was achieved by centrifugation at 3900g.
The supernatant was aspirated and the pellet counted in a gamma counter.
3.5.2 Results andDiscussion
Table 3-6: Results ofIn-House vs. Commercial Tracer
Results expressed as % bound -hBo. Am = Amersham tracer; IH = in-house tracer.
Antibody Dilution 1:20,000 1:30,000
Tracer Am IH Am IH
NSB 1.5 2.0 1.3 2.0
B0 50 45 33 33
5 pg/ml 97 98 91 100
10 pg/ml 96 97 86 96
50 pg/ml 81 83 79 76
100 pg/ml 68 75 61 62
500 pg/ml 28 25 26 24
1000 pg/ml 18 17 18 16
5000 pg/ml 7 8 7 9
Table 3-6 shows the results of the in-house vs. the commercial Amersham tracer. As
expected the NSB was slightly lower for the Amersham tracer. At 1:20,000 dilution
the BO is too high and the sensitivity is lost. At 1:30,000 dilution of the antibody
Amersham tracer gives better sensitivity at 5-10 pg/ml compared to the in-house
tracer which can not discriminate between these two points, but does discriminate
between 10-50 pg/ml well.
Although there is slightly better sensitivity with the Amersham tracer, this is not
enough to warrant the expense of it and from previous studies measuring IL-8 the
in-house tracer will be sensitive enough.
Table 3-7 show the results for total counts, NSB and Bo for standard curves using the
same batch of in-house tracer over a period 38 days. The Bo decreases to 21% which
is the lower limit of practical use, but the NSB remains essentially the same. Graph
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3.2 plots the standards from these curves (expressed as %B0). There is very little
difference between the standard curves over the 5 week period. The tracer will not be
used past 5 weeks of age.
Table 3-7: Resultsfor In-House Tracer over Time.
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3.6 Equilibrated vs. Dis-equilibrated Assay
A radioimmunoassay relies on the reaction between the binding of the antibody and
antigen and the formation of an equilibrium between the bound antigen-antibody
complex and the free constituents. Each reaction (the standard + antibody, and the
standard-antibody + labelled standard) requires time to achieve equilibrium and whilst
it may be beneficial to have short incubation times to lessen the overall assay time, this
may also decrease sensitivity and precision. An equilibrated assay involves the
introduction of all constituents to the tube at once, whereas the dis-equilibrated assay
involves each step in the assay having separate overnight incubations.
3.6.1 Methods
Standard
Standard (NIBSC): 5 ng/ml to 5pg/ml diluted in assay buffer.
Antibody
IL-8 Antibody diluted in assay buffer to 1:30,000.
Tracer
In-house tracer diluted in assay buffer to 15000 cpm.
Volumes
25pl tracer + 25jj.1 antibody + 100pl standard
For both assays the tracer, standard and antibody were added to ten replicates.
For the equilibrated assay they were incubated for 48 hours at 4°C.
For the dis-equilibrated assay standard and antibody were incubated for 24 hours at
4°C and then tracer was added for a further 24 hours incubation at 4°C.
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For both assays 200pl of the precipitating antibody solution was added to each tube
and incubated at 4°C for 1 hour before being spun at 3900G. The supernatant was
aspirated and the pellet counted in a gamma counter.
3.6.2 Results andDiscussion
The reproducibility (% cv) was excellent for both experiments (Table 10-1 and Table
10-2 in Appendix B) with only one value above 6%. This was the NSB which had one
value well above the rest. Graph 3.3 shows a comparison of the two curves plotted
with % cv as the error bars. The equilibrated assay does not discriminate as well as
the dis-equilibrated at the lower end of the standard curve (19.5 - 39.1 pg/ml) and so
sensitivity appears to be lost when the reactions are not allowed time to come to
equilibrium individually. The dis-equilibrated assay will be used.
Graph3.3:Dis-equilibratedvsEquilibrateIL-8As y IL-8pg/ml
Figure3.3:IdenticalL-8stand rdc rv susingdis-equil bratedoequ libr tass y.Errob s%ft nreplic s.
3.7 Specificity
Chapter 3: Development ofInterleukin-8 Radioimmunoassay
This antibody has been previously tested for its cross-reactivity with other related
proteins to IL-8 (see "Materials p38"). However, it is also necessary to ensure that
other substances in the bronchoalveolar lavage samples do not interfere with the assay
and therefore affect the results. The non-specific binding gives us the interference due
to any of the assay constituents, however the samples are tracheal secretions and the
degree to which they interfere must be known. Serial dilutions of tracheal aspirate
samples were prepared and assayed and the resulting curve compared to the standard
curve to ensure parallelism.
3.7.1 Methods
Standard
Standard (NIBSC): 5 ng/ml to 5pg/ml diluted in assay buffer.
Antibody
IL-8 Antibody diluted in assay buffer to 1:30,000.
Tracer
In-house tracer diluted in assay buffer to 15000 cpm.
Volumes
25pl tracer + 25pl antibody + lOOpl standard or sample
Sixteen tracheal aspirate samples TA1 to TA16 were diluted in assay buffer over 4
serial 1:5 or 1:2 dilutions.
Standard or sample and antibody were added to triplicate tubes. They were incubated
for 24 hours at 4°C. Tracer was added and incubated for another 24 hours at 4°C.
200pl of the precipitating antibody solution was added to each tube and incubated at
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4°C for 1 hour before being spun at 3900g. The supernatant was aspirated and the
pellet counted in a gamma counter.
3.7.2 Results
Table 10-3, Appendix B gives the results as the measured value and the expected
value. If the samples dilute in parallel to the standard then we can predict the expected
value by dividing the first measured value by the dilution factor. The results can be
plotted using a Bland-Altmann plot (Graph 3.4) which has the mean of the expected
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3.7.3 Discussion
Nearly all the values lie within one standard deviation of the mean of the differences.
The correlation coefficient is 0.996 and the antibody would appear to be binding
specifically to the IL-8 without any interference from the sample matrix.
3.8 Comparison ofNIBSC and R&D Standards
The NIBSC Standard was used in development of the assay, but for routine use IL-8
was purchased from R&D Systems, Massachusetts. The two standards were
compared to ensure that the both standards measured equivalently.
3.8.1 Methods
Standard
Standard (NIBSC): 2.5ng/ml to 19.5 pg/ml diluted in assay buffer.
Antibody
IL-8 Antibody diluted in assay buffer to 1:30,000.
Tracer
In-house tracer diluted in assay buffer to 15000 cpm.
Volumes
25pi tracer + 25pi antibody + lOOpl standard or sample
Antibody and standard were added to ten replicate tubes for each standard and
incubated overnight at 4°C. The tracer was then added and the tubes incubated at 4°C
overnight. 200pl of the precipitating antibody solution was added to each tube and
incubated at 4°C for 1 hour before being spun at 3900g. The supernatant was
aspirated and the pellet counted in a gamma counter.
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3.8.2 Results andDiscussion
Table 10-4 and Table 10-5 (in Appendix B) show the results for both curves. Percent
cv are <7% for all replicates except the NSB and they are below 12%. Graph 3.4
shows both curves plotted against each with % cvs as error bars. There is no
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3.9 Quality Controls
Three quality controls of IL-8 (NH3SC) were used in 10 assays at approximately 20,
50 and 80 % binding, the straight part of the standard curve. Each was made in one
batch in RPMI-1640 medium (PFC, Edinburgh) and frozen at -20°C as aliquots ready
for use. The RPM3-1640 was used as the samples were to be diluted in this medium
after collection.
3.9.1 Results
Table 3-8: Quality Control Valuesfor 10 IL-8 Assays.











Mean 809.7 157.2 31.9
Standard Deviation 68.9 21.8 3.3
%cv 8.5 13.9 10.5
3.9.2 Discussion
Inter-assay variation is < 14% based on these quality controls. Intra-assay variation is
calculated for each standard and sample replicates by the Gamma-Counter and any
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Samples were diluted appropriately in assay buffer and lOOpl was added to duplicate
tubes. 25pl of rabbit anti-human IL-8 diluted in assay buffer to 1:30,000 was added
125
and incubated for 24 hours at 4°C. 25pl of I labelled human IL-8 (R&D Systems)
was added to all tubes and incubated for a further 24 hours at 4°C. 200pl of
precipitating antibody solution was then added to each tube and incubated for 1 hour
at room temperature. The tubes were then spun at 3900g for 20 mins at 4°C and the
supernatants aspirated. The tubes were counted in a Canberra-Packard gamma
counter. An eight point standard curve (range 5pg/L - 50ng/L) was included as were
three quality controls (see "Section 3.9: Quality Controls").
The assay included three control samples as shown in Table 3-9 below to allow
calculation of results
Table 3-9: Three Control Samplesfor IL-8 Radioimmunoassay.
Tracer Assay Buffer Antibody
Total count (Tc) 25 jal - -
Non specific binding (NSB) 25pl 125pl -
B0 25pl lOOgl 25pl
Results were expressed as percentage of the reference (Bo) bound and were
calculated from the standard curve.
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4. Pilot Study
4.1 Introduction
Donnelly et al (1993) reported that the concentration of the neutrophil activating and
chemotactic cytokine, interleukin-8 (IL-8), was greater in bronchoalveolar lavage
samples from trauma patients who went on to develop adult respiratory distress
syndrome (ARDS) than from patients who did not. The IL-8 could be detected on
admission and before lung damage was clinically evident.
It is now recognised that there is a significant pulmonary inflammatory reaction in the
development of chronic lung disease in premature infants (Robertson., 1989). Many
studies have reported the presence of large amounts of neutrophils in bronchoalveolar
lavage samples from premature intubated infants, (Ogden et al., 1984; Merrit et
al., 1983) and recently Groneck (1993a) showed that EL-8 was the major chemotactic
factor in the lungs of infants at risk for chronic lung disease.
Our aim was to measure the early inflammatory response, illustrated by IL-8, TNF-a
and immune cells in bronchoalveolar lavage samples, in infants at risk of developing
chronic lung disease.
4.2 Study Group
This was a pilot (prospective cohort) study in a tertiary referral neonatal unit for the
south-east of Scotland. Infants of < 30 weeks gestation intubated and ventilated
immediately at birth were enrolled on the study. Our definition of chronic lung disease
was any ventilated infant still in supplemental oxygen at 28 days of age with
radiological abnormalities on chest x-ray.
4.3 Methods
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4.3.1 Bronchoalveolar Lavage Samples
Details of the bronchoalveolar lavage technique are given in Chapter 2. In brief, after
instillation of 0.5mls saline down the endotracheal tube a catheter was inserted and
suction applied. The sample was collected in a mucus trap and placed in the fridge
until assay. The mean (95% confidence interval) for sample volume recovered was
104.5 (82 - 127pl). The mean (95% confidence interval) time until assay was 1.5
hours (1.1 - 1.9) hours. The first sample was taken as soon as possible and always
before surfactant administration. Subsequent samples were taken daily for the first
three days for cytokine and cell measurements. Bronchoalveolar lavage samples were
also sent daily for routine bacteriology.
4.3.2 Sample Preparation
This was as previously discussed (see "Chapter 2 p30"). In brief, the sample was
flushed from the mucus trap using RPMI-1640 medium (SE-BTS, Edinburgh) and
mucus was removed by straining the sample through a cell strainer. The cells were
removed by centrifiigation at 400g for 10 minutes. The supernatant was aliquoted and
immediately frozen at -70°C. The cell pellet was resuspended in RPMI-1640 medium
and the cells counted and the viability assessed by trypan blue exclusion. The viability
(95% confidence interval) was 65.5 (57.5 - 73.5)%. The cell suspension was adjusted
to 1 x 106 cells/ml and lOOpl added to a cytospin slide (Shandon Cytospin 3). The
slide was stained differentially (Diff Quick, Dade) and 300 cells were counted.
4.3.3 Cytokine Measurements
IL-8 was measured by a specific radioimmunoassay as detailed in Chapter 3. In short,
samples were diluted appropriately in phosphate buffer and lOOpl added to duplicate
tubes. 25pi of rabbit anti-human IL-8 was added and incubated overnight at 4°C. A
further 25pi of 125I labelled human IL-8 at 15000cpm was added to all tubes and
incubated overnight at 4°C. 200pl of precipitating antibody solution (see "Appendix A
pi78") was then added to each tube with a further incubation for 1 hour at 4°. The
tubes were then spun at 3950g (Jouan, CR422) for 20 minutes at 4°C and after the
supernatants had been discarded the pellets were counted in a Canberra-Packard
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gamma counter. An eight point standard curve (range 5pg/L - 50ng/L) was included
as were three quality controls and a background level.
TNF-a was measured by a commercially available high sensitivity ELISA (R&D
Systems, Massachusetts). The assay has an intra-assay specificity <9% and an
inter-assay specificity of <10.5%. The minimum detectable dose in serum is <180
fg/ml making this assay very sensitive and TNF-a can be detected in very small
samples.
4.3.4 Bacteriology Sample
Endotracheal secretions are sent for routine analysis to the microbiology laboratories
where they are cultured for common organisms such as group B streptococci,
Staphylococcus and Coliforms. None of the infants in this study were colonised by
any organism in the first 72 hours of life.
4.4 Results
4.4.1 Clinical Details
26 infants were enrolled in the study over a period of 11 months and the clinical
details for all patients enrolled are given in Table 4-1.
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Did not develop CLD
Male 10 7 3
Female 16 8 8
Mean Gestation (wks) 28 26 29.2 *









Prenatal steroids 18 10 8
Surfactant 16 11 5
All infants survived
f Defined as oxygen requirement at 28 days ofage
*p < 0.001 Unpaired T-test **p < 0.0001 Unpaired T-test
Abbreviations: CI = confidence intervals; CLD = chronic lung disease.
It was not always possible to get a sample from an infant at a specific time for clinical
reasons, however every effort was made to get as complete a set of samples as
possible.
All samples were tested firstly for interleukin-8 and only if enough sample were
available was a test for TNF-a done. This means that there are fewer TNF-a results.
As the cytokine data was highly skewed the values shown are medians and
non-parametric statistical analysis were performed.
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4.4.2 Cytokine Resultsfor A11 Infants






















sem = standard error ofthe mean; IQR = interquartile range.
The EL-8 rises over the first 24 hours and levels over the remaining 72 hours staying
relatively high in all infants. The TNF-a was undetectable in most samples so the
median values are all 0. There are also too few TNF-a results on which to perform
statistical analysis. Graph 4.1 is a plot of the IL-8 values for all infants (Table 10-6
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4.4.3 Cytokine Results Chronic Lung Disease vs. No Chronic Lung Disease
Table 4-3: TNF-a pg/L
Infants divided retrospectivelyfor those that developed CLD and those that did not.
Chronic Lung Disease No Chronic Lung Disease
Time (Hrs) n Median n Median
(IQR) (IQR)
2.4 5 0 4 0
0 0
26.0 12 0 5 0
(0 - 708.3) 0
47.6 9 0 4 0
(0 - 54.9) (0 - 148.4)
71.4 7 0 4 42.7
(0-27.3) (0-134.1)
Although the medians are all 0, TNF-a is initially only present in those infants that
later develop chronic lung disease. It is undetectable in the first samples of those
infants who did not develop chronic lung disease, but becomes so after 48 hours.
There number of samples available are too small for statistical analysis of the TNF-a
results.
EL-8 values are plotted in Graph 4.2 and raw data is in Table 10-7 Appendix B. EL-8
starts low in both groups and rises over the first 24 hours. In the infants that later
develop chronic lung disease the concentration of EL-8 at 24 hours is significantly
different ( * = p < 0.01; Mann-Whitney U Test) from the group of infants that do not
develop chronic lung disease. EL-8 values remain relatively high over the first 72
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4.4.4 Cells
For all infants neutrophil numbers rise over the first 24 hours and stay high for the
first 72 hours. The macrophages however never rise above 20% in the first 72 hours
remaining constant for this time period. The epithelial cells constitute 95% of the
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4.4.5 Cell Results Chronic Lung Disease vs. No Chronic Lung Disease
When the data is divided retrospectively into two groups, those infants that developed
CLD and those that did not, the patterns between the two groups remains essentially
the same. The only significant difference is between the first sample of epithelial cells.
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4.5 Discussion
As expected the group that developed chronic lung disease had a significantly lower
birthweight and gestation, but showed no other statistically significant differences for
other clinical characteristics.
TNF-a was only detectable over the first 24 hours in the infants that later developed
chronic lung disease. There were, however, too few TNF-a samples to show if this
was a significant difference. The initially high level of TNF-a in this group does
suggest an overall increase in inflammatory response and fits with the significantly
increased level of IL-8 seen at 24 hours in the infants that developed chronic lung
disease. We know that TNF-a alone, as one of the pro-inflammatory cytokines, is
enough to increase the secretion of IL-8 from lung fibroblasts (Smart et al., 1994)
(own data chapter 7).
The inflammatory cells present in the bronchoalveolar lavage samples were as
expected from other studies. Over the first 72 hours, an initially high % of epithelial
cells was replaced by neutrophils which remained high in both groups. The level of
macrophages remained constant not going above 15% of the total cell population.
The infants that later developed chronic lung disease had a higher initial level of
epithelial cells which may reflect that the ventilator damage these infants received
initially was greater than in infants that did not develop chronic lung disease.
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5. Genital Mycoplasmas and Erythromycin
5.1 Introduction
Recent studies have suggested an association between genital mycoplasma infection in
the lungs of preterm infants and the development of chronic lung disease, but these
organisms have not been shown to be causal. Their mode of action is unknown but
given that infants that develop chronic lung disease have a persistent inflammatory
response in their lungs, these organisms may be responsible for it.
We wished to test whether treatment with erythromycin would reduce the problem of
chronic lung disease in infected infants.
We were also interested in the possible anti-inflammatory properties erythromycin,
which may prove significant in this group of infants.
5.2 Study Design
This was a randomised study but it was not double blind. There were three people
involved, a consultant neonatologist, a research nurse and myself. Either the
consultant or myself were on call through the night (between 5 pm and 8 am) and
were immediately alerted to any new infants admitted to the unit. Permission was
obtained from the parents to enrol the infant in the study and they were then
randomised to receive erythromycin or not. I was not aware which infants were in the
treatment group. For the next four days a research nurse collected and processed the
samples which were stored until analysed by me.
5.2.1 Patient Criteria
Any infant admitted to the Neonatal Intensive Care Unit, <30 weeks gestation who
was immediately ventilated. Exclusions were those infants with any congenital
abnormalities. Infants were randomised to receive 15 mg/kg/dose of erythromycin
which was infused intravenously three times a day until the baby was tolerating feeds,
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when treatment was given orally. There was no placebo for those in the non-treatment
group. All other treatments were as per normal unit policy.
5.2.2 Definition ofChronic LungDisease
Oxygen requirement with abnormalities on x-ray at 36 weeks corrected gestational
age which predicts abnormal findings at follow-up in infants < 30 weeks gestation
(Shennan et al., 1988).
5.2.3 Measurement of the Severity ofLung Disease
Assessing the severity of lung disease can be difficult, but is important in predicting
the likelihood of an infant of further hypoxemic episodes and readmission to hospital.
Measuring the mean individual alveolar/arterial oxygen saturation (AaD02) (lies et
al., 1996a) of these infants may give some indication of the severity of chronic lung
disease, and we wished to see if infected infants had more severely damaged lungs
compared to uninfected infants. AaDC>2 was measured at 36 weeks gestational age
from an arterial blood gas done while the baby was in a steady state breathing 50%
oxygen in a headbox.
5.3 Methods
5.3.1 Sample Collection andProcessing
Once enrolled in the study, two bronchoalveolar lavage samples (see "Chapter 2
p30") were taken. The first as soon as possible after admission, and the second at
approximately 4 hours postnatal age. Both were kept at 4°C until processed. The first
sample was taken for bacterial culture and PCR and the second for cell staining and
cytokine measurement. Mean time until the second sample was processed was 1 hour
and 37 minutes ±10 minutes (95% confidence limits). If surfactant treatment was
clinically indicated then the second bronchoalveolar lavage was taken before
surfactant administration. Samples were then taken daily whilst the infant remained
ventilated, up to the first 5 days of life.
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Samples were prepared as described previously (see "Chapter 2 p30"), and if any
RPMI-1640 was added the volume was noted. The mean sample recovery volume
was 90pl ± 15pl (95% confidence limit) and the range was 10 to 500|il. Five samples
were >500pl and this was because after the sample was taken the nurse flushed the
line with 1ml saline. These samples were used but not diluted as the others were and
all dilutions were noted and accounted for in the final analysis.
5.3.2 Culture of the GenitalMycoplasmas
Previous studies have relied on culturing the genital mycoplasmas, but these
organisms are difficult to culture due to pH sensitivity. It is more sensitive to use
polymerase chain reaction (PCR) amplification of the urease genes of U. urealyticum,
which also results in a more rapid test, taking < 24 hours compared to 2 - 5 days for
culture (Blanchard et al., 1993). The samples were examined for U. nrealyticum using
both culture and PCR. We do not have suitable PCR primers for M. hominis and so
results for these organisms are given for culture only.
Culture was carried out by Mr S. Fergusson, Medical Microbiology, Edinburgh
University. Samples were inoculated into 1.8 mis ureaplasma broth or mycoplasma
broth and serial 1:10 dilutions were made over 5 pots. These were incubated at 37°C
for at least 72 hours and checked twice daily. Any pots that had turned red were
deemed to be positive for growth. The colour change is due to an increase in the pH
and the lowest concentration which turned red was taken as the titre.
5.3.3 Ureaplasma PCR
This was carried out by Dr. N. Cunliffe, Medical Microbiology, Edinburgh University
as previously described (Cunliffe et al., 1996).
All of the culture positive samples were PCR positive, but 6 of the 100 samples tested
were culture negative and PCR positive, giving a 93% agreement between methods.
The results given in this chapter for the Ureaplasma are the PCR positives and forM.
hominis the culture positives.
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5.3.4 UreaMeasurements
A 50|ul aliquot of the bronchoalveolar lavage sample (when available) was heated for
1 hour at 60°C in a water bath to kill any organisms and then sent to Paediatric
Biochemistry, RHSC for urea measurement. The Hitachi Kinetic UV method is used
routinely in this laboratory and the principle of the assay is detailed in Figure 5.1.
urease
urea + H20 -> 2 NH3 + C02
glutamate dehydrogenase
2 a-oxoglutarate + 2 NR,+ + 2 NADH A 2 L-glutamate + 2 NAD+ + 2 H20
Figure 5-1: Hitachi Kinetic UVmethodfor measuring urea relies on the production
o/NAD+ which is directly proportional to the amount ofurea (mmol/L).
The rate at which NAD+ is produced is directly proportional to the urea concentration
and is measured by the decrease in absorbance at 340nm by a BCL Hitachi analyser.
The method relies on a two point calibration and is linear up to 50 mmol/L urea with a
lower detection limit of 0.3 mmol/L. The normal blood reference range in infants is
1.4 - 5.4 mmol/L.
Urea measurements were also available from serum samples taken daily and routinely
in our unit. To correct for dilution of bronchoalveolar lavage samples the following
equation is used;
BAL urea
Serum urea x BAL volume
where BAL stands for bronchoalveolar lavage.
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5.3.5 Arterial Oxygen Measurements
Measurements were taken before discharge from the unit on all infants that survived.
This was carried out by Dr. Richard lies and detailed methodology are described
elsewhere (lies et al., 1996a).
5.3.6 White Blood Cell Counts
On admission to the unit blood samples are taken and the white cell counts measured.
5.3.7 Pathology ofPlacenta
The placentas were all sent for routine pathology, where if an influx of immune cells
was confirmed by histological examination, chorioamnionitis was diagnosed.
5.3.8 CytokineMeasurements
Interleukin-8
In-house radioimmunoassay as detailed in Chapter 3. 50pl samples were diluted 1:6
and 1:36 in RPMI-1640 (PFC, Edinburgh) and measured in duplicates.
Tumour Necrosis Factor-a
High sensitivity kit (R&D Systems, Cat. No. HSTAO) with standard curve range of
0.5-32 pg/ml and a sensitivity of <180 fg/ml.
Interleukin-1 f3
High sensitivity kit (R&D Systems, Cat. No. HSLBO) with standard curve range of
0.125 - 8 pg/ml and a sensitivity of 100 fg/ml
Samples for both the TNF-a and IL-1(3 were diluted 1:20 in RPMI-1640 to obtain
enough volume to test in duplicates. Results were expressed as an average of these
two values extrapolated from a standard curve.
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5.3.9 Cells
The cells were prepared as previously described (see "Chapter 2 p30"). One slide was
stained differentially using Diff-Quik (Dade) and any others were air dried overnight
before storage at -20°C with a silicon packet to act as a desiccant. These slides were
then stained immunohistochemically (see "Section 6.5 pl24").
5.4 Results
5.4.1 StatisticalAnalysis ofData
The distributions of data in all sets was highly skewed so the data was analysed after
log transformation. Measurements below the limit of detectability were assigned an
arbitrary value of 10 before transformation. The data was split initially as a
pre-surfactant and post-surfactant sample and thereafter daily up to 5 days. If an
infant had more than one measurement in any time period then the values were
averaged after log transformation. Mann-Whitney U tests were performed on
numerical data and Chi square tests were performed on binary data.
5.4.2 White Cell Counts
Of the 76 infants enrolled white cell counts within the first 24 hours were taken for 67
infants. Mean (95% confidence interval) white cell count for the infected babies was
7.26 (1.27) and for the uninfected babies was 9.93 (0.52). This difference was not
significant (p=0.897) using a Mann-Whitney U test.
5.4.3 Urea
Urea measurements were made when enough sample was available. However, of 264
bronchoalveolar lavage samples taken in the study there was enough sample only to
test 145 for urea. Of these 100 (69%) were below the limit of detection of the urea
assay. Because the majority of samples could not be measured for urea the results
presented in this chapter are not corrected for with urea.
The samples which could be corrected with urea were compared in a separate
analysis. Graphs 5.1 to 5.3 are scatter plots for the three cytokines, TNF-a, IL-8 and
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IL-lp, with log of the uncorrected cytokine on the x-axis and log of the urea
corrected cytokine on the y-axis. The correlation coefficients are shown on each
graph and in each case are high. The variation between different samples is much
greater than the variation in the amount of correction. The rank order of the corrected
values are similar to the uncorrected and the results are not likely to be greatly
affected by correction with urea.
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Graph 5.1: Scatter Plot of IL-8
Graph 5.2: Scatter Plot for IL-1
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5.4.4 ClinicalDetailsfor A11 Infants
The study ran for just over 23 months during which time 172 infants <30 weeks
gestation were admitted to the Neonatal Unit. Of these 52 were not ventilated, 12
died within hours of admission, 3 had congenital abnormalities, and 28 infants were
missed due to there being no one available to collect the samples. Only 1 infants
parents refused permission. In all 76 infants were randomised into the study but one
infant was extubated within 24 hours and no samples were taken.
Table 5.1 gives the clinical details for all infants enrolled on the study.







Length of Stay (days) 48
(1 -214)
Time on Ventilator 6
(days) (1-80)








18 infants were not tested
5.4.5 Cytokine and Cell Results
Graphs 5.4 and 5.5 are plots of the cytokine data for all infants enrolled on the study.
The cell data is given in Graph 5.6.
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Graphs 5.4 and 5.5: Cytokines in bronchoalveolar lavage for all infants in the study
group. Data are means, error bars are 95% confidence intervals.
Graph 5.4: IL-8 Results
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U. urealyticum was isolated in 13% of the study group which is lower than the
incidence of Ureaplasma infection reported from other studies (Payne et al., 1991;
Wang et al., 1988; Cassell et al., 1988), and less than half the rate of our own pilot
study (lies et al., 1996b).
IL-8 was low initially and rose over the first 48 hours reaching a plateau at 96 hours.
The median TNF-a values for all samples was zero and TNF-a was virtually
undetectable in any samples until after 24 hours. Our sampling regime which is only a
small window in 24 hours may be unsuitable to detect TNF-a. IL-lp follows the same
pattern as EL-8 rising over the first 24 hours and remaining at a plateau for the next 72
hours.
The total cells for all infants rises after 24 hours and then remains level for the
duration of the study. The percentage of different cell types within the total cell
numbers changes dramatically. Initially the epithelial cells are the predominant cell
type, but they are replaced by neutrophils after 24 hours, which then remain the
predominant cell type. The macrophages gradually rise over the course of 96 hours
reaching a median of 16% of the total cell count of the sample at 72 - 96 hours.
The data can be further analysed by comparing the cytokine and cell data in relation to
several treatments: erythromycin and surfactant, and to outcome: development of
chronic lung disease, and the severity of that disease: AaDOz We were also interested
in whether the group that were infected would have any different inflammatory
responses to the uninfected group.
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5.5 Treatment Vs Control Group
5.5.7 Results
5.5.2 ClinicalDetails
Table 5-2 gives the clinical details sub-divided into infants that were in the
erythromycin treatment group and those that were not.
Table 5-2: Data are medians (range).
Treatment Group Control Group p or F values
n 35 41
Birthweight (g) 1032.5 1050 0.93
(590 - 2300) (500 - 1670)
Gestation (wks) 28 29 0.59
(24 - 30) (23 - 30)
Length of Stay (days) 60.5 45 0.68
(2- 185) (1 -214)
Time on Ventilator 6 5 0.39
(days) (1-41) (1 - 80)
CLD (O2 at 36wks) 13 11 0.46
Males 17 30 0.035
Ureaplasma 3 6 0.61
Ante-natal steroids 9 9 0.64
Chorioamnionitis 9 10 1.00
Surfactant 25 26 1.00
Died 4 8 0.76
AaDC>2 21.8 24 0.051
(2.8-34.3) (13.7-35.2)
There was only one significant difference between the treatment and the control group
for the details given in Table 5-2. The number of males in the control group was
significantly higher than the treatment group. The incidence of chronic lung disease,
defined as oxygen requirement at 36 weeks, was the same in both groups and the
difference in the severity of lung disease (AaD02) did not reach statistical significance.
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Graphs 5.7 - 5.8: Cytokines in bronchoalveolar lavage comparing the treatment and
control groups. Data are medians and error bars are the interquartile range.
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Graphs 5.9 and 5.10: Total cells and neutrophils in bronchoalveolar lavage
comparing the treatment and control groups. Data are medians and error bars are the
interquartile range.
Graph 5.9: Total Cells
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Graphs 5.11 and 5.12: Macrophages and epithelial cells in bronchoalveolar lavage
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There are no significant differences between the two groups at any time point for any
cytokine marker. IL-8 rises in both groups over the study period. IL-ip starts higher
in the non-treated group before any interventions but after 24 hours both groups
follow a very similar pattern. TNF-a is initially only detected in the treatment group
both immediately before surfactant (and treatment) and after surfactant. However the
differences are not significant. As all median values for TNF-a are 0 this data is not
graphed.
The total cells for both groups rise over the first 24 hours and remain at a constant
high level thereafter. The epithelial cells drop drastically over the initial 48 hours and
remain relatively low. There are no significant differences between the two groups.
The macrophages and neutrophils rise sharply after 24 hours with the neutrophils
always being the predominant cell type. In the treatment group both macrophages and
neutrophils rise at about 48 hours and for both cell types the difference at 72 hours is
significant at p < 0.05 (Mann - Whitney U).
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5.6 Ureaplasma Infection Vs No Ureaplasma Infection
5.6.1 Introduction
Although the infection rate was lower than expected the data allows us to analyse the




Table 5.3 gives the clinical details for infants divided into the group that were genital
mycoplasma positive and those that were negative.
Table 5-3: Data are medians (range).
Infected Not Infected p or F values
n 9 51
Birthweight (g) 880 1025 0.12
(765-1450) (500- 1820)
Gestation (wks) 27 28 0.26
(24 - 29) (23 - 30)
Length of Stay (days) 81 50 0.12
(7 - 122) (1 -214)
Time on Ventilator 14 6 0.14
(days) (2 - 80) (1-63)
CLD (O2 at 36wks) 2 20 0.46
Ante-natal steroids 4 26 1.00
Chorioamnionitis 4 11 0.20
Surfactant 4 40 0.048
Died 3 10 1.00
AaD02 25.2 23.7 0.47
(14.6-31.9) (8.4-35.2)
There was only one significant difference at p < 0.05; the infected infants were less
likely to receive surfactant. There were no other significant differences between the
two groups for the rest of the characteristics outlined in Table 5.10. There was a trend
towards infected infants being smaller and staying in the unit longer, but there was no
difference in the severity of chronic lung disease (AaD02) in the infected group.
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Graphs 5.13 - 5.14: Cytokines in bronchoalveolar lavage comparing infants that were
infected with mycoplasmas (I) with those that were not (Nl). Data are medians and
error bars are the interquartile range.
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Graphs 5.15 and 5.16: Total cells and neutrophils in bronchoalveolar lavage
comparing infants that were infected with mycoplasmas (I) with those that were not
(NI). Data are medians and error bars are the interquartile range.
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Graphs 5.17 and 5.18: Macrophages and epithelial cells in bronchoalveolar lavage
comparing infants that were infected with mycoplasmas (I) with those that were not
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Both IL-ip and IL-8 start higher in the infected group but the differences are not
significant. They both rise over the study period and remain elevated at 96 hours. IL-8
is significantly higher in the non-infected group at 48 - 72 hours (p < 0.05). TNF-a is
undetectable in most samples but is significantly higher in the infected group at 24
hours (p < 0.01). The TNF-a data is not graphed.
For the cell data the only significant difference at p < 0.01 is in the very first sample
where the epithelial cells are higher in the non-infected group. Total cells rise and
remain high throughout the 96 hours. Neutrophils and macrophages both rise in the
first 24 hours, but the neutrophils always remain the predominant cell type.
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5.7 Chronic Lung Disease Vs No Chronic Lung Disease
5.7.1 Introduction
The data can be divided retrospectively for those infants that developed chronic lung
disease and those that did not. Only infants who survived past 36 weeks were
included in this analysis as those infants who died before this time could not have
developed chronic lung disease by our definition. The pilot study (Chapter 4) found
that infants that later went on to develop chronic lung disease had a significantly
higher level of IL-8 at 24 hours post-natal age.
5.7.2 Results
5.7.3 Clinical Details
Table 5.4 gives the clinical details for infants divided into the group that developed
chronic lung disease and the group that did not.
Table 5-4 Data are medians (range).
Chronic Lung No CLD p values
Disease
n 23 39
Birthweight (g) 1032 1175 0.24
(500 - 1680) (800 - 2300)
Gestation (wks) 29 29 0.42
(24 - 30) (24 -30)
Length of Stay 99 35 0.0000
(days) (63 - 185) (2-106)
Time on Ventilator 24 7 0.0005
(days) (3 - 86) (1-45)
Males 14 23 1.00
Ureaplasma 2 6 0.44
Ante-natal steroids 23 9 0.20
Chorioamnionitis 2 12 0.033
Surfactant 2 21 0.004
AaDQ2 25.4 21.9 0.037
(9.9-35.2) (2.8-34.3)
The significant differences between the two groups were length of stay and time
ventilated. The group that developed chronic lung disease were more likely to have
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received surfactant (p < 0.005). There was a significant difference (p < 0.05) for the
mean arterial oxygen differences indicating that those infants that developed chronic
lung disease had more severe lung damage than those not being ventilated.
The difference in chorioamnionitis is significant, with those infants that later
developed chronic lung disease being less likely to have had chorioamnionitis. The
difference between the sexes is not significant.
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Graphs 5.19 - 5.20: Cytokines in bronchoalveolar lavage comparing those that
developed chronic lung disease with the group that did not. Data are medians and
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Graphs 5.21 and 5.22: Total cells and neutrophils in bronchoalveolar lavage
comparing those that developed chronic lung disease with the group that did not.
Data are medians and error bars are the interquartile range.
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Graphs 5.23 and 5.24: Macrophages and epithelial cells in bronchoalveolar lavage
comparing those that developed chronic lung disease with the group that did not.
Data are medians and error bars are the interquartile range.
Graph 5.23: Macrophages
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IL-8 and IL-ip are significantly higher (p < 0.003 and p < 0.05 respectively) on
admission in the group that did not develop chronic lung disease. When the data is
analysed using a multiple linear regression analysis which takes into account other
factors such as caesarean section, chorioamnionitis, birthweight and gestation the
differences are no longer significant and the only factor which has a positive
correlation with the initially high IL-8 and EL-ip is chorioamnionitis (p < 0.001).
The TNF-a does not show any significant differences between the two groups and the
median values for all time periods was 0. For this reason the data is not graphed.
There were no significant differences between the cells, total and each cell type at any
time point. The patterns are similar for both groups and they are the same as the
patterns for all infants.
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5.8 Surfactant Vs No Surfactant
5.8.1 Introduction
At the time of the study infants that received surfactant were given Curosurf or
Exosurf. A randomised trial of Curosurf vs Exosurf was also taking place within our
unit and many of the infants that were enrolled on the erythromycin trial were also
enrolled on that study. The data presented here for the erythromycin trial does not
distinguish between the two surfactants.
Cytokine and cell data were collected for many of the infants enrolled on the
surfactant trial and it is presented here as a comparison of samples immediately pre
and post surfactant. We wished to investigate whether Curosurf - which is natural and
has proteins - or Exosurf - which is wholly synthetic- provoked a different initial
inflammatory response.
5.8.2 Resultsfor the Erythromycin Trial
5.8.3 ClinicalDetails
Table 5.5 gives the clinical details for infants that received surfactant and those that
did not.
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Table 5-5: Data are medians (range).
Surfactant No Surfactant p values
n 51 24
Birthweight (g) 1045 1020 0.37
(500 - 1820) (640 - 2300)
Gestation (wks) 29 28 0.43
(23 - 30) (24 - 30)
Length of Stay 51 34 0.061
(days) (2-214) (1 - 122)
Time on Ventilator 6 2.5 0.0009
(days) (2-63) (1 - 80)
CLD (O2 at 36wks) 22 2 0.002
Males 26 12 1.00
Ante-natal steroids 23 9 0.79
Chorioamnionitis 7 8 0.06
Ureaplasma 4 4 0.08
Died 8 5 1.00
AaD02 24.2 22.2 0.26
(2.8-35.2) (11.2-31.9)
Infants that received surfactant had a longer time on the ventilator and were more
likely to develop chronic lung disease.
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Graphs 5.25 - 5.26: Cytokines in bronchoalveolar lavage comparing the group that
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Graphs 5.27 and 5.28: Total cells and neutrophils in bronchoalveolar lavage
comparing the group that received surfactant with the group that did not. Data are
medians and error bars are the interquartile range.
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Graphs 5.29 and 5.30: Macrophages and epithelial cells in bronchoalveolar lavage
comparing the group that received surfactant with the group that did not. Data are
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IL-8, IL-ip, neutrophils and macrophages are significantly different on admission and
are lower for those infants receiving surfactant, but these values are lower before
surfactant administration, and are therefore unrelated to it. The TNF-a is lower after
surfactant administration but only at p < 0.05. So the infants that receive surfactant
had lower early cytokine and inflammatory cells on admission, but significantly more
of them developed chronic lung disease. The group of infants that had higher early
cytokines had a positive correlation with histological chorioamnionitis (p < 0.01), and
in a multiple linear regression taking account of this there was no differences between
the two groups pre-surfactant cytokine levels were zero.
5.8.4 Results of the Different Surfactants
5.8.5 Study Group
23 ventilated newborn infants on the first day of life with respiratory distress
syndrome and an A/a ratio < 0.22 were randomised to receive Curosurf or Exosurf.
Samples were bronchoalveolar lavage fluid taken immediately prior to and 24 hours
post-surfactant administration.
Table 5-6: Clinical Details. Data are medians (range) or number.
All Infants Curosurf Exosurf
n 23 12 11
Gestation (wks) 29 29 29
(26 - 32) (26 - 32) (27 - 32)
Birthweight (g) 1450 1395 1543
(755 - (755 - (880-
2345) 2320) 2345)
Prenatal steroids 12 6 6
Male 14 9 5
There were no significant differences between the groups that received Curosurf or
Exosurf by Mann-Whitney U Test.
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5.8.6 Cytokine and Cell Data
Table 5-7: Cytokine Levels and Cell Differential Counts Pre vs Post Surfactant
Treatment. Data are medians.
All Infants Exosurf Curosurf
1L-8 ng/ml 4.4 vs 20.7 4.2 vs 23.7 6.2 vs 15.6
(p - 0.078) (p = 0.04) (p = 0.58)
TNF pg/ml 0 vs 0 0 vs 0 0 vs 0
(p = 0.29) (P= io) (p = 0.28)
% neutrophils 2 vs 77 22 vs 75 1 vs 77
(p = 0.001) (p = 0.06) (p = 0.01)
% 0 vs 5 6 vs 5 0 vs 8
macrophages (p = 0.13) (p = 0.76) (p = 0.10)
Statistics were performed with a Wilcoxon Signed Ranks test.
TNF-ot was not detectable in either group, but IL-8 rose after surfactant in both
groups. The infants that received Exosurf showed a greater rise that was statistically
significant. The percentage of the total cells that were neutrophils also rose in both
groups and at 24 hours the levels were similar. However the rise in those infants that
received Curosurf was significant at p = 0.01, whereas the rise for Exosurf did not
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Infants < 30 weeks gestation on ventilatory support in our unit showed an
inflammatory response, measured by EL-1(3 and EL-8, which rose and remained high
over the first 96 hours of life. In contrast, TNF-a was undetectable in most samples.
The cellular response in the lungs showed a neutrophil influx at 24 hours with the
neutrophils remaining the predominant cell type. Macrophage numbers also rose but
never constituted more than 15% of the total cell population.
Ante-natal steroids in recent years have become a very important treatment to
promote maturation of the lungs in utero. They also have known anti-inflammatory
properties, but had no effect on the inflammatory response in this study nor did they
correlate with an improved outcome. Infants that received steroids were equally likely
to have received surfactant and be colonised by the genital mycoplasmas, but less
likely to have had chorioamnionitis. Chorioamnionitis did not correlate with
colonisation with the genital mycoplasmas.
High IL-1|3 and IL-8 in the admission sample correlated significantly with histological
chorioamnionitis (p < 0.0001; Mann-Whitney U test), which has also been reported
elsewhere (Watterberg et al., 1996).
Infants at < 30 weeks gestation with a diagnosis of severe respiratory distress
syndrome (RDS) due to immaturity of the lungs and surfactant deficiency were given
exogenous surfactant. Around 20% of infants with RDS can be expected to develop
chronic lung disease (Verma.,1995). Infants without RDS had a significantly higher
IL-ip, IL-8, neutrophil and macrophage cell counts on admission which correlated
with chorioamnionitis. Normal lung development is under the control of
glucocorticoids which act directly at the protein synthesis level to induce surfactant
production (Gross., 1990). IL-ip can directly stimulate the production of
corticotrophin-releasing hormone (Sapolsky et al., 1987) which in turn stimulates the
production of several hormones including glucocorticoids (Bernton et al., 1987). Thus
infants in utero with chorioamnionitis may have surfactant production stimulated
earlier than those without chorioamnionitis and be less likely to have RDS. This was
also shown in a recent study by Watterberg et al 1996, though their infants with
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chorioamnionitis were more likely to developed chronic lung disease, which is not
shown in our study. Watterbergs study had small numbers, and were defining chronic
lung disease as oxygen dependence at 30 days - which others does not correlate well
with outcome (Shennan el al., 1988). In our study, of infants with chorioamnionitis,
12/15 were in oxygen at 28 days but this was not significantly different from the
non-chorioamnionitis group (p = 0.06). Only 2/14 infants went on to develop chronic
lung disease defined by oxygen dependence at 36 weeks and this was significant (p =
0.003). In our study infants that developed chronic lung disease were more likely to
have had RDS. Giving surfactant had no effect on the cytokine response at this early
stage, although there was a trend in a smaller sub-group that received Exosurf to have
a larger rise in DL-8 over the first 24 hours compared to Curosurf. The group that
received surfactant did go on to develop chronic lung disease more often than those
infants not having chronic lung disease, but this did not correlate with an
inflammatory response.
Infection with the genital mycoplasmas did not increase the early inflammatory
response in the lung nor did it correlate with incidence or severity of chronic lung
disease. The infection rate (13%) was lower compared to other clinical studies where
rates have been 17 - 30% for U. urealyticum isolated from bronchoalveolar lavage
samples (Payne el al., 1991; Wang et a/.,1988; Cassell et al., 1988). All of these
studies showed a correlation between U. urealyticnm colonisation and the
development of chronic lung disease. Ours was a relatively large study and in addition
to culture used PCR to identify U. urealyticum so this is likely to be a true reflection
of the infection rate in the unit.
As the colonisation with the genital mycoplasmas did not significantly alter the clinical
course of the infants, treatment with erythromycin could not have had any
anti-bacterial effect.
Erythromycin is readily internalised by phagocytes in an energy (Viggiano et al., 1994)
and calcium ion dependent (Rowen et al., 1995) manner, and phagocytosis of particles
increases its intracellular concentration (Santoro et al., 1995). It has been suggested
that its immune suppression is related to its internalisation which affects neutrophil
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chemotaxis (Nelson et a/.,1987; Esterley et al., 1990), elastolytic properties, (Ichikawa
et al., 1992) and apoptosis (Aoshiba el al., 1997). Preterm neonatal phagocytes have
less Fc receptors on their cell surface compared to adults (Carr et al., 1992a; Falconer
et al., 1995a) and these receptors are very important in chemotaxis and phagocytosis.
Studies have suggested that in neonates both these functions of neutrophils are
deficient (Eisenfeld et al., 1994; Falconer et al., 1995; Hill.,1987). If neonatal
neutrophils were unable to internalise erythromycin then this might explain why the
reported anti-inflammatory effects in adult airway diseases (Esterley et al., 1990;
Ichikawa et al., 1992; Oishi et al., 1994) were not duplicated here.
Our initial pilot study investigating EL-8 in the development of chronic lung disease
showed that at 24 hours postnatal age infants that later developed chronic lung
disease (defined as an oxygen requirement at 28 days) had a higher EL-8 level than
those that did not develop chronic lung disease. In this larger study group the pilot
study findings were not confirmed. Infants who did not later develop chronic lung
disease were admitted to the unit with a higher level of IL-8 and EL-1(3 which
correlated very strongly with histological chorioamnionitis. Although previous studies
have shown that isolation of U. urealyticum correlates with chorioamnionitis (Wang
et «/.,1993), it did not in our study. We did not culture the placenta for genital
mycoplasmas.
5.10 Conclusions
The early inflammatory response is not altered by infection with the genital
mycoplasmas, treatment with erythromycin or surfactant. The incidence of chronic
lung disease and its severity, as measured by alveolar arterial oxygen difference, were
also unrelated to the early pro-inflammatory cytokines, or cellular response.
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6. Cell Staining
6.1 Introduction
In chronic lung disease it has been speculated that immune cells that have migrated
from the peripheral circulation into the lung may be important in disease progression
(Ogden et al., 1984; Merrit et al., 1981). There is disagreement between studies with
some suggesting only the presence of neutrophils contributes to the outcome (Arnon
et al., 1993). The roles of neutrophils and macrophages are vastly different in the
progression of an inflammatory response with only macrophages having a role in the
development of pulmonary fibrosis.
In our samples of bronchoalveolar lavage we would expect to find epithelial and
immune type cells and possibly red blood cells depending on the degree of lung
damage. Most reported studies have used a standard differential stain to distinguish
cells based on their morphology, where mature neutrophils are easily recognised but
monocytes/macrophages are not. A recent paper (Murch et al., 1996b) has suggested
that because there is great phenotypic differences between cells of the
monocyte/macrophage lineage identification by routine staining is difficult. The use of
more specific immunocytochemical staining methods is required to establish the cell
types.
6.1.1 NeutrophilMaturation
Neutrophils differentiate in the blood marrow from precursors common to all
haematopoietic cells. They undergo six distinct developmental stages the penultimate
of which are band cells which have an unsegmented horse-shoe shaped nucleus and in
this respect they are not unlike monocytes in appearance. The last two stages are held
in a large reserve pool within the bone marrow and are normally released upon
stimulation. The band cells do not normally constitute more than 10% of the
circulating neutrophil population (Balado.,1996), but under stress and a high demand
for neutrophils a greater proportion of the cells will be less mature. Premature
newborns are particularly vulnerable to infections due to a diminished storage pool
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and this is exacerbated by their neutrophils having an impaired ability to migrate to the
site of infection (Eizioni.,1994).
6.1.2 Differential Stain
Differential staining relies on the properties of cells organelles and proteins to acquire
colour in the presence of reagents, but also requires the observer to distinguish
morphological features distinctive to cell types. Cells of the immune system can be
separated using eosin and a thiazine dye, which results in the nuclei of neutrophils
staining purple and cytoplasm staining pink. Further morphological features of
neutrophils are granules in the cytoplasm and the multi-lobed nucleus. Cells of the
monocyte/macrophage lineage stain blue in the nuclei and pale blue in the cytoplasm.
The nuclei is characteristically kidney shaped and if the cells are active, the cytoplasm
can be well spread and vacuoulated. With this stain red blood cells appear pale pink
and are characteristically non-nucleated and indented, whereas epithelial cells have a
dense blue nuclei and pale blue, well spread, smooth cytoplasm (See Photos 6.1 and
6.2).
6.1.3 Immunocytochemical Stain
Immunocytochemistry exploits the different cell surface proteins which appear
uniquely on different cell types. Each of these cell specific proteins can be targeted by
monoclonal antibodies and by coupling the monoclonal to a specific label the targeted
cell can be visualised.
There are several immunocytochemical techniques commonly used, but due to an
abundance of endogenous peroxidase in haematological preparations the
alkaline-phosphatase anti-alkaline-phosphatase or APAAP technique is the method of
choice. It can be applied in many successive layers and as such is very sensitive. It
involves the application of a primary monoclonal antibody which binds specifically to
a protein found on the surface of the target cell. A second antibody which has been
raised against the species of the primary antibody is then added and binds to the
primary antibody. The next stage adds the APAAP antibody which is the same species
as the primary antibody and to which alkaline phosphatase enzyme has been
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Photo 6-1: Differential Stain (Diff-Ouik) x 200.
Typical bronchoalveolar la\>age sample preparation with distinct cell types seen and
background mucous (Mc). Red blood cells appear small, with no nucleus or internal
structures (r). Individual cell types are difficult to distinguish at this magnification,
but some macrophages (M) and neutrophils (N) are visible.
Photo 6-2: Differential Stain (Diff-Ouik) x 400 oil immersion.
Above sample at a higher magnification. The cell morphology is more easily made
out. Macrophages/monocytes (M) clearly ha\>e darker cytoplasm and a single kidney
shaped nucleus. Neutrophils (N) have a lighter cytoplasm and multi-lobed nucleus.
The neutrophil cytoplasm looks pinker with the naked eye, the blue colour is due to a
blue filter required to take sharp pictures at this magnification.
Photo 6.1: Differential Stain (Diff-Quik) x 200.
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Photo 6.2: Differential Stain (Diff-Quik) x 400 oil immersion.
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conjugated. The APAAP antibody binds to the second antibody to create a sandwich
(See Figure 6.1). With the addition of fast red substrate red colour is produced at the
site of the APAAP sandwich and positive cells are easily recognised using light
microscopy.










Figure 6-1: Diagram of the APAAP sandwich
This staining method gives a more discriminatory method of separating cell types
which are difficult to distinguish via staining and morphology alone. It should be more
accurate and less observer dependent.
6.1.4 Cells Surface Proteins
Cells of the monocyte/macrophage can be identified by the CD68 antigen cluster
which has a molecular weight of llOkD and is probably associated with lysosomal
granules. It is distributed primarily in the monocyte/myeloid cells though it will stain
neutrophils weakly (Pulford et al., 1990).
Neutrophils display several different characteristics which allow them to be identified.
They contain a neutral protease found primarily in the azurophilic granules but which
is also present in small amounts in some human monocytes (manufacturers
specification sheet). This means there is some cross-reactivity with cells of the
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monocyte/macrophage lineage and so the anti-human neutrophil elastase antibody is
not ideal.
Sigma have recently produced a PMN-specific antibody with no known cross-reaction
to monocyte/macrophages. It detects polymorphonuclear (PMN)-specific membrane
antigens and was used when it became available.
The epithelial cells can be stained for cytokeratin, the intermediate filaments which are
associated with the cytoskeleton. However, as slide numbers were limited it was
decided to concentrate on the cells of the immune system.
The two techniques were compared to establish whether differential staining is
adequate to distinguish between cell types.
6.2 Preparation of Test Slides
A buffy coat (a white blood cell enriched pack from South East Blood Transfusion
Service, Edinburgh) was diluted 1:1 with RPMI-1640 and 25 mis carefully layered
onto 25mls of Histopaque 1077 (Sigma, Cat. No. 1077-1) in a 50 ml centrifuge tube.
This was then centrifiiged at 400g for 30 mins (Jouan) ensuring the brake was
switched off. The layer ofwhite blood cells at the interface of the Histopaque and the
plasma was carefully removed with a pasteur pipette and washed three times with
RPMI-1640. Cells were then counted and viability assessed using trypan blue
exclusion (viability > 98%).
The cell concentration was adjusted to 4 x 105 cells/ml in RPMI-1640 and lOOpl of
this was added to slides previously wiped with alcohol in the cytospin (Shandon
Cytospin 3). They were spun at 1000 rpm for 3 mins and treated as below depending
on the staining method.
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6.3.1 Materials




The slide was air dried and stained differentially by sequentially dipping the slide 5
times for 1 second each into first methanol, then the eosin and finally the thiazine dye.
The slide was washed in distilled water and left to air dry before counting 300 cells.
6.4 Immunocytochemical Staining on Test Slide
Slides were air dried overnight and then stored at -20°C with silicon gel packets to act
as a desiccant until stained.
A standard APAAP technique was used to determine the optimum primary antibody
concentration for each antibody.
6.4.1 Materials
Acid hemallum stain (see Appendix A: Solutions)
Acetone
Tris buffered saline (TBS) (see Appendix A: Solutions)
Normal human serum
Substrate (see Appendix A: Solutions)
Aquamount (BDH, Cat. No. 36626)
RPMI-1640 without phenol red (SE-BTS, Edinburgh)
Trypan blue (Sigma, Cat. No. T8154)
Second antibody: 50pl rabbit anti-mouse immunoglobulins (Dako, Cat. No. Z259) +
lOOp.1 normal human serum + 2.5 mis TBS
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Alkaline phosphatase anti-alkaline-phosphatase (APAAP): lOOpl APAAP (Dako, Cat.
No. D651) + 2.5 mis TBS
6.4.2 Primary Antibodies
Anti-CD68 (Dako, Cat. No. M718). Diluted in TBS to 1:100, 1:150 and 1:200.
Anti-human neutrophil elastase (Dako, Cat. No. NP57). Diluted in TBS to 1:200,
1:250 and 1:300
Anti-human neutrophils (Sigma, Cat. No. N1765). Diluted in TBS to 1:50, 1:100,
1:200, 1:300 and 1:400.
Control primary antibody: IgG class 1 mouse anti-human thyroid stimulating hormone
(SAPU). Diluted into TBS 1:50, 1:100, 1:200, 1:300 and 1:400.
6.4.3 Method
Slides were selected for staining and scored round the smear using a diamond pen.
They were allowed to come to room temperature for at least 10 minutes before being
fixed in acetone for 15 minutes. The slides were not allowed to dry out from this point
on and all incubations were carried out at room temperature in a humidified box.
Slides were washed in TBS and dried off round the smear. This drying step was
carried out after every wash with TBS because if the slide is too wet the antibody will
diffuse over the slide and the antibody concentration in contact with the smear will be
too low. 1OOpil of primary antibody was gently dropped onto the smear and incubated
for 1 hour. It was washed in TBS before addition of lOOpl second antibody and
incubated for 30 minutes. After washing in TBS lOOjaL of APAAP was added and
incubated for 30 minutes. Again it was washed in TBS and another 100pl of second
antibody was added and incubated for 20 minutes. The slide was washed with TBS
and lOOjul APAAP was added for 20 minutes. After washing in TBS the substrate was
filtered (Whatman Filter No.l) onto the smear and the colour development watched.
After sufficient colour development (-15 minutes) the slide was placed in running tap
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water for 5 minutes, acid hemallum for 5 minutes and then back to running water for
5 minutes before being mounted in aquamount. After 24 hours to harden it was
viewed under oil immersion and counts were made on 300 cells.
6.4.4 Results
Table 6.1 details the results for the differential stain which are approximately normal
values for a healthy adult.
The CD68 antibody results showed little difference between the three antibody
concentrations except that the 1:100 dilution was clearly the first to develop colour
and stained the strongest. The cell counts in Table 6.2 are therefore given at that
concentration. Background was low for all slides.
The neutrophil elastase antibody had high background staining at 1:100 but very little
other differences between antibody concentrations. The 1:300 dilution showed the
strongest and most discrete staining and so Table 6.2 shows results for that dilution.
The anti-PMN antibody showed cell specific staining for all slides and all slides except
the 1:50 had low background staining. The 1:100, and 1:200 dilution were too intense
and 1:400 too pale. 1:300 results are given in Table 6.2
For the control antibody (anti-TSH) no cell specific staining was seen at any of the
dilutions and this antibody will therefore be a suitable control. There is also no
endogenous alkaline phosphatase activity.
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Red 32 60 54
No Stain 78 40 46
6.4.5 Discussion
Both the neutrophil antibodies are very similar to each other and indeed to the
differential stain. This is not unexpected as these are white blood cells from healthy
donors and as such make an easy population of cells to discriminate from other cell
types. There are no immature nor abnormal cells within this population.
The differential count discriminates between lymphocytes and monocytes based on
size and these can be very difficult to distinguish. This may be why there are slightly
higher macrophage numbers using the CD-68 stain.
The two techniques measure the same on these test slides of healthy cells.
6.5 Immunocytochemical Stain vs. Differential Stain on Bronchoalveolar
Lavage Samples
Bronchoalveolar lavage samples were prepared onto cytospin slides as previously
described (see "Chapter 2 p30"), air dried for 24 hours and frozen at -20°C with
desiccant until use. Sample size for these infants are small as are cell numbers and in
many cases it was not always possible to get enough slides to do a comparison. A
minimum of four slides was required, one for differential stain, one for CD68 stain,
one for neutrophil antigens and a control stain. As the identification of
monocytes/macrophages was under dispute it was decided that if only three slides
were available after the differential stain, the CD68 antigen would be stained for and
neutrophil staining would be omitted.
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6.5.1 Materials andMethods
Both methods are as described above. For differential stain see "Method pi 19" and
for immunocytochemical stain see "Method pi20".
6.5.2 Results
Some slides did not survive the freezing process over a period of time, mostly those
that were frozen for > 2 years. This may have been due freezer breakdowns, thus
causing repeated freeze/thaws, or may be that over that period of time the cells
deteriorate naturally. Of the slides that did survive there were 60 available for CD-68
analysis and 32 available for neutrophil analysis.
Photos 6.3 - 6.7 give typical examples of each of the samples.
The results were plotted on scatter plots Graphs 6.1 and 6.2 and the correlation
coefficient (r) is given.
123
Photo 6-3: Anti-TSH antibody x 200.
Control antibody stains no cells.
Photo 6-4: Anti-CD68 x 400 oil immersion.
The cytoplasm of the macrophage stains bright red (M) compared to the unstained
neutrophils and epithelial cells (U). Mucous (Mc) contributes to the background
colour.
Photo 6.3:Anti-TSH
Photo 6-5: Anti-neutrophil elastase x 200.
This photo gives an overview ofa typical sample, where the red-stained neutrophils
are clearly distinguishable from the blue negative cells.
Photo 6-6: Anti-neutrophil elastase x 400 oil immersion.
This above photo at higher magnification shows the strongly staining red neutrophils
(N) and the unstained macrophages and epithelial cells (U). The mucous (Mc) also
stains slightly red.
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Photo 6.6: Anti-neutrophil elastase x 400 oil immersion.
Photo 6-7: Anti-PMNx 400 oil immersion.
The neutrophil (N) stains red, but the cuboidal epithelial cells are unstained (U).
Photo 6.7: Anti-PMN x 400 oil immersion.
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6.5.3 Discussion
The neutrophils methods agree well with only a few results being completely in
disagreement. On the whole the correlation was good.
The differential stain and CD-68 stain do not appear to be measuring the same cell
types and the differential stain underestimates the amount of monocytes/macrophages
present. There is a cluster of samples at approximately 60% where both methods
agree. Perhaps a clear abundance of macrophages makes them easy to recognise
morphologically. There are slides where the immunohistochemical stain would appear
to underestimate the number ofmacrophages compared to the differential stain.
6.5.4 Conclusion
The neutrophils are easily identified by differential stain but macrophage numbers are
under-estimated. The use of immunohistochemical stains in the studies of
bronchoalveolar lavage cell populations may be more accurate.
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7. Cell Culture Model of Inflammation
7.1 Introduction
The study of the inflammatory process in the lungs of preterm neonates is hampered
by many factors. Whilst it is relatively easy to sample lung effluent from intubated
neonates, the samples vary greatly in size and current methods do not allow
bronchoalveolar lavage samples to be adjusted for dilutions factors. This makes
comparison between studies difficult. We can only sample from infants that are
intubated and as infants in whom respiratory problems resolve are extubated, we do
not have an adequate control group for comparison. Infants that are intubated receive
many different clinical treatments e.g. surfactants, steroids; some of which may have a
direct bearing on the lung inflammatory response. Infants may also be infected with U.
urealyticum or colonised with other organisms. As clinical practices between neonatal
units vary it is almost impossible to produce two infants with exactly the same clinical
course and outcome. It would be useful to elaborate the lung inflammatory response
under more controlled conditions.
7.1.1 AnimalModels
Several investigators have used animal models in an attempt to standardise conditions
and treatments that may lead to the development of chronic lung disease and
(deLemos et al., 1992) recently reviewed the current animal models. Premature labour
is rare in most species except man, however rabbits, sheep, rats, baboons and guinea
pigs can all be electively delivered prematurely. Rabbits, rats and sheep cannot be
maintained successfully for prolonged periods but provide models of respiratory
distress syndrome. Newborn guinea pigs have relatively mature lungs compared to
humans with events such as differentiation and alveolarisation which occur
pre-dominantly postnatally in humans occurring prenatally in guinea pigs
(Frank., 1983). Non-human primates provide the best model as they can be maintained
for longer periods but generally recover without developing chronic lung disease.
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7.1.2 Cell BasedModels
A cell based model has many advantages over animal models. It is cheap, requires
little specialist equipment or staff and avoids any moral or ethical considerations.
There are many cell types present in the lung which are involved in the inflammatory
response. The alveolar macrophage is the most important as it regulates the response.
However fibroblasts, epithelial cells and endothelial cells which greatly outnumber
macrophages have a very important role to play in the migration of neutrophils into
the lungs, a central event in the inflammatory process. They express adhesion
molecules which facilitate the migration of neutrophils and are capable of IL-8
production.
A recent study by Stancombe et al 1993 investigated neonatal pulmonary fibroblasts
from primary cell culture and used U. urealyticum to stimulate cytokine production.
Their results showed that U. urealyticnm was stimulatory and induced the production
of IL-8 and IL-6 in a dose dependent manner.
Cells from a primary culture of premature neonatal lungs would be the ideal for an
assay, however this is not practical. It would require repeated sampling from infants
or the transformation of the neonatal cells. There are commercially available human
cell lines which are immortalised but their transformation may cause their responses to
differ from any in vivo responses. Their advantages are that they are relatively easy to
keep and obviate the need for continual sampling of neonates. Our model uses a
human lung epithelial cell line (A549).
7.1.3 A549 Cells
A549 (ATCC CCL-185) cells are human lung carcinoma cells which are
epithelial-like. They can synthesise lecithin using the cytidine diphosphocholine
pathway and have multilamellar inclusion bodies. These are characteristics of type II
lung epithelial cells, but they can not be definitively characterised as such.
Studies using A549 cells have shown that these cells can be stimulated by TNF-a,
IL-a/p, viruses and bacteria to express IL-8, IL-6, RANTES, eotaxin and ICAM-1
(Kwon et al., 1994; Smart et al., 1994; Bittleman et al., 1995; Palfreyman et al., 1997;
Arnold et al., 1996; Burkegaffney et al., 1996; Lilly et al., 1997; Arnold et al., 1994;
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Kwon et al., 1995; Mizuno et al., 1994). They do not express TNF-ot (Arnold et
al., 1994) or MlP-la (Kwon et al., 1995). The kinetics of their EL-8 response is
different to primary cultures (Kwon et al., 1994). Primary cultures produce a peak of
IL-8 at 2 hours and then a steady increase in IL-8 from about 8 hours. This second
increase is probably due to de novo protein synthesis stimulated by another factor
released from A549 cells in an autocrine manner. This second factor has not been
elucidated. A549 cells produce a peak of IL-8 at about 4 hours with no secondary
increase. The IL-8 produced from the A549 cells is much more immunoreactive than
from primary cultures which suggests that primary cells have a regulatory mechanism
which dampens IL-8 effects. Both these differences are likely related to the
transformation of the A549 cells.
7.1.4 Cidture of Ureaplasma urealyticum
U. urealyticum culture is carried out in growth medium supplemented with urea
which is essential for the organism to grow. Urease enzymes breakdown urea which
causes the pH to rise, and a colour change from orange to red. If dilutions of samples
are incubated then the titre of bacteria present can be calculated from the lowest
concentration of bacteria that causes a colour change. U. urealyticum has no cell wall
and is sensitive to pH. The rising pH or red colour, which confirms bacterial growth in
the medium, also kills the bacteria. U. urealyticum is a surface parasite, attaching via
adhesins (Henrich et al., 1993) and the cell model requires live organisms. We
therefore need to count the organisms in culture before the medium turns red. U.
urealyticum is not visible using conventional light microscopy. The most accurate
method of counting U. urealyticum is to count colonies grown in solid phase culture
which are 15-3Opm in diameter. A drop of liquid containing U. urealyticum can be
cultured on solid A7 agar and incubated anaerobically for 48 hours. The colonies
grown are black due to manganese sulphate which oxidises in the presence of U.
urealyticum. Colonies can be counted on an inverted microscope and the titre of the
specimen then calculated. This method takes 48 hours in which it is impossible to hold
the culture in stasis. The culture must be used in the stimulation experiments "blind"
i.e. without knowing the exact count of U. urealyticum until after the experiment is
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finished. By using freeze-dried vials supplied from the Public Health Laboratories
there is a good chance that reconstitution will result in counts of around 105 colony
forming units per ml which based on other results (Stancombe et al., 1993) should be
adequate for our experiments.
The aim of the following experiments was to further investigate the production of
DL-8 from lung epithelial cells. The role of U. urealyticum and another genital isolate
of E. coli on IL-8 production was investigated. The high oxygen concentrations an
infant is subjected to by ventilation is thought to increase the level of oxygen radicals
(Zimmerman., 1995; review) which are thought to cause tissue damage. Premature
infants have reduced anti-oxidant enzyme defences so this tissue damage goes
unchecked. Experiments investigating the stimulation of A549 cells cultured in a high
concentration of oxygen were included to assess its effects on epithelial cells. In
clinical practice infants receive surfactants, antibiotics and steroids and as these may
have a direct effect on the IL-8 produced from lung epithelial cells these were also
investigated.
7.2 Cell Culture Methods
7.2.1 Materials
75 cm" flasks (Costar, Cat No. 3376)
PBS (Life Technologies, Cat. No. 14190094)
Trypsin-EDTA (Life Technologies, Cat. No. 45300019)
DMEM (Life Technologies, Cat. No. 22320-022)
Fetal bovine serum (FBS) (Life Technologies, Cat. No. 10108-074)
L-glutamine (Life Technologies, Cat. No. 25030-032)
Penicillin/streptomycin (Life Technologies, Cat. No. 15070-022)
Dimethyl Sulphoxide (DMSO) (Sigma, Cat. No. D-2650)
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Growth Medium (GM)
DMEM + 10% FBS + 2mM L-glutamine + 100U penicillin/streptomycin
Cell FreezingMedium (CFM)
DMEM + 10% FBS + 2mM L-glutamine + 100U penicillin/streptomycin + 1%
DMSO
7.2.2 A549 Cell Line
All cell culture was carried out in a class II hood under sterile aseptic conditions. The
cells were grown in an Heraeus incubator at 37°C with humidity and 5% CO2. A549
cells were a gift from the Rayne Laboratory, Edinburgh University and were supplied
as a living culture. The cells were cultured in 12.5 mis growth medium (GM) in 75
cm3 flasks and split when confluent, approximately twice weekly. When confluence
was reached the GM was removed and replaced with 12.5 mis sterile PBS and washed
for 2 minutes. This was discarded and the cells were incubated with 5mls
trypsin-EDTA at 37°C until the cells had become dislodged. 20 mis ofGM was added
to inactivate the trypsin. The resulting mixture was poured into a labelled 50 ml
centrifuge tube and spun at 200g (Sigma 6K10) for 10 mins at room temperature. The
supernatant was discarded and the cell pellet resuspended by first gently flicking the
bottom of the tube and then adding 5mls GM. This wash step was repeated twice. 1ml
was added to the new flasks containing 12.5 mis GM. These were incubated at 37°C
until confluent and the process repeated.
7.2.3 Storing Cells in LiquidNitrogen
For long term storage the cells must be kept in liquid nitrogen. Cells were trypsinised
and spun down as described above. They were counted and resuspended in freezing
medium (See "Appendix A pi76) to a cell suspension of 2 x 106 - 8 x 106 cells/ml.
They were then aliquoted into 1ml cryotubes and frozen at -70°C overnight. The
following morning they were transferred to liquid nitrogen and stored until revival.
Revival was performed by pre-warming GM to 37°C. The cryotube was removed
from liquid nitrogen and the temperature rapidly raised to 37°C in a water bath. Once
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the pellet could be dislodged from the cryotube it was transferred to a flask containing
12.5 mis of pre-warmed GM and left overnight at 37°C, 5% CO2. The next day the
medium was removed and replaced with fresh GM and the cells maintained as before.
7.3 Bacterial Culture Methods
7.3.1 Materials
Nutrient Broth (NB) (South East Blood Transfusion Centre, Edinburgh)
Bacterial Freezing Medium (BFM) - Nutrient broth + 10% glycerol
Urea-arginine LYO broth (UAL) (bioMerieux, France Cat. No. 42 504)
A7 solid agar plate (bioMerieux, France Cat. No. 43 003)
7.3.2 Eschericia coli Culture
A clinical genital isolate of Eschericia coli (E. coli) was streaked onto a blood agar
plate. It was inoculated into 200 mis NB and incubated for 24 hours at 37°C with
constant shaking. The culture was then spun at 3000g for 5 mins and the supernatant
discarded. The pellet was resuspended in 20ml freezing medium and the culture was
checked for purity both by Gram-stain (See "Section 7.3.3: Gram Stain for Purity")
and blood agar (See "Section 7.3.4 Blood Agar Test for Purity"). The bacterial cell
concentration was counted and adjusted to 1 x 1010 cells/ml and 1ml aliquots were
frozen at - 70°C until use. Viability was assessed weekly to ensure the cultures had
survived freezing.
7.3.3 Gram Stain for Purity
A 5-1 Opil drop of culture was placed onto a glass slide and allowed to air dry before
being passed through a naked flame. The slide was flooded with methyl violet for 1-2
mins and rinsed off with tap water. The slide was flooded with iodine for 1-2 minutes
and the excess drained off. The slide was flooded with acetone for 10 seconds and
washed immediately with tap water. Finally, the slide was flooded with basic fuschin
for 30 seconds, rinsed in tap water and blotted dry. The slide was viewed under oil
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immersion at x400 magnification. Red cells are Gram positive, purple are Gram
negative.
7.3.4 BloodAgar Testfor Purity
A sterile metal loop was used to place a small drop of culture onto a blood agar plate.
The loop was flamed and then used to streak the culture in three straight lines across
the plate. The loop was flamed again and at the end of those three lines streak three
more straight lines were streaked across the plate. This process was repeated once
more until the plate boundary was completely covered in streaks. The plate was
incubated overnight at 37°C and checked for purity.
7.3.5 Viability Count
Four concentrations of each culture were made in NB. Five 1 Opil aliquots of each
dilution were then dropped onto blood agar plates and allowed to air dry before being
transferred to a 37°C incubator. They were incubated overnight and the colonies in
each drop were counted and averaged over the five aliquots.
7.3.6 urealyticum Culture
U. urealyticum was obtained as a freeze dried sterile culture from the NCTC
(National Collections of Type Cultures, The Public Flealth Laboratory Service, UK,
Cat. No. 10177). It was reconstituted in 3 mis of UAL and the colony forming units
counted (See below). However, as this process takes 48 hours to gain an accurate
count the reconstituted culture was used in the stimulation assay, and a retrospective
count of colony forming units was taken.
Colony Forming Units (CFUs)
To estimate the CFU 3 x 20(j.l of reconstituted freeze dried vial was cultured on solid
A7 agar and incubated anaerobically for 48 hours. Anaerobic environment was
generated using CampyPak™ Microaerophilic system (Becton Dickinson) which
produces an atmosphere of 5 to 12% carbon dioxide and a residual atmosphere of 5
to 15% oxygen.
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The colonies are black due to manganese sulphate which oxidises in the presence of
U. urealyticnm. Five random fields of view were counted in each of the 20pl drop
using an inverted microscope at xlOO and the counts averaged. The titre of the
specimen is then calculated using the formulae supplied by bioMerieux shown in Table
7.1.
Table 7-1: Calculation of U. urealyticum Titre
Colonies per field Titre of specimen
(CFU)
< 1 io3 ;
1 - 5 104
5 - 15 105
> 15 106
7.4 InterIeukin-8 Measurements
This was the radioimmunoassay as described in Chapter 3 p60. Samples were tested in
triplicates.
7.5 Assay Constituents Concentrations
7.5.1 Tumour Necrosis Factor - a
A549 cells were plated out as per 7.6.2 in a 96 well plate at 2 x 105 cells/ml. TNF-a
(NIBSC, batch 87/650) was diluted in AsM from 2500 pg/ml to 0.15 pg/ml (100
IU/ml to 0.006 IU/ml). 50pl of each dilution was incubated triplicate wells and the
resultant supernatants assayed for EL-8 production. Wells containing no TNF-a were
also included in the assay.
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Results andDiscussion
The raw data are given in Table 10-20, Appendix B. The first four dilutions of TNF-a
were above the highest value on the standard curve and so were not plotted on Graph
7.1. All concentrations ofTNF-a above 7.81pg/ml gave a significantly increased IL-8
response from the A549 cells (students T test). To increase the IL-8 response
marginally and not maximally TNF-a was used at 32 pg/ml (1.28 IU/ml) in
stimulation assay, which gives approximately a doubling of the IL-8 response from the
cells alone.
7.5.2 Antibiotics andDexamethasone
It is difficult to establish an in vitro dose to use that is relative to the clinical dose. It
was therefore decided to use a high, medium and low dose of these constituents,
namely lOpg/ml, 1 pg/ml and lOOng/ml, with 50 pi added to each well.
7.5.3 Surfactants
Exosurf and Curosurf were too expensive to buy and our pharmacy had none spare.
On administration to an infant there is usually 1-2 mis left in a vial and this was
collected over successive days, pooled and stored at 4°C until use. Both surfactants
are reconstituted to different amounts of the active constituent
dipalmitoylphospatidylcholine (DPPC); Curosurf has 80 mg/ml and Exosurf has 13.5
mg/ml. However they are administered differently and it was decided to keep DPPC
levels of each of the surfactants the same. As high concentrations of Exosurf can be
toxic to cells (Findlay et al., 1995) both surfactants were used at 500ng/ml, 50ng/ml
and 5ng/ml DPPC, with 50 pi added to each well.
7.5.4 Bacterial Cell Concentrations
E. coli was used at three concentrations 1 x 108, 1 x 106 and 1 x 104 E. coli/ml diluted
in AsM. U. urealyticum was more difficult to calculate due to the retrospective nature
of the CFU count. In general reconstituting a vial of freeze-dried U. urealyticum
resulted in about 106 CFU/ml. This was diluted in 20 mis of AsM to give roughly a
final concentration of 5 x 105 CFU/ml in 3 mis UAL. This was further diluted to 5 x
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104 and 5 x 103 in assay medium (see below). Each assay with U. urealyticum gives
the exact CFU count.
7.6 Stimulation Assay Development
7.6.1 Materials
Gentamicin (Sigma, Cat. No. G1272)
Erythromycin (Sigma, Cat. No. E-5389)
Dexamethasone (Sigma, Cat. No. D2915)
Curosurf (Serono, Italy)
Exosurf (Wellcome Burroughs)
96-well culture plates (Costar, Cat. No. 3599)
AssayMedium (AsM)
DMEM + 10% FBS + 2mM L-glutamine
Fetal Bovine Serum
Fetal bovine serum (FBS) contains proteins and growth factors essential for cell
growth in culture. It may also stimulate IL-8 production from A549 cells. At the
beginning of the assay development several samples of batches were obtained from
Life Technologies and were incubated with the A549 cells for 24 hours. The IL-8
levels were compared to unstimulated cells and a batch of FBS which produced no
increase in IL-8 was used throughout all of the following experiments.
7.6.2 Plating Cells ontoMicrotitre Plates
The cell monolayer in each well should be ~ 90% confluent and 2 x 105 cells/ml was
found to be that on visual examination of several experiments (results not shown).
The cells were trypsinised as before and washed three times in DMEM before being
resuspended into 5 mis GM. The cell number was counted in a haemocytometer and
then adjusted to 2 x 105 cells/ml. lOOpl was added to each well of a 96-well culture
plate and the cells were left to adhere overnight at 37°C. The GM was removed by
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aspiration and the cells were washed in 100|al/well of PBS which was aspirated before
stimulation.
7.6.3 Microlitre Plate Layout
All plates were laid out in the same way as shown in
Figure 7-1. All constituents were added at 50p.l per well. Wells were made up to a
final volume of 200pl using AsM and the plates were incubated for 24 hours either in
an oxygen enriched atmosphere as described in
Figure 7-2 or at 37°C with 5% CC^in an Heraeus incubator.
Figure 7-1: Plate layoutfor all constituents in the stimulation assays.








To generate an oxygen enriched atmosphere an airtight box was connected to an inlet
and outlet through which oxygen gas could be passed (
Figure 7-2). The box was filled with oxygen and once the oxygen monitor read 80%
the box was sealed and incubated for 24 hours at 37°C. The oxygen levels in the box
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were measured after 24 hours incubation and were generally between 30 - 40 %
which is significantly above room air concentration.
Figure 7-2: Schematic of the box used to provide an oxygen enriched atmosphere in




For each bacterium three stimulation assays were performed using identical plate
layouts. Each bacterium was therefore stimulating A549 cells in the presence or
absence of TNF-a; with three different concentrations of antibiotic, surfactant or
steroid; in CO2 or an oxygen enriched environment.
Each bacterium with one of the mediators was set up exactly the same on six plates on
one day; three plates were incubated in the Heraeus incubator at 37°C with 5% C02
and three plates were incubated at 37°C in the oxygen enriched atmosphere. All six
plates were incubated for 24 hours. lOOpl was removed from each well taking care
not to dislodge any cells on the bottom of the microtitre plate and frozen at -20°C
until IL-8 assay.
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7.8 Statistical Analysis
The EL-8 values were averaged for the three plates and a multi-factor analysis of
variance was performed on the logarithms of the IL-8 values. The main factors were
TNF-a, oxygen, bacterial cell concentration and mediator concentration and these
were tested for main effects. Two-way and three-way interactions between the main
factors were also explored. Further analyses were t-tests.
The p values for the ANOVA are given in Table 7.2 for U. urealyticum and in Table
7.3 for E. coli. Graphs for all the data follow the results tables and results and
discussion starts on pagel58.
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7.9 Results and Discussion
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The problems of culture of U. urealyticum make this assay which requires live
organisms difficult to set up. U. urealyticum is sensitive to pH due to its lack of a
rigid cell wall. As a culture grows the pH of the culture medium rises which requires
that cultures must be harvested before a fatal rise in pH has occurred. This timing is
very difficult to establish and indeed there is considerable variation between cultures.
The second problem is that these organisms are not visible using a light microscope
due to their size. To estimate numbers they must cultured on solid agar and the
colonies at 15 - 30pm can be counted using an inverted microscope. This process
takes 48 hours during which time it is not possible to keep U. urealyticum cultures in
stasis. The cultures must therefore be used without knowing the number of organisms
present.
Three batches of U. urealyticum were grown U. urealyticum at different times and
used to stimulate the A549 cells without knowing the number of CFU present. The
first batch was used in the erythromycin and gentamicin experiments and yielded a
concentration of 2.4 x 104 CFU/ml. The second batch used in the CurosurfTExosurf
experiments yielded 8 x 105 CFU/ml and the third batch used in the dexamethasone
experiment yielded 1.5 x 105 CFU/ml. From Table 7.2 it is clear that U. urealyticum
stimulates EL-8 production at > 105 CFU/ml as there was a significant main effect
(p<0.001) for Exosurf, Curosurf and Dexamethasone, but not for erythromycin and
gentamicin experiments. Graph 7.2 shows 105 CFU/ml produces an increase in IL-8 of
35% compared to when no U. urealyticum is present and this is significant at p =
0.03, t-test.
It was not possible to repeat the erythromycin and gentamicin experiments because of
time constraints.
There was a significant main effect of E. coli concentration as shown in Table 7.3 in
all experiments. E. coli can be frozen at -20°C until use and so the same bacterial
concentration and batch was used in each experiment. Graph 7.3 is the average EL-8
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stimulated from controls in all experiments and shows that at 108 E. coli/ml less IL-8
was stimulated than at 106 bacterial/ml from A549 cells. 108 E. coli/ml caused the
A549 cells in culture to round up and detach from the surface of the cell culture flask
which was visible under the inverted microscope. Such an overwhelming
concentration of bacteria at 108 bacterial/ml probably out competed the A549 cells for
the available nutrients causing the cells to detach. At 106 bacterial/ml there was an
approximate doubling of the IL-8 response which was statistically significant (p =
0.0002) and at 104 bacterial/ml very little difference was seen compared to the control
and this was not significantly different from the control.
Previous studies of lipopolysaccharide (LPS) have shown it is less stimulatory than U.
urealyticum for IL-8 production from lung fibroblasts (Stancombe el al., 1993). The
results presented here are from whole live organisms, although LPS is a component of
the outer cell wall of these organisms. This may account for their ability to stimulate
greater IL-8 concentrations compared to U. urealyticum in these experiments. It is
also possible that had we been able to culture greater numbers of U. urealyticum then
IL-8 levels would have been comparable to those stimulated by E. coli.
In nearly all assays TNF-a has a significant main effect, raising the IL-8 response.
Graphs 7.4 and 7.5 are, respectively, IL-8 values averaged for the higher batch of U.
urealyticum and for all E. coli experiments. Although the differences are only marginal
this was deliberate. A higher dose of TNF-a would have stimulated IL-8 maximally
and prevented any synergisitic effects between assay components from being
investigated.
Oxygen also has a significant main effect in all assays. Graphs 7.6 is the EL-8 values
for the more concentrated U. urealyticum batch averaged for all controls, and 7.7 is
the IL-8 values for all the E. coli assays averaged for all controls. Oxygen
concentration generally reduces the IL-8 response, though the degree to which it does
this varies between assays. A previous study (Stancombe et al., 1993) had shown that
lung fibroblasts were unaffected by high oxygen concentration alone. The medium
A549 cells grow in maintains its buffering capacity in a 5% CO2 atmosphere. Without
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this CO2 the medium cannot maintain a steady pH. The cells may be affected by the
high oxygen concentration and low pH and be responding with a reduced level of
EL-8. Stancombe et al 1993 also demonstrated that U. urealyticum in the presence of
high oxygen stimulated a greater IL-8 response than U. urealyticum alone. These
results are not repeated here.
The presence of TNF-a in a high oxygen concentration increases or has no effect on
the IL-8 response compared to when the cells are stimulated by oxygen alone. Graphs
7.8 and 7.9 are, respectively, EL-8 values averaged for the higher batch of U.
urealyticum and for all E. coli experiments. Whatever mechanism causes a reduction
of IL-8 production in high oxygen it is partially overcome by the presence of TNF-a.
There were no synergistic effect of oxygen and TNF-a.
The various clinical treatments these infants may receive in the course of their stay in
the unit may have a direct bearing on the lung inflammatory response. A549 cells
were cultured with E. coli or U. urealyticum in the presence of antibiotics, surfactants
and steroids and the effect on the production of IL-8 investigated. The following
discussion of the effects of mediators concentrates on the bacterial concentrations
that were stimulatory i.e. 105 CFU U. urealyticum/ml and 106 E. coli/ml.
Erythromycin is an antibiotic effective against the genital mycoplasmas, but not
against E. coli. It is effective in adult chronic airway diseases (Sawakai et al., 1986;
Kudoh et al., 1987) where it has also been shown to play an anti-inflammatory role. It
can reduce neutrophil chemotaxis (Nelson et al., 1987; Esterley et al., 1990),
elastolytic activity (Ichikawa et al., 1992) and phagocytosis (Hand et al., 1990),
probably by blocking the mobilisation of calcium ions in the cells. It may also perturb
cAMP intracellularly and promote neutrophil apoptosis (Aoshiba et al 1997) so
neutrophils commit suicide before any damage can be done.
161
Chapter 7: Cell Culture Model ofInflammation
Erythromycin had a significant main effect in the U. urealyticum experiment but did
not in the E.coli experiment, which suggests for the U. urealyticum experiment at
least, its presence affected the IL-8 response.
The stimulation experiments with erythromycin used a batch of U. urealyticum which
was too low in concentration to produce an increase in IL-8 production from the
A549 cells. The EL-8 values in Graph 7.10 are therefore averaged for all bacterial
concentrations as this factor did not influence IL-8 values. The curve does rise over
the erythromycin concentrations, but these differences are not significant from the
control in a t-test. There are no other significant interactions of erythromycin and any
other factor in either experiment.
Given that erythromycin is effective against U. urealyticum it would have been useful
to have had a culture ofU. urealyticum that had provoked an inflammatory response.
This would have allowed for analysis of the effect of erythromycin on the production
of IL-8 in the presence ofU. urealyticum.
Gentamicin had a significant main effect in both experiments. The raw data is in
Tables 10.22 and 10.27. The same batch of U. urealyticum was used in these
experiments as for the erythromycin experiments so no stimulation of IL-8 response
above control levels was seen. Graph 7.11 has the IL-8 values averaged over the
different bacterial concentrations as this did not affect IL-8 levels. Gentamicin appears
to inhibit the IL-8 compared to controls. However one plate in the triplicate for the
controls produced twice the amount of EL-8 as the other two and skews the result.
This is reflected in the much higher standard error of the mean in these groups (shown
as bold in 10.22, Appendix B). There is a main effect seen with gentamicin (p =
0.005), and three other significant interactions, but because of the one skewed result
the controls seem very high compared to when gentamicin is present. When this one
result is excluded from the analysis there is a no difference between controls and when
gentamicin is present.
As gentamicin is not active against U. urealyticum it would have been unlikely to have
had any major effect, but we can not rule this out, due to the lack of stimulation of IL-
8 at this U. urealyticum concentration.
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Gentamicin can be effective against E. coli and this particular isolate was known not
to be gentamicin resistant. As expected it reduced the IL-8 response in a
dose-dependent manner at 106 E. coli/ml, shown in Graph 7.12, presumably by
preventing E. coli growth and lowering the number of bacteria in culture that could
stimulate the cells. In the gentamicin experiment the IL-8 levels at 108 bacterial/ml
were higher than at 106 bacterial/ml (results not shown). This would seem to confirm
that at 108 bacterial/ml there are just too many organisms, but that gentamicin can
prevent their multiplication to the extent that the cells get enough of the available
nutrients to survive. There was no synergy between gentamicin and TNF-a or oxygen
and no other significant interactions.
Surfactant is given intratracheally i.e. directly into the site of the inflammation
whereas antibiotics are given systemically. In the surfactant experiments the U.
urealyticum batch was concentrated enough for stimulation of the A549 cells.
Both surfactants had significant main effects in both experiments. In the U.
urealyticum experiments both surfactants had p < .001. Graphs 7.13 and 7.14 are
respectively Exosurf and Curosurf concentrations for 103 CFU U. urealyticum/ml.
Both surfactants are inhibitory in a dose dependent manner with Exosurf showing a
stronger inhibition than Curosurf at 500ng/ml. When Exosurf is compared to Curosurf
in a separate ANOVA the trend of inhibition by Exosurf is stronger than that of
Curosurf (p > 0.001).
The degree of significance in the E. coli experiments is less than the U. urealyticum
experiments and the data is plotted in Graphs 7.15 and 7.16. There is a trend towards
inhibition with Exosurf but this does not appear to be true of Curosurf. None of these
differences are statistically different from the control which is probably due to the
greater variability between plates for this set of assays. It seems unlikely that the
difference between the U. urealyticum experiments and the E. coli experiments reflect
that Exosurf works differently in the presence of the different bacteria. If this was the
case then the controls without bacteria would both show the same results. Graphs
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7.13 to 7.16 all have the IL-8 values in the presence of the varying surfactant
concentrations without bacteria. In the U. urealyticum experiments there is inhibition
even when U. urealyticum is not present, but in the E. coli experiments there is no
IL-8 inhibition. The surfactants are acting differently especially at the highest Exosurf
concentration. This may be due to experimenter error, which is always a problem with
any assay and if time had permitted this experiment would have been repeated.
The highly significant inhibition by Exosurf in the U. urealyticum experiments is not
surprising as surfactant lipids have an immunosuppressive role in vivo (Shimizu et
al., 1988) directed against the alveolar macrophage. The two hydrophilic proteins
SP-A and SP-D are immunomodulatory facilitating macrophage phagocytosis by
opsonisation of inhaled particles (Malhotra et al., 1993) and bacteria (Lim et al., 1994;
Kalina et al., 1995). They stimulate proinflammatory cytokines (Eizioni.,1994) and
oxygen radicals from alveolar macrophages (van Iwaarden et al., 1992) and have been
suggested to scavenge LPS which may be important in the prevention of septic shock
(Creuwels et al., 1997).
The two surfactants produce different inhibitory responses in the U. urealyticum
experiments. Both are dose-dependent but Curosurf, which is a natural porcine
derived surfactant, barely reduces the IL-8 produced even at high DPPC
concentrations. Exosurf, the synthetic surfactant on the other hand reduces the IL-8
response by more than half at the equivalent concentration of DPPC. The two
surfactants have quite different components. Curosurf has the natural proteins that are
associated with surfactant in vitro, whereas Exosurf has only synthetic components
which mimic the surface spreading activities of the proteins.
As the lipids are inhibitory and the proteins immunomodulatory it is not surprising
that the surfactant with no proteins should produce a significantly larger inhibition of
the IL-8 response. As the importance of the epithelial cell response in recruitment of
the neutrophils into the lung has now been established the effects of surfactant on the
epithelial cells would be worth further investigation.
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Dexamethasone is an anti-inflammatory which binds to a specific TATA sequence on
DNA and prevents transcription of EL-8 mRNA (Kwon el al., 1994). In both the U.
urealyticum and E. coli experiments it had a significant main effect at p < 0.001.
Graph 7.17 shows that as expected it abolished the stimulated IL-8 response in a dose
dependent manner. It also reduced the constitutive response from A549 cells.
7.9.1 Further Study
Further study is definitely required to establish further the effect of these important
clinical treatments on other aspects of the epithelial cells role in the inflammatory
response. Epithelial cells whilst abundant in the lung and important in the progression
of chronic lung disease are not the only cell type involved. Coincubation with
monocytes, macrophages and neutrophils would give a fuller picture of the effect of
the clinical treatments. A549 cells have been used in experiments to investigate
neutrophil migration across the epithelial membrane (Smart et al., 1994; Bittleman et
al., 1995). These cells express ICAM-1 on their surface (Arnold et al., 1996), an
important molecule which mediates the migration of neutrophils via their LFA-1
integrin. Neutrophil recruitment is an early event in RDS, and important in the
progression to chronic lung disease. The effect of these clinical treatments on this
event would be very important especially as erythromycin is thought to prevent
neutrophil migration into the lungs in adult airways disease. Ideally further study
would also involve neonatal cells, and premature ones where possible. Their responses




Chronic lung disease of prematurity is a major cause ofmortality in infants born <30
weeks gestation. The immaturity of the lung, structurally and biochemically, accounts
for many of the problems faced by these infants. The highly compliant chest wall is
inadequate to generate sufficient pressure for inflation. The lung has less terminal
airspaces, a thick respiratory membrane and higher lung fluid levels, and there is little
or no surfactant or anti-oxidant enzymes until approximately 32 weeks gestation. This
causes a high surface tension within the lung and the build up of toxic oxygen radicals,
both ofwhich result in damage.
Birth at < 30 weeks gestation usually requires ventilation and high oxygen
supplements for survival. These contribute to increased barotrauma and toxic oxygen
radicals which result in direct tissue damage and the onset of an inflammatory
reaction.
The inflammatory response has increasingly been recognised as vital in the
progression of chronic lung disease. These infants do not present with an
inflammatory response at birth, although there has been recent speculation about in
utero inflammation (Ghezzi et al 1997), but it is evident within hours by the presence
of activated neutrophils and monocytes and increased levels of cytokines. Most
studies use bronchoalveolar lavage to measure cells and cytokines but this has proven
difficult to standardise. The technique itself involves squirting saline down the
endotracheal tube into the lung and aspirating the fluid by suction. There is no one
standard protocol between neonatal units and there is no current way of estimating
the dilution of the epithelial lung fluid by the saline. None of the proteins so far used -
urea, albumin, secretory component of IgA - have been shown to be accurate. They
are affected by the inflammatory response and the damage to the epithelial lining
caused by barotrauma and enzymic degradation. Clearly a marker of dilution would be
advantageous, but so far no one protein has proven reliable.
The lack of a control group also poses problems of interpretation. Infants that are
intubated at birth but which subsequently do well are weaned from the ventilator as
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soon as possible. We have no indication of the cytokines and cells involved in the
resolving inflammatory response.
Comparisons between studies have therefore been complicated but almost all studies
have shown high levels of locally produced cytokines and cellular infiltrates.
With the understanding of the role of inflammation in the development of chronic lung
disease, studies have been directed at defining the cytokines involved and the role of
the infiltrating cells. Early studies of inflammatory mediators in at risk infants showed
elevated levels of fibronectin (Watts et al., 1992b), TNF-a (Murch et al., 1992) and
IL-6 (Ng.,1993) associated with the development of chronic lung disease. The role of
neutrophils was established by Merrit et al (1981), who classified the polymorphs and
monocytic cells and recorded that they might have been characteristic of different
stages of the disease. Subsequent studies of cellular infiltrates showed that neutrophils
were the predominant cell types (Ogden et al., 1984; Arnon et al 1993) and it was
suggested that neutrophils were the only cells involved in the pathogenesis of chronic
lung disease (Arnon et al 1993). Macrophages were not seen early in the
inflammatory but in resolving cases of RDS and were linked to an eventual "good"
outcome.
IL-8 belongs to the a-chemokine family which are specific chemoattractants for
neutrophils. It was therefore unsurprising that it was discovered in bronchoalveolar
lavage samples of patients with adult respiratory distress syndrome (ARDS) (Donnelly
et al 1993) a disease characterised by an infiltration of neutrophils into the lung. What
was interesting was that it was evident in patients 48 hours before they developed
ARDS and not in a control group. This suggested that cytokines may predict the
development of disease in at risk groups.
Given that the classical view of neonatal chronic lung disease is an infiltration of
neutrophils into the alveolar spaces we conducted a pilot study to establish if IL-8 was
detectable in at risk infants (<30 weeks) and if it was of predictive value for those
infants that later developed chronic lung disease. 26 infants were enrolled and IL-8
167
Chapter 8: Discussion
was measured using a radioimmunoassay on admission to the unit and for 72 hours
after birth. There was a significantly higher IL-8 level at 24 hours in the group that
later went on to develop chronic lung disease. This early rise in IL-8 confirmed that
the inflammatory response was provoked almost immediately and that we may have
been able to predict the infants that were to progress to chronic lung disease. It also
gave rise to the hope that early intervention with anti-inflammatories may prevent the
further long term chronic inflammation. Current treatment for chronic lung disease is
steroids which are anti-inflammatory but also have serious side-effects. The ability to
identify a sub-group 24 hours after birth of the at risk infants who would likely
develop chronic lung disease would allow the administration of anti-inflammatories to
the group most likely to benefit, without exposing unnecessarily the group that were
unlikely to develop chronic lung disease. This would a major benefit in the care of
severely preterm infants.
Studies in the mid-90s continued to show an array of inflammatory cytokines that
were present in the lungs of ventilated neonates immediately after birth. IL-ip (Jones
et al., 1996; Liau et al., 1996), IL-6 (Bagchi et al., 1994), IL-8 (Jones et al., 1996) and
MlP-la (Murch et al., 1996b) were all found to be higher in infants with RDS
compared to those without. The persitence of soluble ICAM-1 (Kotecha et al., 1995;
Silver et al., 1996), TNF-a (Murch et al., 1992; Bagchi et al., 1994), IL-8 (Groneck et
al., 1994a; Kotecha et al., 1995a), C5a (Groneck et al., 1994a), IL-lp (Murch et
al., 1996b) and MEP-la (Murch et al., 1996b) was correlated to the development of
chronic lung disease. However none of these were of predictive value early on. The
role of anti-inflammatory cytokines was also investigated with IL-10 shown to be
undetectable within the first 96 hours of life in preterm infants, but present in term
infants (Jones et al., 1996). Neonatal phagocytes have been shown in vitro to be
functionally deficient (Hill., 1987;) and after birth require time to mature and acquire
normal functions (Bellanti., 1979; Usmani et al., 1991; Carre et aL, 1992). The
persistence of inflammatory mediators may be due in part to a defect in the regulation
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of the inflammatory responses by preterm neonates who are unable to down-regulate
the inflammatory response leading to tissue damage and chronic lung disease.
In ARDS a recent study has suggested an imbalance between the matrix
metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs)
(Ricou., et al 1996). These are important in the maintenance of lung architecture and
in the repair of damaged tissue. Their imbalance may lead to increased turnover of
ECM during disease and play a role in disordered tissue remodelling. This is an area
for future research and may lead to new discoveries in the regulation and development
of neonatal chronic lung disease.
The role of the macrophage in chronic lung disease has been disputed. Macrophages
have an essential role in fibrosis (Kovacs., 1991) and are therefore likely to be
involved early on in the inflammatory response. This was shown by Murch et al 1996b
when they used cell surface markers to identify the macrophage populations present in
bronchoalveolar lavage samples. Most studies to this point had used differential stains
to discriminate between cell types, but this makes identification of the heterogeneous
monocyte/macrophage population difficult. This was confirmed by investigating the
bronchoalveolar lavage samples obtained in the clinical studies and performing both
differential stain and immunohistochemistry. The differential stain significantly under¬
estimated the number ofmacrophages present.
Macrophages and their products promote the development of fibrosis by stimulating
fibroblast proliferation and the accumulation of connective tissue. Their early presence
suggests that this process is being initiated rapidly and that early intervention in at risk
infants may prevent the development of chronic lung disease.
The role of the genital mycoplasmas in the initiation and sustained provocation of the
inflammatory response within the lungs has yet to be clearly defined. The genital
mycoplasmas M. hominis and U. urealyticum are common vaginal organisms of
pregnant women and are transmitted vertically during birth (Sanchez., 1993). These
organisms are capable of provoking an inflammatory response in vitro (Stuart., 1993;
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Quentmeier et al., 1990; Sugama et al., 1990; Stancombe et al., 1993) and in vivo
(Groneck et al., 1994b; Groneck et al., 1996). During an infants treatment in the
neonatal unit they are not cultured for routinely and are not susceptible to the
commonly administered antibiotics penicillin or gentamicin. If an infant is colonised
these organisms are not being eradicated and they may be contributing to the early
inflammatory response as well as to the ongoing inflammatory response in infants that
later develop chronic lung disease.
Several recent studies have found a strong association between colonisation with the
genital mycoplasmas in the lung of preterms and the development of chronic lung
disease (lies et al., 1996b; Wang et al., 1993b). A causal relationship however, has not
been established. Groneck et al (1994b & 1996) showed that colonised infants had
higher levels of IL-8, IL-1{3 and IL-6 though they did not correlate this with outcome.
Erythromycin is effective in the treatment of the genital mycoplasmas and the drug of
choice in neonates. It is effective in adult chronic airways disease where a neutrophil
influx is also important in disease progression (Sawakai et al., 1986; Kudoh et
al., 1987). However it is thought to be acting as an anti-inflammatory in these patients
by reducing neutrophil activity and recruitment into the lungs (Ichikawa et al., 1992;
Nelson et al., 1987; Esterley et al., 1990).
A randomised, clinical trial of erythromycin was carried out which would allow us to
assess;
i) the level of infection in at risk babies
ii) the effect of the genital mycoplasmas on the early inflammatory response
iii) the effect of an antibiotic effective against the genital mycoplasmas on the early
inflammatory response
iv) the effect of erythromycin on the early inflammatory response
v) how all of the above factors related to an outcome of chronic lung disease.
Although the trial ran for nearly two years we were unable to recruit our target
number of infants. This was most likely due to changes in prenatal management of
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mothers threatening preterm labour compared to our two pilot studies. Any mother
admitted with the risk of premature labour was given steroids to promote the
maturation of the foetal lungs in utero. Corticosteroids stimulate surfactant
production, improve lung compliance and decrease the risk or respiratory distress
syndrome. Infants are therefore less likely to require ventilation and this may have
reduced the number of infants available for our study. Only 9 babies (13%) were
infected compared to 30% in the pilot study and as the study used PCR to determine
U. urealyticum infection this was likely to be a true reflection of the infection rate.
This made analysis of the data in the infected infants difficult. There was no difference
in the early inflammatory response between infected and uninfected infants. There was
also no difference between infants treated with erythromycin and the control group.
Erythromycin is known to be phagocytosed by neutrophils and is thought to promote
apoptosis (Aoshiba et al 1997), the controlled suicide of cells. In this way it may
prevent neutrophils from causing tissue damage. In vitro studies have shown that
neutrophils from premature infants are functionally immature (Hill., 1987; Eisenfeld et
al., 1994; Santos et al., 1993), with a greatly reduced ability to phagocytose (Falconer
et al., 1995b). This may prevent them from internalising erythromycin and explain its
apparent lack of any anti-inflammatory effect.
In this study infection with the genital mycoplasmas did not correlate with the
development of chronic lung disease, nor did it influence the severity of that lung
disease as measured by arterial-oxygen differences. Treatment with erythromycin also
had no effect on an outcome of chronic lung disease. These organisms may therefore
be of less importance than other factors such as ventilation and high oxygen
supplements in the development of chronic lung disease.
None of the cytokines measured correlated to outcome. This was in contrast to our
pilot study which had clearly shown IL-8 as a predictor of the development of chronic
lung disease. Pilot studies are not as strictly controlled as a randomised clinical trial.
Although the infants studied during the pilot were sequentially admitted to the unit,
there was no attempt made before hand to define the number of infants that would be
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required to provide statistically relevant data. The decision was made after 26 infants
to analyse the data and significant results were obtained. The goal in the clinical trial
was to enrol 90 babies as this would have given us a statistically large enough sample
from which to draw conclusions. That we failed to recruit enough numbers may have
had some bearing on the results. A pilot study is a necessity to any large trial and it
may have been that the infants recruited during the period of the pilot were
unrepresentative of the population as a whole.
Another difference between the studies was the definition of chronic lung disease. The
pilot study was using a definition of supplemental oxygen at 28 days postnatal age
with abnormalities on x-rays. In the erythromycin trial a baby who had an oxygen
requirement at 36 weeks corrected gestational age with abnormalities on x-ray was
defined in the chronic lung disease group. Only the second definition predicts
abnormal findings at follow-up in infants < 30 weeks gestation (Shennan et al., 1988).
The cytokines measured < 4 hours after birth did correlate strongly with
chorioamnionitis. Chorioamnionitis has been associated with preterm labour, an
increased infection in the baby (Hillier et al., 1988) and an outcome of chronic lung
disease (Watterberg et al., 1996). However, in this study chorioamnionitis was not
correlated to lung infection and infants with chorioamnionitis were less likely to be
treated with surfactant and had a significantly lower incidence of chronic lung disease.
The placentas of these infants were not cultured for genital mycoplasmas so we can
not be certain that these infants were already infected in utero. The cytokines in all
infants were similar by 24 hours suggesting that chorioamnionitis may provoke an
early rise but that in the longer term this has no significance on outcome. The
persistence of inflammatory cytokines may be more important in the development of
chronic lung disease.
Studies on human populations are always compounded by the individual differences
between subjects. It is very rare to get two infants with the same clinical course and
the same outcome. For this reason animal models and in vitro studies are often very
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useful in elucidating disease mechanisms. Natural animal models of chronic lung
disease do not occur as premature labour is rare in most species except man, however
rabbits, sheep, rats, baboons and guinea pigs can all be electively delivered
prematurely. Rabbits, rats and sheep cannot be maintained successfully for prolonged
periods but provide models of respiratory distress syndrome. Newborn guinea pigs
have relatively mature lungs compared to humans with events such as differentiation
and alveolarisation which occur pre-dominantly postnatally in humans occurring
prenatally in guinea pigs (Frank., 1983). Non-human primates provide the best model
as they can be maintained for longer periods but generally recover without developing
chronic lung disease. Within the budget of this study a primate model was not a viable
option and instead a cell based model was developed.
A cell model of the inflammatory response was developed as a means to further
understand the interactions of lung epithelial cells and mediators used clinically in the
treatment of preterm infants. Treatment of preterm infants varies on a case by case
basis depending on the clinical needs of the patient.
Infants with RDS will invariably receive surfactant, either natural or synthetic. At the
time of this study a clinical trial was underway in the neonatal unit evaluating porcine
natural surfactant (Curosurf) and synthetic surfactant (Exosurf). Surfactant is known
to decrease the lung surface tension, and contribute to the alveolar stability associated
with normal respiration preventing the collapse of the alveoli. Surfactant lipids
suppress the immunological activities of alveolar macrophages (AM) (Shimizu et
al., 1988) whilst the proteins stabilise the alveolar film (Baatz et al., 1990; Perez-Gil et
al., 1992). SP-A has been shown to stimulate proinflammatory cytokine production
(Eizioni.,1994) and SP-D can induce production of oxygen radicals from alveolar
macrophages (van Iwaarden et al., 1992).
Curosurf is derived from the minced lungs of pigs and contains both the lipid and
protein parts of surfactant. Exosurf is synthetic and contains lipids but no proteins.
Instead it contains two synthesised components hexadecanol and tyloxapol which
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mimic the proteins SP-B and SP-C, and which are essential if the surfactant is to form
a surface film at the air/water interface.
Exosurf inhibits alveolar macrophage production of IL-ip, TNF-a and IL-6
(Thomassen et al., 1994) but not IL-8 (Thomassen et al.,1992) and may function as an
antioxidant by scavenging oxygen radicals (Ghio et al., 1994). Curosurf in contrast
inhibits monocyte TNF-a and superoxide anion production (Ciccimarra.,1994), and
phagocytosis of S. aureus (Speer et al., 1991). Exogenous surfactant has been shown
to promote endogenous surfactant production (Gerdes et al., 1992).
The make-up of these two surfactants suggests they may have different
immunomodulatory roles.
Dexamethasone is a steroidal anti-inflammatory given to infants in whom little clinical
progress is seen. It is not routinely used in our unit due to its side-effects (Ng.,1993),
though it could be argued that if given early in the course of a ventilated infant it
reduces inflammatory markers and may prevent the development of chronic lung
disease (Groneck et al., 1993c; Groneck et al., 1993b; Murch et al., 1996b). Early and
prolonged treatment would seem to be more beneficial in reducing the long term
complications (Rastogi et al., 1996; Kari et al., 1993; Sanders et al., 1994).
Another common treatment used is antibiotics. Routinely infants receive gentamicin
which is effective against a range of common Gram-negative organisms, but has no
known immunomodulatory effects. To assess erythromycin as an anti-inflammatory it
too was included in our model of inflammation.
Lung epithelial cells are important in modulating the migration of neutrophils into the
lungs. They express cell surface adhesion molecules and can produce IL-8 on
stimulation with TNF-a and EL-lp. A human lung epithelial cell line (A549) was
cultured in vitro and exposed to U. Urealyticum and E. coli which stimulated IL-8
production. E. coli produced a significantly larger response than U. urealyticum.
Dexamethasone completely blocked the production of IL-8, erythromycin and
gentamicin had no direct effect and the surfactants Exosurf and Curosurf also
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inhibited the response in a dose dependent manner. Exosurfwas much more inhibitory
than Curosurf on the epithelial cells. In contrast, in a randomised clinical study of
Curosurf vs. Exosurf the infants that received Exosurf had a larger rise in
bronchoalveolar lavage EL-8 after 24 hours which was statistically significant. The
two groups in the study had no other significant differences in clinical characteristics,
although the numbers were small (n = 23). Whilst the cell model reflects changes in
the epithelial cells, in vivo there are also macrophages and large numbers of
neutrophils contributing to the IL-8 present. Exosurf may inhibit epithelial cell
production of EL-8 but it may also promote its local production by other cells.
Alternatively, Curosurf may be much better at inhibiting IL-8 production from
inflammatory cells within the lung and this may relate to its composition which
includes proteins.
The further development of this model could include these cell types in co-culture
experiments with macrophages and neutrophils. This would reflect more accurately
the situation in vivo. It would also be of interest to culture cells from preterm
neonates although numbers would inevitably be small and a great deal of effort would
be required to collect enough samples for analysis. Further assays could investigate
the regulation of neutrophil migration across the epithelial membrane (Smart et
al., 1994; Bittleman etal., 1995). A549 cells express ICAM-1 on their surface (Arnold
et rr/.,1996), the molecule which mediates the migration of neutrophils. The effect of
these clinical treatments on this event would be very important especially as
erythromycin is thought to prevent neutrophil migration into the lungs in adult
airways disease. Ideally further study would also involve neonatal cells, and premature
ones where possible. Their responses to infection and clinical treatments may possibly
be different to adult cells responses.
Conclusions
Whilst inflammation is undoubtedly the underlying cause of tissue damage in these
infants the early pro-inflammatory cytokines do not appear to provide a marker for
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the longer term outcome of chronic lung disease. Colonisation with the genital
mycoplasmas does not appear to influence the development of chronic lung disease
nor of the early pro-inflammatory response. Recent reports have suggested that
neonatal cells are incapable of producing IL-10 (Jones et al., 1996), a cytokine which
down-regulates the pro-inflammatory cytokines. There is no evidence from this study
that infants that develop chronic lung disease do so because of a different early pro¬
inflammatory response. It may be that neonates who develop chronic lung disease do
so because they are unable to down-regulate their inflammatory responses leaving
their lungs under persistent immune cell attack. Infants that do not develop chronic
lung disease are extubated and we therefore have no knowledge of pro- or anti¬
inflammatory cytokines that may be present in their lungs. Current investigations in
this unit are concentrating on the cytokine IL-10 to measure differences between
infants ability to regulate their inflammatory response and its contribution to the
development of chronic lung disease.
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9. Appendix A: Solutions
Iodination Buffer
0.5M sodium dihydrogen phosphate
pH to 7.4 with sodium hydroxide
Non-stickBuffer
6.05g Trizma Base (Sigma)




pH to 7.6 and make up to 500mls in distilled water







IL-8 assay phosphate buffer and 8% PEG were mixed in a 1:1 ratio. To this donkey
anti-rabbit was added at 1:20 and normal rabbit serum at 1:200.
GrowthMedium (GM) for A549
DMEM (Life Technologies, Cat. No. 22320022)
100 units/ml penicillin/streptomycin (Life Technologies, Cat. No. 15070030)
2mM L-glutamine (Life Technologies, Cat. No. 15032014)
10% fetal bovine serum (Life Technologies, Cat. No. 10106, Batch No. 40G3251F)
FreezingMedium (FM) for A549
Add 1% DMSO (Sigma, Cat. No. D2650) to growth medium.
AcidHemallum Stain
5g haematoxylin in 700 mis of distilled water
50g ammonium alum
0.25g sodium iodate
Dissolve the above with heat then add
300g glycerine
20 mis glacial acetic acid
Normal Human Serum
Whole blood was collected and allowed to clot. The mixture was then spun at lOOOg





Dissolve 8mg of napthol-AS-MX-phosphate (Sigma, Cat. No. N4875) in 0.2 ml N,N,
dimethyl formamide (Sigma, Cat. No. D8654)
Add 10 mis 0.1M tris
Adjust pH to 8.2
Add 2.5 mg levamisol (Sigma, Cat. No. L9756)
Immediately prior to staining add 10 mg fast red TR (Sigma, Cat. No. F2768)




1 litre distilled water
Adjust to pH 7.6 and make up to 10 litres in distilled water
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Chapter 3: IL-8 Assay Development Results
Table 10-1: Resultsfor the EquilibratedEssay.
Values are counts per minute. Stdev = standard deviation; N/A = no sample available; % cv = mean
+ stdev x 100; % BO = Counts expressed as a percentage ofBO.
Tc NSB Bft 19.? 39,1 7S.1 1?f>,3 312.5 62? 12?0 2500
18353 351 4744 4613 4392 4202 3861 3069 2602 1836 1393
18027 398 4703 4524 4371 4075 3882 3259 2571 1792 1357
18068 399 4722 4455 4522 4114 3917 3140 2638 1915 1415
18133 416 4744 4378 4443 4205 3526 3283 2606 N/A 1366
18147 418 4670 4605 4482 4373 3853 3171 2546 1931 1356
18087 409 4523 4418 4286 4281 3653 3275 2593 1919 1305
18123 436 4551 4539 4329 4056 3727 3152 2411 1864 1314
17746 386 4538 4441 4359 3993 3618 3180 2479 1806 1579
17186 393 4748 4528 4493 3981 3733 3183 N/A 1808 1342
17970 352 4502 4683 4342 3987 3705 3181 2425 1832 1424
averaae 17984 396 4644 4518 4401 4126 3747 3189 2541 1855 1385
stdev 319.3 27.4 103.1 96.5 78.9 134.5 128.3 66.5 83.1 53.6 78.5
%cv 1.8 6.9 2.2 2.14 1.8 3.3 3.4 2.1 3.3 2.9 5.7
% Tc 25.8
%B0 97.8 94.8 88.9 80.7 68.7 54.7 40.0 29.8
Table 10-2: Resultsfor the Dis-equilibrated Assay.
Values are counts per minute. Stdev = standard deviation; N/A = no sample available; %> cv =
average -r stdev x 100; % B0= Counts expressed as a percentage ofBO.
Tc NSB BO 19,? 39.1 78.1 156.3 312,? 62? 12?0 2500
17814 421.6 5364 4728 4241 3929 3138 2265 1667 1342 1213
17910 621.9 4993 4572 4337 3828 3170 2389 1720 1360 1021
18253 420.7 5000 4477 4215 3817 3135 2263 1844 1311 1045
17690 379.2 4681 4484 4351 3848 3182 2303 1808 1413 1102
17546 431.4 5142 4462 4227 3912 3056 2310 1798 1277 1135
17950 470.8 4776 4506 4247 3941 3065 2280 1841 1327 1066
17852 446.9 4892 4532 4243 3637 3074 N/A 1658 1547 1077
17691 420.1 4866 4585 4227 3677 3047 2317 1721 1363 1084
18026 428.9 4956 4584 4249 3747 3224 2302 1776 1310 1110
179427 436.9 4910 4670. 4247. 3691. 3150. 2296 1668. 1295. 1060.
averaae 17867 447.8 4958 4560 4258 3803 3124 2303 1750 1354 1091
stdev 199.13 65.39 190. 86.67 46.59 109.8 60.78 37.59 72.54 78.23 54.02
%cv 1.11 14.60 3.84 1.90 1.09 2.89 1.95 1.63 4.14 5.77 4.95
%Tc 27.75
%B0 91.97 85.89 76.70 63.01 46.45 35.30 27.33 22.02
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Table 10-3: Measured andExpected Values ofSerially Dilute Tracheal Samples.
Values are pg/ml 1L-8. DF = dilution factor. The expected values are calculated by dividing the
measured value by the dilution factor.
Sample Measured Neat Value DF Measured Value Expected Value
1 1303 5 242 260.6
2 1018 2 570 509
2 284 285
2 133 142
3 1188 5 254 237.6
4 776 5 158 155.2
5 465 5 66 93
6 1051 2 595 525.5
2 314 297.5
2 144 157
7 1178 2 617 589
2 321 308.5
8 595 5 113 119








11 492 5 91 98.4
12 670 5 118 134
5 40 23.6
13 983 5 175 196.6
14 1415 5 306 283
5 58 61.2




16 297 2 129 148.5
2 62 64.5
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Table 10-4: Ten Replicates of the R&D Standards
R&D
Standard
Tc NSB BO 19.5 39.1 78.1 156.3 312.5 625 1250 2500
18054 427 4814 3999 5161 3893 3016 2439 1711 1359 1051
18108 484 4886 4613 4414 3669 3026 2327 1703 1371 1118
17735 411 4961 4595 4169 3829 3365 2362 1796 1262 1201
17862 468 4956 4643 4272 3699 3281 2289 1774 1377 1026
17776 425 4941 4618 4268 3787 3130 2378 1633 1328 1069
17938 350 5045 4619 4297 3842 3077 2264 1565 1305 997
17975 457 4824 4541 4299 3717 3116 2290 1781 1244 1032
18365 400 4793 4639 4450 3721 2958 2265 1880 1284 1049
17838 390 4801 4649 4334 3789 3009 2317 1823 N/A 1129
17890 379 4716 4927 4367 3797 3014 2368 1808 1358 965
average 17954 419 4873 4584 4403 3774 3099 2329 1747 1320 1063
stdev 185.29 41.9 100.6 229.9 277.9 71.06 130.4 56.46 94.76 49.41 69.19
% cv 1.03 10.0 2.06 5.02 6.31 1.88 4.21 2.42 5.42 3.74 6.50
% Tc 27.15
%B0 94.06 90.34 77.44 63.59 47.80 35.85 27.10 21.82
Table 10-5: Ten Replicates of the N1BSC Standard
NIBSC
Standard
Tc NSB BO 19.5 39.1 78.1 156.3 312.5 625 1250 2500
18110 419 5034 4474 4282 3247 N/A 2486 1687 1315 1101
18127 434 5113 4462 4373 3696 3106 2157 1787 1209 1007
18473 421 4990 4609 4398 3794 2934 2293 1696 1293 1007
18063 395 4900 4529 4338 3600 2979 2344 1740 1207 1036
18184 529 4813 4679 4111 3693 2912 2316 1589 1236 980
17777 493 4854 4658 4170 3695 3036 2212 1673 1290 1065
17249 428 4879 N/A 4321 3643 3123 2162 1572 1257 1056
17727 426 4748 4355 4344 3760 3019 2211 1590 1325 1076
17958 530 4837 4425 4137 3661 3031 2114 1667 1277 1046
18095 411 4916 4322 4234 3876 3078 2074 1692 1278 1148
average 17976. 448.6 4908 4501 4270 3666 3024 2236 1669 1268 1052
stdev 330.52 49.59 109.6 127.5 102.2 167.4 72.74 123.7 68.81 40.95 49.33
% cv 1.84 11.05 2.23 2.83 2.39 4.57 2.41 5.53 4.12 3.23 4.69
% Tc 27.30
% BO 91.71 87.01 74.70 61.61 45.57 34.01 25.85 21.44
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Chapter 4: Results
Table 10-6: IL-8 (/ug/L) for All Infants Enrolled on the Study





















See also Graph 4.1. sem = standard error ofthe mean; IQR = interquartile range.
Table 10-7: Interleukin-8 pg/L
Infants divided retrospectivelyfor those that developed CLD and those that did not.
Chronic Lung Disease No Chronic Lung Disease
Time (Hrs) n Median n Median
(IQR) IQR
2.4 8 4.1 8 2.3
(2.7-18) (0 - 7.9)
26.0 14 25.0 * 7 4.7 *
(10.3 - 58.1) (3.3-20.7)
47.6 10 21.0 6 28.0
(16.9-44.8) (4.2-71.4)
71.4 9 11.8 5 16.2
(3.0-31.4) (2.2-61.4)
See also Graph 4.2. * = p < 0.01; Mann-Whitney U
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Table 10-8: Cells in Bronchoalveolar Lavage









2.5 4.1 0.4 0.06 1.9
(1.0-15.4) (0 - 0.9) (0 - 0.4) (0.5 - 6.5)
26.0 7.0 3.8 1.0 0.5
(1.8-18.3) (0.6 - 9.7) (0.1-3.7) (0.02- 1.9)
47.6 3.1 2.2 0.4 0.03
(9.0-81.0) (1.1 -6.0) (0.04 - 0.6) (0 - 0.2)
71.4 5.8 2.9 0.8 0.4
(2.2- 12.3) (1.5 - 10.1) (0.4- 1.3) (0-1.2)
See also Graph 4.3
Table 10-9: Cell Results Chronic Lung Disease vs. No Chronic Lung Disease
Values are x 105 median (range).
Samp e Time (Hrs) 2.5 26 47.6 71.4
































































§p< 0.05 Mann Whitney U test.
See also Graphs 4.4 to 4.7
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Chapter 5: Results
Table 10-10: Cytokine Data. Medians (interquartile range) for all infants enrolled
on the study. See also Graph 5.7.
Sample Time (Hours Postnatally)
Pre-S Post-S 24-48 48-72 72-96 96 - 120
IL-8 pg/L 5.8 9.0 28.3 39.9 42.9 50.4













EL-lp ng/L 3.6 56.2 213.6 297.6 258.4 407.5
(0 -122) (17-173) (55-639) (140 -833) (106-834) (41 - 973)
Table 10-11: Cell Data. Medians (interquartile range) for all infants enrolled on the
study. See also Graph 5.8
Sample Time (Hours Postnatally)












































Appendix B: Raw Data Tables
Table 10-12: Cytokine Data. Medians (interquartile range) for infants divided into
the group that received erythromycin (E) and the non-treated group (NT). See
Graphs 5.6 and 5.7.
Hours Pre-S Post-S 24-48 48-72 72-96































































































Table 10-13: Cell Data. Medians (interquartile range) for infants divided into the
group that received erythromycin (E) and the non-treated group (NT). See Graphs
5.8 to 5.11.
Hours Pre-S Post-S 24 -48 48 72 72 96
Cells/ml x 104 E NT E NT E NT E NT E NT
Total Cells 16 13 48 39 61 56.0 70 48 92 64
(8- (8- (30 - (15.5- (40- (30- (28 - (30- (44.5 (20.8
38.5) 43) 84) 62.5) 114.5) 102) 143) 86) - 114) -88)
Neutrophils 2.0 0.7 25.7 30.8 33.2 23.2 52.4 26.7 37.6 15.8
(0- (0- (1.2- (2.7- (1.5- (10 - (0- (0- (8.1- (2.8-
14.0) 8.1) 54.9) 51.6) 80.5) 66.0) 106) 59.8) 65.9) 45.5)
Macrophages 0.2 0.02 2.4 2.7 3.9 4.1 7.3 1.8 6.5 6.4
(0 (0- (0.5- (0- (0- (1.4- (0- (0- (0.7- (0.2 -
-1.7) 1.0) 5.9) 11.4) 8.6) 9.5) 24.3) 5.8) 26.8) 16.1)
Epithelial 4.4 8.7 1.1 0.5 0 0.04 0.4 0.4 0.2 0.6
Cells (1.0- (3.6- (0- (0- (0- (0- (0- (0- (0- (0-
28.2) 23.5) 9.6) 7.2) 4.5) 4.0) 4.7) 3.6) 3.6) 10.8)
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Table 10-14: Medians (interquartile range). *
Graphs 5.12 to 5.13.
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= p < 0.05, ** = p < 0.01. See
Hours Pre-S Post-S 24--48 48 -72 72 -96
I NI I NI I NI I NI I NI
1L-8 pg/L 7.7 3.6 9.0 8.3 12.1 29.7 25.2 * 47.5 * 18.2 72.5
(4.2- (0- (1.7- (3.3- (3.7- (9.9- (3.5- (22- (6.4- (14-
6.6) 12.2) 15.2) 20.1) 114.9) 71.4) 41.8) 112.8) 47.9) 105.1)
TNF-a ng/L 0 0 0 ** 0 ** 46.2 0 0 0 0 0
(0- (0-0) (0- (0-0) (0- (0- (0- (0- (0- (0-
44.8) 71.0) 59.0) 28.8) 68.4) 60.9) 46.2) 227.4)
EL-1(3 ng/L 38.2 1.8 43.9 56.2 139.1 200.5 225.8 260 207.7 601.6
(0- (0- (22- (0- (78- (47- (43- (118- (0- (141 -
618.6) 121.2) 69.5) 172.8) 770.5) 796.0) 543.9) 900.5) 635) 931.3)
Table 10-15: Medians (interquartile range) * = p < 0.05, ** = p < 0.01. See Graphs
5.14 to 5.17.
Hours Pre-S Post-S 24--48 48 -72 72--96
Cells/ml x 104 I NI I NI I NI I NI I NI
Total Cells 8 * 17 * 66 48 68 56 39 60 58 73
(2- (10- (30 - (19 - (54- (27 - (29.5 (29 - (37 - (38.5
24) 43) 80) 84) 134) 79) - 124) 98.5) 98.5) - 114)
Neutrophils 1.9 0.1 51 19.3 43.7 29.8 33 35.3 31.5 29.9
(0- (0- (15.3 (0.05 - (0- (6.1- (6.0 - (0- (0.3 - (3.1-
18.7) 5.9) -73) 51.8) 89.4) 61.3) 94.1) 87.6) 54.1) 64.8)
Macrophages 0.08 0 2.7 1.4 7.8 3.4 3.8 4.0 2.6 7.8
(0- (0- (1.0- (0- (0- (0.6- (0.4 - (0- (0.09 (0.8 -
1.4) 0.8) 5.4) 7.1) 9.4) 9.2) 17.3) 18.1) -15) 35.8)
Epithelial 1.0 ** 11 ** 2.6 0.09 4.0 0 0.1 0.6 2.4 0.4
Cells (0- (4- (0- (0- (0- (0- (0- (0- (0.1- (0-
3.6) 37.3) 16.7) 7.8) 6.8) 0.6) 5.0) 5.4) 8.3) 4.8)
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Table 10-16: Cytokine Data. Medians (interquartile range) for infants divided into
the group that developed CLD (DC) and the group that did not (NC). See Graphs
5.18 to 5.19.
Hours Pre-S Post-S 24 -48 48 -72 72 -96
DC NC DC NC DC NC DC NC DC NC
IL-8 pg/L 2.4 " 8.3 ** 10.4 13.3 28.7 40.1 54.9 40.3 73.2 36.5
(0- (3-4 - (2.6- (3.3- (11 " (10.9 (33- (19.6 (9.1- (10.8
4.9) 49.7) 21.3) 20) 85.2) -73) 147) -90) 161) -76)
TNF-a ng/L 0 0 0 0 0 0 0 0 0 0
(0-0) (0-0) (0-0) (0-0) (0- (0- (0- (0- (0- (0-
24.5) 39.6) 30.5) 68) 242.7) 23.1)
EL-ip ng/L 0 ** 17 ** 51.2 84.6 226 374.0 656 297.6 425.3 229.7
(0- (0- (9.8- (26.3 (40.6 (73.2 (98.1 (198- (96.6 (133 -
4.8) 222.2) 183) -208) -784) -771) -825) 1001) -760) 950.8)
Table 10-17: Cell Data. Medians (interquartile range) for infants divided into the
group that developed CLD (DC) and the group that did not (NC). See Graphs 5.20 to
5.23
Hours Pre-S Post-S 24 - 48 48 -72 72 -96
Cells/ml x 104 DC NC DC NC DC NC DC NC DC NC
Total Cell 19 14 62 42 58.7 56 72 48 85 46
(9- (8- (33 - (30- (24 (39- (32- (28- (47.8 - (35 -
54.5) 38) 132) 68) -124) 83) 88) 142) 107) 97)
Neutrophils 0 2.4 34.6 36.5 32.8 47.1 55.5 29.5 26.6 34.5
(0- (0- (0- (12.1- (10.8 - (16.8 (1.9- to¬ (16.5- (12.8-
6.5) 16.8) 61.9) 52.9) 65.5) -75) 88) rn) 62.9) 61.4)
Macrophages 0 0.2 3.0 2.7 5.1 6.3 3.7 2.8 8.2 3.8
(0- (0- (0- (0- (1.3- (1.9- (0- (0- (0.2 - (2.1-
0.9) 1.6) 12.4) 6.8) 8.9) 9.4) 9.7) 19) 49.1) 13.3)
Epithelial 11 4.2 0 1.7 0.2 0.02 0.7 0 2.9 0.4
Cplk (0.4- (2.5- (0- (0- (0- (0- (0- (0- (0- (0-v_/vll)
39.8) 18) 3.4) 6.8) 5.0) 3.6) 4.4) 0.7) 8.1) 7.9)
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Table 10-18: Cytokine Data. Medians (interquartile range) * = p < 0.05, ** = p <
0.01. See Graphs 5.24 to 5.25
Hours Pre-S Post-S 24 -48 48 -72 72 -96
S NS S NS S NS S NS S NS

























































































Table 10-19: Cell Data. Medians (interquartile range). * = p < 0.05, ** = p < 0.01.
See Graphs 5.30 to 5.33
Hours Pre-S Post-S 24 48 48 72 72 •96
Cells/ml x 104 S NS S NS S NS S NS S NS
Total Cells 13 24 48 38 56.0 82 48 72 76 36
(8- (8- (30- (13.5 (27.5 (43.1 (28 - (44- (43- (20-
33.5) 50) 66.5) -86) -86) - 134) 100) 94) 110) 108)
Neutrophils 0 ** 5.9 ** 27.5 30.8 29.9 29.8 28 61.9 33.2 15.8
(0- (0.9 - (0.2 - (10- (6.1- (0.1- (0- (41- (6.4 - (0-
4.7) 31.1) 49.0) 68.1) 64.6) 97.2) 94.1) 86.5) 66.3) 45.5)
Macrophages 0 ** 14** 2.3 3.1 3.6 9 2.7 3.9 7.3 3.4
(0- (0- (0- (0 (1.2- (0- (0- (1-8 - (1-0 - (0-
0.7) 2.7) 6.9) 8.4) 7.8) 10.6) 15.5) 10.4) 25.0) 16.1)
Epithelial Cells 9.7 4 1.8 0.2 0 1.6 0.04 0.7 0.6 0.4
(1.3- (2.7 - (0- (0- (0- (0- (0- (0.3 - (0- (0-
26.1) 17.8) 8.2) 6.2) 2.9) 4.3) 4.4) 7.5) 8.0) 2.0)
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Chapter 7: Ureaplasma urealyticum Results
Table 10-20: Values are interleukin-8pg/ml.
> = out with the range ofthe standard curve. NTT = not tested, stdev = standard deviation. 95 % =
95% confidence interval. % inc = the percentage increase from 0 pg/ml TNF-a. See also Graph 7.1.
TINF-a Concentration pg/ml
2000 1000 500 250 125 62.5 31.3 15.6 7.8 3.9 2 1 0.5 0.3 0.1 0
> > > > 828 512 358 320 200 189 194 178 201 217 240 227
> > > > 853 498 415 274 233 211 182 189 222 218 286 251
> > > > 854 424 385 319 238 226 230 232 212 227 264 219
> > > > 947 579 464 376 NT NT 257 235 223 214 292 227
> > > > 1022 598 438 349 236 241 207 NT 217 219 266 244
> > > > 843 617 424 344 246 252 233 238 242 243 267 222
> > > > 841 539 368 246 213 187 191 150 256 169 186 236
> > > > 844 449 358 250 238 170 194 165 211 187 225 235
> > > > 820 491 335 278 218 186 227 198 187 184 224 213
mean 872 523 394 306 228 208 213 198 219 209 250 230
st dev 67.1 66 43.3 46.2 15.7 29.5 25.1 33.8 20.6 23.6 34.1 12.2
95% 43.8 43.2 28.3 30.2 10.2 19.3 16.4 22.1 13.4 15.4 22.3 8
% inc 379 227 171 133 99 90 93 86 95 91 109 100
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Table 10-21: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with U. urealyticum in the presence oferythromycin.
Sem = standard error of the mean.
Ureaplasma 2.4 x 104 2.4 x 103 2.4 x 102 0
Concentration/
ml
Erythromycin 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0
concentration
Pg/ml
Control 788 760 758 718 622 720 728 670 720 763 668 653 757 755 725 627
sem 46 22 53 58 58 62 58 37 59 12 54 66 71 63 91 64
TNF-a 858 862 812 821 830 847 804 759 827 923 805 775 796 797 810 800
sem 124 46 71 78 62 31 35 77 34 50 55 85 13 51 27 57
Oxygen 273 297 293 232 285 275 275 264 297 293 289 257 263 282 269 247
sem 11 28 23 27 19 14 6 31 15 38 12 37 16 25 22 22
Oxygen+TNF-a 345 336 328 307 358 335 321 303 344 313 303 305 412 322 312 318
sem 7 16 3 17 3 29 8 12 28 16 1 29 23 42 28 64
Table 10-22: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with Ureaplasma urealyticum in the presence ofgentamicin. Sem = standard error of
the mean. Results in bold have very high variation due to one triplicate in the
controlsproducing very high IL-8 levels.
Ureaplasma 2.4 x 104 2.4 x 103 2.4 x 102 0
Concentration/
ml
Gentamicin 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0
concentration
pg/ml
Control 721 663 902 1057 664 557 891 1034 642 682 789 955 720 548 815 684
sem 48 53 184 302 68 62 156 327 114 30 63 273 75 87 108 14
TNF-a 825 712 897 818 852 772 929 760 951 711 912 818 871 726 846 754
sem 140 122 58 77 66 81 87 60 77 69 47 68 114 104 89 6
Oxygen 273 277 309 245 266 294 279 254 297 302 315 297 269 269 310 299
sem 37 11 29 14 14 9 16 13 7 10 6 6 8 9 11 38
Oxygen+TNF-a 326 356 345 353 342 373 361 375 325 383 379 369 318 353 335 345
sem 14 21 3 21 13 6 10 45 13 18 24 20 19 10 17 17
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Table 10-23: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with Ureaplasma urealyticum in the presence ofExosurf Sem = standard error of

















































































































































Table 10-24: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated




















































































































































Appendix B: Raw Data Tables
Table 10-25: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with Ureaplasma urealyticum in the presence of Dexamethasone. Sem = standard
error of the mean.
Ureaplasma
Concentration/
1.4 x 10s 1.4 x 104 1.4 x 103 0
ml
Dexamethasone 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0
concentration
Hg/ml
Control 359 332 506 1267 285 222 319 815 227 225 323 713 224 235 342 827
sem 15 48 33 258 15 30 21 176 15 10 20 23 19 20 51 84
TNF-a 343 327 503 1442 297 269 388 1107 273 281 357 919 257 264 384 859
sem 18 16 2 88 25 22 20 110 15 5 37 109 33 10 10 89
Oxygen 211 219 258 407 177 180 209 309 192 183 181 285 204 194 182 280
sem 20 27 10 23 10 34 17 16 6 24 21 33 17 12 16 20
Oxygen+TNF-a 251 269 269 465 217 220 225 428 167 194 199 374 188 183 211 365
sem 23 7 17 30 11 13 26 1 24 14 29 6 24 4 23 22
Table 10-26: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with E. coli in the presence ofErythromycin. Sem = standard error of the mean.
E. coli
Concentration/ml














































































































Appendix B: Raw Data Tables
Table 10-27: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with E. coli in the presence ofgentamicin. Sem = standard error of the mean.
E. coli 1 x 106 1 xlO4 0
Concentration/ml
Gentamicin 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0
concentration
Hg/ml
Control 1586 1487 1688 1864 820 744 781 861 763 747 787 857
sem 108 108 215 189 67 24 29 72 49 33 46 86
TNF-a 1804 1463 2232 2116 836 928 980 1021 961 1091 1067 1051
sem 174 79 276 136 70 30 107 103 63 8 55 96
Oxygen 1009 925 1043 1199 465 565 531 576 475 549 564 607



























Table 10-28: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with E. coli in the presence ofCurosurf Sem - standard error of the mean.
E. coli 1 x 106 1 x 104 0
Concentration/ml
Curosurf 500 50 5 0 500 50 5 0 500 50 5 0
concentration
ng/ml
Control 2437 2361 2752 2240 960 915 939 859 765 668 655 755
sem 52 147 271 171 48 132 39 24 69 111 29 86
TNF-a 2637 2745 2709 2481 1288 985 1133 1024 991 835 875 917
sem 52 309 133 131 162 29 61 57 60 60 68 69
Oxygen 2401 2480 2291 2316 737 579 671 732 523 425 496 529




























Appendix B: Raw Data Tables
Table 10-29: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with E. coli in the presence ofExosurf. Sem = standard error of the mean.
E. coli
Concentration/ml













































































































Table 10-30: Mean IL-8 pg/ml results from triplicate plates ofA549 cells stimulated
with E. coli in the presence ofdexamethasone. Sem = standard error of the mean.
E. coli 1 x 106 1 x 104 0
Concentration/ml
Dexamethasone 10 1 0.1 0 10 1 0.1 0 10 1 0.1 0
concentration
|ig/ml
Control 275 163 216 562 144 121 171 311 137 161 192 332
sem 23 13 10 24 15 11 32 31 20 26 27 44
TNF-a 334 190 288 676 159 165 211 416 148 205 222 406
sem 4 26 15 39 18 17 15 50 10 31 35 51
Oxygen 518 272 401 1104 233 239 278 593 236 237 277 559
sem 28 27 31 30 34 34 30 7 30 24 33 11
Oxygen+TNF-a 626 342 454 1360 320 260 320 776 316 316 392 770
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Interleukin-8 in bronchoalveolar lavage samples as a predictor of chronic lung
disease in premature Infants.
SIR - Donnelly et afi reported that the concentration of the neutrophil activating and chemotactic
cytokine, interleukin-8 (IL-8), was greater in bronchoalveolar lavage (BAL) samples from trauma
patients who went on to develop adult respiratory distress syndrome than from patients who did not.
The IL-8 could be detected on admission and before lung damage was clinically evident. It is now
recognised that there is a significant pulmonary inflammatory reaction in the development of chronic
lung disease (CLD) in premature infants^. Many studies have reported the presence of large amounts
of neutrophils in BAL samples from premature intubated infants,and IL-8 has been shown to be
the major chemotactic factor in the lungs of infants at risk ofCLD5. We wished to test the hypothesis
that IL-8 was associated with the development of CLD in premature infants.
BAL samples were obtained daily for 7 days at the time of normal endotracheal suction from 12
consecutive newborns who were born between 23 and 30 weeks' gestation (median 27). The samples
were kept at 4°C (mean 1.9 h) until mucus was removed by straining the sample through sterile
gauze and the cells were removed by centrifugation at 400g for 10 min. Aliquots of the supernatant
were taken and immediately frozen at -70°C. IL-8 was measured by a specific radioimmunoassay
(detection limit of 50ng/L, intra-assay variation of <5%, inter-assay variation of <13%).
7 infants (58%) developed CLD (defined as an oxygen requirement at 28 days of age). 2 of these did
not receive surfactant as they initially were not diagnosed as having respiratory distress syndrome. 5
infants (42%) did not develop CLD. 3 of these received surfactant because they were initially
diagnosed as having respiratory distress syndrome. All infants from both groups survived. IL-8
concentrations the day after admission, taken at a mean age 21.7 hours (range 14.6-29.2 hours). A
higher concentration of EL-8 was found in those infants who went on to develop CLD than in those
who did not (p=0.042, Mann-Whitney U test):
Median Range
Infants later developing CLD 41.7ug/L 2.3 -351.9ug/L
Infants that did not develop CLD 5.7ug/L 0.4 - 20,7ug/L
It seems possible that IL-8 in BAL may be a useful very early prognostic indicator for the
development of CLD in premature infants.
We thank DrR W Kelly, MRC Reproductive Biology Unit, Centre for Reproductive Biology, Edinburgh for the
gift of the IL-8 assay reagents.
J R McColm, NMcintosh
Department Child Life and Health, University of Edinburgh, Edinburgh EH9 7UW, UK
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TRACHEAL IL8 AS A PREDICTOR OF CHRONIC LUNG DISEASE
Jan McColm. Neil Mcintosh
Department ofChild Life and Health, University ofEdinburgh.
Hypothesis: Is the neutrophil activating cytokine IL8 associated with chronic
inflammation and development of chronic lung disease in the immature infant?
Study type/Setting: Prospective cohort study in a tertiary neonatal service.
Patients: 12 consecutive newborn =< 30 weeks gestation (median 27).
Interventions: 8 infants received surfactant because of respiratory distress syndrome
(rescue situation) and all were ventilated using a standard technique.
Measurements: tracheal secretions and washings were collected daily for 7 days at
the time of normal endotracheal suction. The EL8 concentrations of the supernatants
were measured by a specific RIA (cv 5,13%). Chronic Lung Disease was defined as
an oxygen requirement at 28 days of age.
Results: 7 of the 12 infants (58%) developed chronic lung disease typical of
bronchopulmonary dysplasia - 2 did not receive surfactant as they initially did not
have an oxygen requirement or a diagnosis of RDS. 5 infants (42%) did not develop
chronic lung disease - 3 received surfactant because of the initial diagnosis of RDS.
All infants survived. The median (range) of IL8 in the tracheal secretions on day 2 in
the group who did not develop BPD was 5.7(0.4-20.7)mcg/ml: the corresponding
levels in the group going on to develop CLD was 42(22-352) mcg/ml (p=0.042,
Mann-Whitney U test).
Conclusions: The acute inflammatory cytokine IL8, is present at high concentrations
early in the tracheal secretions of babies who go on to develop chronic lung disease.
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Changes in Inflammatory Cells and Inflammatory Mediators in
Bronchoalveolar Lavage Fluid after Surfactant
JR McColm, BJ Stenson and N Mcintosh.
Department ofChild Life andHealth, University ofEdinburgh.
Background: Tumour Necrosis Factor-a (TNF-a), and interleukin-8 (IL-8) are
produced by alveolar macrophages in response to many insults and a high level of IL-
8 at 24 hours may predict the development of chronic lung disease.1 The aim of this
study was to explore the inflammatory response to two different surfactants.
Setting: A tertiary neonatal intensive care unit, Edinburgh, Scotland.
Subjects: 23 ventilated newborn infants on the first day of life.
Interventions: Infants with respiratory distress syndrome and an A/a ration < 0.22
were randomised to receive Curosurf (n=12, median gestational age 29 weeks,
birthweight 1395g), or Exosurf (n=ll, median gestational age 29 week, birthweight
1543g).
Results: Data are medians before and 24 hours after surfactant treatment.
(pre vs post) All Infants Exosurf Curosurf
IL-8 ng/ml 4.4 vs 20.7 (p-0.078) 4.2 vs 23.7 (p=0.04) 6.2 vs 15.6 (p=0.58)
TNF-a pg/ml 0 vs 0 (p=0.29) 0 vs 0 (p=0.29) 0 vs 0 (p=0.29)
% Neutrophils 2 vs 77 (p = 0.001) 22 vs 75 (p=0.06) 1 vs 77.5 (p=0.01)
% Macrophages 0 vs 5 (p = 0.13) 6 vs 5 (p=0.76) 0 vs 8 (p=0.10)
Statistics performed with a Wilcoxon Signed Ranks Test
Conclusions: This preliminary data suggests ther is a larger early inflammatory
response of the inflammatory chemokine IL-8 with artificial surfactant.
1. McColm JR and Mcintosh N. IL-8 as a predictor of chronic lung disease in
premature infants. Pediatric Research 1994 34: 28A
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COMPARISON OF TWO TECHNIQUES FOR ASSESSING
INFLAMMATORY CELLS IN BRONCHOALVEOLAR LAVAGE FLUID Jan
R McColm. Andrew J Lvon. Linda Middlemist and Neil Mcintosh. Department of
Child Life and Health, University ofEdinburgh, Edinburgh, Scotland, UK.
Background: The development of chronic lung disease is associated with an
infiltration of activated immune cells which cause tissue damage by the release of
oxygen radicals and enzymes. There has been controversy with most investigators
suggesting only the presence of neutrophils contributes to the outcome (1). Most
reported studies have used a standard differential stain to distinguish cells based on
their morphology, where mature neutrophils are easily recognised but macrophages
are not.
Immunohistochemical stains (IHS) rely on cell-specific proteins to distinguish cell
types. This should be more accurate and less observer dependent.
Samples: BAL was performed on infants <30wks gestation and the sample collected
in a mucus trap. The cells were separated by centrifugation, counted and adjusted to
4xl05cells/ml. lOOpl of sample was added to a cytospin and spun onto slides, which
were air dried and either differentially stained or stored at -20°C for later IHS.
Methods: The differential stain was a commercially available kit (Diff Quik, Dade).
The EHS used the alkaline phosphatase anti-alkaline phosphatase (APAAP) technique
with monoclonal antibodies to the pan-macrophage marker CD68 (Dako) and the
neutrophil specific membrane antigens (Sigma). Counts were made on 300 cells per
slide and the percentage of cell types present was compared using the Mantel-
Haenszel j2 test.
Results: Neutrophils counts were not significantly different between techniques
(where n = 23, p=0.3) but there was a significant difference (n = 38, p<0.05) between
macrophage counts, with the IHS counts being higher.
Conclusions: Routine differential staining may not be the best way of assessing
macrophage numbers in BAL fluid as morphological differentiation is difficult. A
technique based on the identification of cell-specific proteins by IHS is more
discriminatory.
1. Arnon S et al. Arch Dis Child 1993; 69:44-48.
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